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CHAPTER 1 
LECTINS AND THE INVESTIGATION 
OF PLASMA PROTEIN GLYCOSYLATION 
1.1. Introduction 
Glycoproteins consist of a protein part and a carbohydrate (or glycosylated) 
part. The latter may be investigated by using carbohydrate binding proteins called 
lectins. This chapter describes, in detail, aspects of protein glycosylation and 
its study using lectins. The feasability of a new approach is also discussed. This 
would involve using lectins to replace the immobilised or enzyme-linked antibody 
in sandwich ELISA techniques. 
1.2. Lectins 
1.2.1. History (compiled from Liener et aL, 1986) 
Exactly one hundred years ago Stillmark (1888) observed the hemagglutination 
of red blood cells by a solution from ground castor beans. His work started 
a series of papers and theses from Kobert's laboratory at the University of Dorpat, 
Estonia (now Tartu, USSR) on agglutinating toxins. Erythrocytes from different 
animals reacted differently. Other seeds and plants were found to possess similar, 
but not identical properties. Lectinology was born. 
Subsequent experiments established the protein nature of the lectins, and 
their agglutinating, as well as precipitating activities, their varying selectivity 
of interaction with different cells, and the inhibition of their activity by certain 
substances. Eminent investigators such as Paul Ehrlich, the father of modern 
immunology and Karl Landsteiner, discoverer of the ABO and Rhesus blood 
groups, studied plant agglutinins in the early period. The use of certain lectins 
as blood group specific reagents initiated a new wave of interest in lectins that 
resulted in an avalanche of papers in the first half of the century, many of 
them dealing with systematic screening of thousands of plant species. Another 
important finding was the mitogenic properties of lectins of Phaseolus vulgaris 
seeds, inappropriately named "phytohemagglutinin" or PHA. 
Lectins were found to be widely distributed in nature: seeds, plants, fungi, 
bacteria, viruses, invertebrates and vertebrates all contained soluble or membrane-
bound lectins. Some proved to be extremely toxic, the compounds responsible 
for the toxicity were later termed toxins. 
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Watkins and Morgan were the first to show that simple sugars are capable 
of inhibiting lectin activity. These studies helped to resolve the carbohydrate 
structures of the blood group determinants (Watkins, 1980). 
Terminology has changed to some extent during the first hundred years. The 
oldest names of lectins were derived form the plant source: ricin from Ricinus 
communis, crotin from Croton tiglium, robin from Robinia pseudoacacia, abrin 
from Abrus precatorius, and many others. Later collective names were suggested 
such as "phasins", "hemagglutinins", "phytagglutins", and "prolectins". The word 
"phytohemagglutinin" and its abbreviation PHA is still used for the lectins from 
the red kidney bean Phaseolus vulgaris. 
The term "lectin" was introduced by Boyd in 1954: "It would appear to 
be a matter of semantics as to whether a substance not produced in response 
to an antigen should be called an antibody even though it is a protein and 
combines specifically with certain antigens only. It might be better to have a 
different word for these substances and the present writer would like to propose 
the word "lectin", from the Latin "lectus" the past principle of "legere" meaning 
to pick, choose or select" (Boyd et al., 1954). 
With increasing knowledge of the nature of lectins it became evident that 
most of them were carbohydrate specific. During the second half of the 1960s 
"lectin" gradually replaced the term "hemagglutinin" and some agglutinins of 
animal and bacterial origin were also classified as lectins. On the other hand, 
with most of the viral hemagglutinins the name lectin has been used with some 
hesitation up to the present. 
1.2.2. Definitions 
Lectins are usually defined as carbohydrate-binding proteins of non-immune 
origin that agglutinate cells or precipitate polysaccharides or glycoconjugates 
(Goldstein et al., 1980). This definition has been adopted by the Nomenclature 
Committee of the International Union of Biochemistry IUB (Dixon, 1981). The 
emphasis on "non-immune" origin distinguishes lectins from anti-carbohydrate 
antibodies, such as anti-blood group antibodies which may also act as cell 
agglutinins. 
The definition is an operational one which excludes monovalent proteins 
and other sugar-binding proteins such as glycosidases and glycosyltransferases. 
The border between enzymes and lectins is still unclear in a number of instances 
where proteins seem to be able to act as both (Hankins et al., 1978; Kelleher 
et al., 1988). An example is the copper containing enzyme galactose oxidase, 
which is also a hemagglutinin, especially at lower temperatures where the enzyme 
function is diminished. In its apo form with copper removed the enzymatic activity 
is lost, but the protein fully retains its lectin function (Horejsi et al., 1979). 
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1.2.3 Occurrence 
Although known as plant and seed proteins for exactly a century, it is only 
during the last decade that it has become clear that Iectins occur in all living 
matter. In human beings, for instance, the first lectin to be discovered was the 
hepatic galactose receptor or hepatic binding protein (Ashwell et al., 197 4 ). 
The paper became a "citation classic" (Current Contents 1986, 29: l8). 
Subsequently lectins were found in nearly all cell types and tissues and even 
in plasma. Well-known human proteins such as Laminin, Thrombospondin, CRP, 
Glycophorin, Amyloid P component, C 1 q, Interleukin-1, Interleukin-2, Conglu-
tinin, Tumor Necrosis Factor and von Willebrand's factor have lectin properties 
(Ikeda et al., 1987; Summerfield et al., 1986; Kawasaki et al., 1986; Matsumoto 
et al., 1986; Lieberman et al., 1984; Hamakazi, 1986, 1988; Li et al., 1984; 
Taylor et al., 1984, 1987; Kataoka et al., 1985; Bowles et al., 1977; Uhlenbruck 
et al., 1979; Hirabayashi et al., 1984; Roberts et al., 1986; Oka et al., 1988; 
Baatrup, 1987; Thiel et al., 1987; Sherblom et al., 1988). Lectins can be looked 
upon as the "immunoglobulins" of invertebrates (Renwrantz, 1983), although 
no inductive synthesis stimuli are apparent, and their occurrence on vertebrate 
cell membranes may represent an evolutionary ancient binding mechanism 
(Simpson et al., 1978). 
The striking amino acid sequence homology of the human lymphocyte receptor 
for IgE and the chicken liver asialoglycoprotein receptor (hepatic lectin) suggests 
the existence of a membrane lectin /receptor superfamily (Kikutani et al., 1986; 
Matsunaga et al., 1987). The puzzling relationship between the receptor for 
insulin-like growth factor II (IGF-11) and the lysosomal mannose-6-phosphate 
receptor suggests the same (Morgan et al.,l987; Roth, 1988). 
Membrane-associated lectins are thought to function in the clearance of 
glycoproteins and cells from the circulation, in intracellular routing of glyco-
proteins and as recognition determinants between cells. Bacterial surface lectins 
mediate the sugar-specific adherence of bacteria to epithelial cells, which is 
an essential prerequisite for infection. In plants, they may serve as packaging 
aids for other proteins in the so-called protein bodies (Freier et al., 1987). 
1.2.4. Specificity 
Originally it was believed that the specificity of a lectin could be described 
in terms of the monosaccharides that best inhibited lectin-induced agglutination 
of animal cells. MakeHi (1957) suggested that lectin-reactive monosaccharides 
could be divided into four classes based on their configuration at C-3 and C-
4 of the pyranose ring. As yet, no lectin has been discovered that interacts with 
Makela's group IV sugars (idose, gulose, L-glucose, L-xylose). 
Many techniques have been described to determine the carbohydrate specificity 
of lectins. They include: 
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- precipitation reactions 
- hemagglutination reactions 
- equilibrium dialysis 
- UV-spectroscopy 
- fluorescence spectroscopy 
- solid-phase adsorption-elution 
- lectin column chromatography. 
The present work describes lectin-enzyme binding assays. 
In the later years it has become clear that most lectins bind to carbohydrate 
structures extending to three or more monosaccharides (Kabat, 1978). They allow 
some variation at C-2 of the sugars th~t they bind, but in general they tolerate 
very little variation at C-3. The C-4 hydroxyl group is often also critically involved 
in lectin binding. Besides, hydrophobic interaction with protein structures may 
add to the lectin binding. 
1.2.5. Lectin methods 
In recent years methods have been developed to study protein glycosylation. 
Table 1-1 lists a number of methods that have been described. 
Table l-l. Some methods used to study protein glycosylation 
Lectin column chromatography 
Lectin affino-diffusion 
Crossed affino-immuno-electrophoresis 
Isoelectric focusing 
Chromatofocusing 
SDS-PAGE followed by lectin-autoradiography, 
lectino-fixation, 
lectin-enzyme blotting 
Radio-lectin immunoassay 
Enzyme-linked lectin binding assay 
Purification, followed by GLC, NMR or MS 
To describe the exact composition of the glycans of plasma glycoproteins, 
purification of the glycoprotein is necessary, followed by removal and charac-
terisation of the carbohydrates. However, methods have been developed to get 
an impression of the constitution of the glycan chains of the protein while it 
is still present in a mixture or in crude form. These methods use lectins as 
an affinity adsorbent in affinity electrophoresis, crossed affinity immuno-elec-
trophoresis (crossed "affino-electrophoresis") and lectin column chromatography. 
These methods are very time consuming, and do not allow the simultaneous 
binding study of a number of samples with a number of lectins, although the 
latter allows the study of several glycoproteins (Jackson et al., 1988). 
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In conclusion, until recently no sensitive and fast techniques have been 
developed to characterise the glycan chains of a glycoprotein present in a complex 
mixture such as plasma. It is the subject of the present work to develop enzyme-
linked binding assays using lectins to investigate glycoprotein glycosylation. 
1.3. Protein glycosylation 
Concentrations of plasma glycoproteins may change in disease. These changes 
may provide diagnostic information, which will not be discussed here. Inde-
pendently, a number of co-translational or post-translational modifications in 
the structure of glycoproteins may also be found (Rucker et al., 1988; Wold, 
1981 ). Tyrosine sulfation for instance, occurs in trans-Golgi (Baeuerle et al., 
1987). Incomplete precursor peptide cleavage has been observed in liver disease 
(Peters, 1986, 1987). Sulfhydryl crosslinking takes places (Lernmark et al., 1987). 
The non-enzymatic addition of glucose as a fructosamine group to plasma proteins 
and hemoglobin is well established in patients with diabetes (Armbruster, 1987). 
Tests have been developed to quantitate these products. The y-carboxylation 
of some clotting factors may also be modified as the result of nutritional or 
liver disorders (Soulier et al., 1986). And last but not least, modification of the 
enzymatic plasma protein glycosylation may occur. 
Glycosylation occurs in the Golgi system (Kornfeld et al., 1985). Two main 
structures have been discovered: one has a linkage of a Man(Man-) Man- GlcNAc 
- GlcNAc - unit to the amide nitrogen of asparagine of an Asn-X-Ser (Thr) 
sequence on the glycoprotein. The N-linked glycosylation steps are shown in 
figure 1-1. The other is the linkage of a -GalNAc- unit to the oxygen of serine 
or threonine. Examples of the two basic structures are given in figure 1-2. 
Dol 
KEY 
A G!c 
oMan 
• G!cNAc 
C. Fuc 
• Got 
• NeuAc 
® phosphate r----- ---1 
I TRANSPORT TO I 
~ _ L~~O~O_M~~ _; 
Figure 1-1. Intracellular synthesis ofN-linked glycan chains (from Bergeret al., 1982, with permission). 
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NeuNAccx2-6Galj31-4GicNAc/H-2Mana 1 
"6 
Manj31-4GlcNAcj31-4GlcNAcj31-Asn 
3 
/ NeuNAccx2-6Galj31-4GlcNAcj31-2ManO' 1 
NeuNAc0'2-3Galj31-3GalNAcO' 1-Ser(Thr) 
Figure 1-2. The basic N-and 0-linked glycan structures. 
Most proteins present in human plasma carry one or more N-linked 
carbohydrate side chains. A few also have 0-linked chains (Uhlenbruck et al, 
1979). As table 1-2 shows, only albumin and a few minor proteins are not 
glycosylated. 
GLYCO 
Carbohydrate part 
has influence on: 
- half-life 
- solubility 
-
11 homing 11 
- activity of protein part 
- conformation in solution 
- resistance to proteolysis 
- antigenicity 
- cellular uptake and 
processing 
- postsynthesis intracellular 
routing and organelle 
localisation 
- heat stability 
- etc. 
PROTEIN 
Protein part 
determines function: 
- hormone 
- clotting factor 
- transport protein 
- immunoglobulin 
- complement component 
- enzyme inhibitor 
- other 
Text-figure 1-1. Functions attributed to protein part and carbohydrate part of glycoproteins. 
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Table 1-2. Plasma concentration and carbohydrate content of a number of plasma glycoproteins. 
Protein Plasma concentration Carbohydrate content 
(g /I) (%) 
Prealbumin 0.25 0 
Albumin 40 0 
0' 1 -acid glycoprotein I 45 
0' 1-lipoprotein 3 2 
0' 1 -antitrypsin 3 12 
0'2-macroglobulin 3 8 
Haptoglobin 2 16 
Ceruloplasmin 0.2 7 
Fibronectin 0.3 3 
Hemopexin 0.9 23 
Transferrin 2 5 
,8-lipoprotein 3 2 
Complement C3 3 
Fibrinogen 2.5 4 
IgG 12 3 
IgA 2.1 8 
IgM 1.4 10 
CRP 0.01 0 
1.3.1. Roles of glycosylation 
A number of characteristics that have been attributed to the glycan structure 
is given in text-figure 1-1. However, large differences between individual 
glycoproteins have been noted. The role of a certain glycan structure in one 
glycoprotein may not be the same in another glycoprotein. On the other hand, 
certain characteristics appear to be generalized. It has been found that glycan 
structures may carry information that could be clinically useful. For instance, 
organ-specific glycosylation occurs which allows in theory the determination 
of the contribution of an organ to the plasma concentration of a glycoprotein 
(Parekh et a!., 1987; Yamashita et a!., 1983). The determination of the bone 
isoenzyme of alkaline phosphatase by affino-electrophoresis in wheat germ 
agglutinin containing gels is the first application in the clinical setting of a 
separation method based on organ-specific glycosylation (Rosalki et a!., 1986; 
Behr eta!., 1986; Onica eta!., 1987). Possible roles of the glycan chains have 
been reviewed recently (Olden eta!., 1985; West, 1986; Baenziger, 1985; Jourdian 
eta!., 1981; Hatton eta!., 1983; Schachter, 1984; Martinez eta!., 1987; Burgi, 
1988; Rademacher eta!., 1988). 
Table 1-3 lists a number of recent representative reports describing correlations 
between certain cellular or biochemical characteristics and alterations in gly-
cosylation pattern. 
18 
Table 1-3. Cellular and biochemical processes in which glycosylation plays a role. 
Process 
Growth 
Differentiation 
Migration 
Stimulation 
Viral genome expression 
Leukemic transformation 
Metastatic pattern 
Phagocytosis 
cytotoxicity 
Suppressor T-cell activity 
Cell localisation 
Homing 
Adhesion 
Embryonic development 
Aplastic anemia 
Sickle cell anemia 
Thalassemia 
ESR 
Complement lysis 
Plasmodium falciparum invasion 
Mycoplasma pneumoniae attachment 
Hypertension 
Senescent cell removal 
HLA recognition 
IgE synthesis 
B-cell suppressor factor 
Regeneration 
T cell: B cell interaction 
Enzyme activation energy 
Ageing 
Inflammation 
Tumorigenicity 
Hormone receptor binding 
Hormone biological activity 
Plasma protein half life 
Intracellular trafficking 
Glycoprotein activity 
Aberrant blood group expression 
Malignant transformation 
Glycoprotein immunoreactivity 
Reference 
(Ceccarinietal., 1975) 
(Katoaka et a!., 1985) 
(Lin eta!., 1985) 
(Yoheetal., 1985) 
(McClure eta!., 1983) 
(Westrick et al., 1983) 
(Varani eta!., 1983) 
(Sharon, 1984) Nk-cell 
(Pospisil et a!., 1986) 
(Tosato et a!., 1983) 
(Madyastha eta!., 1980) 
(Hooghe eta!., 1984) 
(Rauvala et al., 1983) 
(Lcnnarz, 1983) 
(Yoshida et al., 1987) 
(Riggs et a!., 1977) 
(Rachmilewitz et a!., 1980) 
(Levinsky et al., 1980) 
(Rademaker et a!., 19 81) 
(Cartron eta!., 1983) 
(Loomes eta!., 1984) 
(Reznikova et a!., 19 84) 
(Schlepper-Schdfer eta!, 1983) 
(Pimlott et a!., 1986) 
(Huff eta!., 1986) 
(Fleisher et a!., 19 81) 
(Enrich et a!., 19 8 8) 
(Kearse eta!., 1988) 
(Delanghe eta!, 1988) 
(Nakamura et al., 1988) 
(Hachulla eta!., 1988) 
(Pettijohn eta!., 1988) 
(Ulloa-Aguirre et a!., 19 8 8) 
(Ulloa-Aguirre eta!., 1988) 
(Gross et a!., 1988) 
(Baenziger et a!., 1988) 
(Terasaki eta!., 1988) 
(Yamada eta!., 1988) 
(Hakomori, 1985) 
(Pellegrini et a!., 1988) 
Pregnancy 
Antibody valency 
Subunit assembly 
Fetal development 
IL 1 modulation 
Membrane anchoring 
Immunosuppression 
Enzyme activation energy 
Macrophage migration 
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(Avvakumev eta!., 1988) 
(Margni et a!., 1988) 
(Matzuk et a!., 1988) 
(Wong et a!., 1988) 
(Bories et a!., 1987) 
(Fukuda eta!., 1988) 
(Prokazova et a!., 1988) 
(Delanghe et a!., 1988) 
(Gordon et a!., 1987) 
Tumor ceiis show aberrant cell membrane glycosylation (Warren eta!., 1978; 
Yamada eta!., 1978; Warren, 1981; Yogeeswaran, 1983; Fukuda, 1985; Debray 
et a!., 1986; Bolscher et a!., 1986; Gavazova et a!., 1987; Itai et a!., 1988). 
The neoexpression of certain gangliosides by fibroblasts after oncogene 
transfection points at a possible mechanism at the molecular level (Nakaishi 
et a!., 1988). Tumors also produce plasma proteins (Yoshimura et al, 1978). 
As a result, the aberrant expression of blood group antigens and other carbohydrate 
determinants on the ceil membrane (Tsuji, 1987; Hakomori, 1986) and in plasma 
of patients with cancer (Thompson et a!., 1987) is observed, with diagnostic 
and therapeutic implications (Bernier et a!., 1988). In this context it is of interest 
to note that a number of lectins have been found to posses anti-tumor activities, 
such as the lectins from mistletoe (Holtskog et a!., 1988), from Loach eggs 
(Sarcophaga peregrina) (Yamazaki eta!., 1984; Ohkuma eta!., 1985) from wheat 
germ (Esumi-Kurisu et a!., 19 8 3 ), from Griffonia simplicifolia (Maddox et a!., 
1982; Eckhardt eta!., 1982) and from bitter melon (Momordica charantia) (Jilka 
eta!., 1983). Lectins may also have applications in other diseases (Levi eta!., 
1983). 
A number of compounds have shown to have an influence on the glycosylation 
of glycoproteins and glycolipids, such as estrogens (Raynes, 1982; Dutt et a!., 
1988), monokines (Mackiewicz et a!., 1987) retinoids and hormone-releasing 
hormones. All these agents may have a role as anticancer drugs. The influence 
on glycoprotein hormone glycosylation by glycoprotein-releasing hormones has 
recently been described (Taylor et al, 1986; Mori et a!., 1986; Gesundheid et 
a!., 1986, 1987). The use of releasing hormones (i.e. LHRH and analogs) in 
the therapy of prostatic cancer has been weii established. Retinoids have a 
profound effect on the synthesis of carbohydrate chains (Lotan et a!., 1987; 
Campbel et a!., 1987; Reiss et a!., 1985; Cope et a!., 1984; Nakhasi et a!., 
1984; Kume et a!., 1983; Deutsch et a!., 1983; !etten et al, 1983; Couch et 
a!., 1988). They have been tried as experimental anti-tumor agents (Meromsky 
et a!., 1984, Lotan et a!., 1984) as well as anti-rheumatoid arthritis agents 
(Brinckerhoff et a!., 1985; Bussiere et a!., 1988), diseases in which modified 
glycosylation patterns are involved (Hakomori, 1986, Pekelharing eta!., 1988). 
Thus, the investigation of a number of glycosyltransferases in malignancy has 
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detected important changes in the relative activities of these enzymes (Yazawa 
et a!., 1986). Carcinogens may induce certain enzymes involved in the synthesis 
of carbohydrate structures (Holmes eta!., 1987). 
The importance of carbohydrate structures is also indicated by the fact that 
the recently introduced tumor markers CA 125, CA 19-9, CA 50, CA 15.3, 
CA 1 (Oxford antigen), SSEA-1 and T-antigen are all of carbohydrate nature 
(Feizi, 1985; Hakomori, 1985; Hakomori eta!., 1983, Smets eta!., 1984; Itzkowitz 
eta!., 1986). Simple tests for cancer-associated sugar moieties are being developed 
(Shamshuddin eta!., 1988). 
The investigation of cellular carbohydrate receptors (membrane lectins) during 
development and in tumor tissues is a new and exciting area, with promising 
results both for diagnosis and for therapy of cancer (Lotan et a!., 1988; Raz 
et a!., 1987; Gabius et a!., 1988, 1987 a,b,c; Raz et a!., 1981, 1984; Lotan 
et a!., 1985; Gabius et a!., 1985, 1985, 1985; Gabius et a!., 1984; Roche et 
a!., 1983; Aizawa et a!., 1988). The inhibition of metastatic potential by certain 
saccharides and glycosidases underlines the importance of cell-cell recognition 
mechanisms by membrane lectin - carbohydrate interaction (Wright et a!., 1988; 
Beuth et a!., 1987). 
Summarizing, the patterns of glycosylation of glycoproteins and glycolipids 
show interesting correlations with processes of development and disease, although 
their precise functions are largely unknown at present. 
1.3.2. Changes in plasma glycoprotein glycosylation 
Approximately ten years ago, using a rat hepatocyte plasma membrane 
inhibition assay, elevated levels of "serum desialylated glycoproteins" were 
detected in patients with hepatobiliary dysfunction (Marshall et a!., 1978; Arima 
et a!., 197 6, 1977). In cirrhosis greatly increased quantities of a heterogeneous 
population of desialylated glycoproteins are present in serum, responsible for 
inhibition of the hepatocyte membrane assay (Marshall et a!., 1978). The term 
"asialoglycoproteinemia" was introduced a few years later to describe a most 
unusual finding of a generalized absence of sialic acids from plasma glycoproteins 
in a patient with primary hepatic cancer (Sobue et a!., 1980). Subsequently, 
a modified assay was developed to quantitate asialoglycoproteins in serum (Byrn 
et al., 1984). In patients with chronic liver disease or liver cell carcinoma 
"hyperasia1oglycoproteinemia" was found (Sawamura et a!., 1984). Hepatoma 
cells in culture indeed synthesize abnormally glycosylated glycoproteins (Carlson 
et al., 1984). 
In the following paragraph the modifications are described of the glycosylation 
during development and disease of the few plasma g1ycoproteins for which this 
aspect has been recently investigated. These proteins include the tumor products 
0'-fetoprotein (AFP) and chorionic gonadotropin (HCG) which are aberrantly 
glycosylated by the tumor cells, as well as ubiquitous plasma proteins such as 
IgG, transferrin and 0'1-acid glycoprotein for which altered glycosylation has 
been described. 
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1.3.2.1. Transferrin 
With respect to its glycan structure, transferrin is one of the best characterized 
glycoproteins. Human plasma transferrin contains two N-linked diantennary 
glycans, at aminoacid positions 413 and 611 (Spik et a!., 1975; Macgillivray 
et a!., 1982). 
tetra-sialo penta-sialo hexa-sialo transferrin 
Figure 1-3. The g1ycosylation of human transferrin (from de Jong et a!., 1987, with permission). 
Small amounts of tri-antennary and even tetra-antennary chains do occur 
(Wong eta!., 1978; Marz eta!., 1982; Spik eta!., 1985). Thus, 4-sialo transferrin 
is the major compound, followed by the 5-sialo and 3-sialo variants. Other sialo 
variants occur as minor fractions in plasma as well as in cerebrospinal fluid, 
amniotic fluid and synovial fluid, although the various patterns (obtained with 
crossed immunoelectrofocusing) are clearly different (van Eijk et al., 1983; Arrer 
et a!., 1987). In contrast to cell membrane glycans, the half-life of the plasma 
transferrin glycan probably equals that of the protein part of molecule (Josie 
eta!., 1987). 
Changes in the glycosylation of plasma transferrin have been described (Jaeken 
et a!., 1984; van Eijk et al., 1987; Bierings et a!., 1987; Poupon et al., 1985; 
Stibler et a!., 1986; van Noort et a!., 1987). As the liver is the major transferrin 
producing organ (but not the only one (Kitada et a!., 1985; Lum et al., 1986; 
Yoshimura et a!., 1978; Morrore et a!., 1988)), liver pathology may lead to 
a different distribution of the transferrin subfractions. Changes in tissue car-
bohydrate receptors, leading to changes in half-lives of glycoprotein subfractions, 
may also play a role as well as alterations in biosynthesis. 
Hepatoma cell cultures secrete abnormally glycosylated proteins such as 
transferrin, a 1-antitrypsin, a 1-chymotrypsin and a 1-acid glycoprotein (Carlson 
et a!., 1984; Aim et al. 1985). In patients with hepatoma this defect is not easy 
to recognize because the proportion of hepatoma-produced glycoproteins is small 
compared to their normally glycosylated counterparts produced by the healthy 
part of the liver. One case has been described of a hepatoma patient producing 
very large amounts of asialoglycoproteins, enough to be detected with immuno-
electrophoresis (Sobue et al., 1980), a technique which is usually too insensitive 
in detecting these modifications. 
In patients with cirrhosis, a disease affecting the liver as a whole, the less 
sialylated transferrin subfractions with pi values of 5.7 and 5.9 are significantly 
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elevated (Poupon et al., 1985). A method has been described to quantitate these 
fractions in the clinical setting (Stibler et al., 1986). On the other hand, liver 
cancer plasma samples were not different from controls. This finding does not 
exclude abnormal glycosylation, as higher branching but incomplete sialylation 
may lead to a normal distribution pattern with respect to isoelectric points. 
Uncharged additional sugar groups are not detected using methods based on 
charge differences. They may be detected by binding studies with lectins that 
are sensitive for the branching pattern of the glycans. 
Stibler and Borg showed the incomplete sialylation of transferrin from 
alcoholics in a number of studies (Stibler et al., 1981, 1986). Others have confirmed 
these findings using chromatofocussing, indicating an increase in the pi 5.7 
component (Storey et al., 1987; Petren et al., 1988). Carbohydrate analysis of 
purified whole transferrin showed that not only were sialic acids missing, but 
also some galactose and N-acetyl-glucosamine units. Even the mannose content 
was diminished (Stibler et al., 1986). The different reductions of these sugars 
indicated that apart from incomplete synthesis, an altered structural composition 
may also occur. Using chromatofocusing, desialy1ated transferrin in serum was 
separated from normal transferrin. Only in alcoholic subjects were values raised 
above 2% as measured by radioimmunoassay (Storey et al., 1987). Notably, 
no raised values were found in non-alcoholic steatohepatitis patients, in diabetes 
patients and in non-alcoholic liver disease patients. The results from patients 
with steatohepatitis were of particular interest because their liver disease is 
morphologically indistinguishable from alcoholic hepatitis. The test for desi-
alylated transferrin compared favourably with routinely used blood tests such 
as MCV, '}'-GT, uric acid, ASAT, ALAT, LDH, alkaline phosphatase and HDL 
(Storey et al., 1987; Gjerde et al., 1988). It is the first test to provide a retrospective 
quantitation of alcohol consumption, reminiscent to the Hba1c assay as a long-
term control for glucosemia in diabetic patients. Using isoelectric focusing and 
crossed immunoelectrophoresis in the second dimension a shift to higher sialylated 
forms of transferrin was noted in various other diseases (van Eijk et al., 1987). 
Other charged molecules or abnormal linkages may also be involved (Narita 
et al., 1987). 
1.3.2.2. Alpha-Fetoprotein 
AFP is a glycoprotein of 69000 Dalton molecular weight. It contains one 
N-linked diantennary glycan which is responsible for the heterogenity of AFP. 
Fetal production starts in the yolk sac, where the Con A non-binding form 
is produced having a bisected diantennary glycan. In the second trimester of 
pregnancy the fetal liver takes over and produces AFP of the Con A binding 
form having a non-intersected biantennary glycan. This is an example of tissue-
specific glycosylation. After 33 weeks AFP synthesis decreases sharply with 
a concomitant increase in the synthesis of a very similar but non-glycosylated 
protein: albumin. 
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Apart from a change in Con A binding due to a shift from a intersected 
to a non-intersected glycan, the Lens culinaris (LCA) binding changes as well 
(Toftagar-Larsen et al., 1983). As LCA binds fucosylated diantennary glycans 
(Kornfeld et al., 1981) the observed reduction in binding indicates a shift in 
a 1-6 fucosylation of the first N-acetyl-glucosamine of the glycan towards less 
fucose incorporation. 
Abnormalities in the developmental changes of both the Con A and the 
LCA binding AFP fractions have been found in a number of neural tube defects 
and other fetal abnormalities (Toftagar-Larsen et al., 1983; Buamah et al., 1981; 
Kolho et al., 1983; Mackiewicz et al., 1984). Thus, the quantitation of the Con 
A and LCA binding fractions has been devised as an ancillary diagnostic test 
in pregnancy, next to the AFP concentration in serum or amniotic fluid, although 
Con A-results have been challenged (Jones et al., 1988). 
In adults, AFP reappears in serum of patients with primary hepatomas and 
germ cell tumors, especially endodermal sinus tumors. This observation has led 
to the idea of oncofetal gene expression. However, the relationship with 
histological findings is inconsistent AFP-producing and non-producing cells may 
be present in the same tumor. Some tumors produce AFP but do not secrete 
the material into the circulation. (This may be caused by aberrant AFP 
glycosylation). Teratocarcinomas often consist of a mixture of cell types, some 
of which have been shown to produce AFP while others do not Hepatoblastomas 
on the one hand, and pure endodermal sinus tumors on the other always seem 
to produce AFP. The glycosylation of AFP in the two groups is different Yolk 
sac tumor AFP is Con A non-binding because it contains an intersecting GlcNac, 
just as fetal yolk sac AFP (Yamashita et al., 1983; Tsuchida et al., 1984). 
Hepatoma-produced AFP is glycosylated the same as fetal liver AFP: it contains 
a fucosylated diantennary glycan (Yoshima et al., 1980). 
Using three galactose specific lectins (from Allomyrina dichotoma, from 
Ricinus communis and from Phaseolus vulgaris) large differences in reactivity 
of AFP fractions were found. Tumor associated fractions were detected but 
patterns varied between patients indicating heterogeneity between tumors (Taketa 
et al., 1986). In conclusion, the differential reactivity of serum AFP towards 
Con A and lentil lectin provides a simple test which has its place in the diagnosis 
of various liver diseases (Buamah et al., 1987; Aoyagi et al., 1988; Breborowicz, 
1988). 
1.3.2.3. a 1-acid glycoprotein (AGP) 
AGP is an unusual plasma glycoprotein. It has an extremely low pi of 2.9, 
partly due to the large number of sialic acids present on the molecule. AGP 
contains 5 highly branched N-linked glycans; its carbohydrate accounts for 45% 
of its molecular weight of 44.000 daltons (Fournet et al., 1978). It is an acute 
phase protein with normal plasma concentrations between 0.6 and 1.4 g /l. 
In a number of diseases the glycan composition of AGP is modified (Moule 
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et a!., 1987; Bleasby et a!., 1985). In hepatic disorders desialylation of AGP 
is found (Serbource-Goguel et a!., 1983). A number of cancers induce altered 
lectin binding as shown with crossed affinoimmunoelectrophoresis (Hanson et 
a!., 1984) indicating changes in the di-triantennary glycan ratio. The glycan 
composition of AGP isolated from liver metastases of lung, colon and breast 
tumors is different from plasma AGP. a 1-6 fucose linked to the diantennary 
chain is also a unique finding (Chandrasekaran et a!., 1984). In patients with 
rheumatoid arthritis significant changes in the microheterogeneity patterns were 
observed (Mackiewicz eta!., 1987). 
The physiological role of AGP is unclear. It has chemokinetic and immu-
nosuppressive properties, dependent on the composition of the carbohydrate 
groups (Castello et a!., 1984; Cheresh et a!., 1984; Bennett et a!., 1980). In 
the pig, AGP is the major fetal serum protein (50% of total), decreasing to 
0,3% in the adult pig (Lampreave et a!., 1984). This development-dependent 
change in concentration is accompanied by an increase in fucose content and 
in Con A binding. The modifications ofthe N-glycans offour acute phase proteins 
in patients with severe burns was recently investigated (Mallet et a!., 1987). 
A major shift towards diantennary glycans in a 1-acid glycoprotein as well as 
in a 1-antitrypsin was detected using Con A-Sepharose column chromatography. 
1.3.2.4. Immunoglobulin G (IgG) 
The plasma of patients with rheumatoid arthritis (RA) contains aggregated 
immunoglobulins (Mannik et a!., 1985). These so-called "immune-complexes" 
differ from antigen-antibody complexes in several ways. Because of the absence 
of antigen it is suggested that the aggregates consist of certain immunoglobulins 
with affinity for other immunoglobulins (autoantibodies). The strength of the 
interaction between the immunoglobulins (Ka = 105 M- 1) is less than that observed 
for normal antigen-antibody interactions, indicating that a different type of 
interaction may be involved. 
Immunoglobulin G is a major plasma glycoprotein containing, on average, 
2.8 N-linked carbohydrate chains per molecule of which 2 are located in the 
Fe fragment (Rademacher eta!., 1984; Mizuochi eta!., 1982). The carbohydrate 
chains consist of a variety of diantennary complex-type structures, some 
containing an extra "bisecting" N-acetylglucosamine or a fucose residue (Mi-
zuochi et al., 1982). 
The recent finding of a reduced galactosylation of the diantennary carbohydrate 
chains of total IgG (Parekh et al., 1985; Pekelharing et al, 1988; Tomana et 
al., 1988) in patients with RA, due to a reduced B-cell galactosyltransferase 
(Axford et al, 1987) has led to a new hypothesis concerning the aggregation 
of IgG molecules (Parekh et al., 1985). Less sugar constituents in the N-linked 
glycans of IgG could make IgG more "sticky" due to a lectin-like activity. 
IgG from RA patients bound significantly more to the immobilised plant 
lectins Concanavalin A and Peanut agglutinin than IgG from normals (Malaise 
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et a!., 1986, 1987). This could either be due to a modified IgG glycosylation 
(Parekh et a!., 1985), or due to an altered conformation of IgG (Hansson et 
a!., 1985) or both, leading to a change in lectin binding. Our own results (chapter 
5.2) suggest a decrease in IgG galactose content in RA patients and an increase 
during pregnancy, which might explain the temporary remission ofRA commonly 
observed during gestation (Pekelharing et a!., 1988) 
1.3.2.5. Human Chorionic Gonadotropin (HCG) 
HCG is a glycoprotein hormone produced by the placental trophoblast and by 
choriocarcinoma tissue, and secreted into serum and urine. It is composed of 
two dissimilar subunits, a and /3, joined non-covalently. The common a subunit 
also occurs in the hormones LH, FSH and TSH, while the hormone-specific 
{3 units are different (Green et al., 1986). Both a- and {3-subunits contain two 
asparagine-linked sugar chains, the {3-subunit of HCG contains an additional 
four 0-linked sugar chains (Pierce et al., 1981). The carbohydrate residues appear 
to be essential for the biological activity of the hormones. (Sairam et al., 1985; 
Manjunath et a!., 1982; Rosa et al., 1984; Kalyan et al., 1983; Baenziger et 
al., 1988). 
The asparagine-linked sugar chains of choriocarcinoma HCG are quite 
different from the normal hormone (Mizuochi et al., 1983; Imamura et al., 1987; 
Takeuchi et al., 1984; Koyama et al., 1986; Cox, 1986; Nishimura et al., 1985; 
Yazaki et al., 1987; Endo et al., 1987, 1988). The number of sialic acid groups 
is highly decreased or increased, while unique triantennary glycans are present 
together with anomalous biantennary chains. Increased a 1-6 linked fucose was 
also found. By contrast, the HCG purified from patients with hydatiform mole, 
one of the trophoblastic diseases, gave almost the same profile of asparagine-
linked sugar chains as that of normal HCG. 
A method designated by the authors as a lectin-immunoradiometric assay 
(LIRMA) was developed to quantitate desialylated forms of HCG in urine 
(Imamura et al., 1987) Both with RCA, which recognises Galf31-4GlcNAc, as 
with PNA, which recognises Galf31-3GalNAc, elevated levels were found in 
patients with choriocarcinoma compared to pregnant women and hydatiform 
mole patients. This indicates loss of sialic acids both from the N-linked as well 
as the 0-linked glycans (Endo et al., 1988). 
The major difference in 0-glycosylation of HCG or its subunits produced 
in choriocarcinoma and in pregnancy appears to be the abundance of the 
hexasaccharideNeuAca 2-3Galf31-3(NeuAca2-3Galf31-4GlcNAc{31-6) GalNAc 
in tumor HCG (Cole, 1987 a,b). 
A major question left to be answered concerns the link between malignancy 
and abnormal glycosylation of cell membranes and secretory proteins (Kobata, 
1988). The glycosylation of most proteins produced by tumors studied thus far 
suggest that this relation indeed exists. But is it a prerequisite or an 
epiphenomenon? 
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1.3.2.6. Fibrinogen 
Fetal fibrinogen contains more sialic acids than the adult form, as a function 
of gestational age (Francis et al., 1982; Galanakis et al., 1983). It also contains 
more phosphate while being less active in the clotting process (Witt et al., 1982). 
At birth the major difference between fetal (cord) and adult fibrinogen appears 
to be the 3-4 times higher phosphorus content of cord fibrinogen (Hamulyak 
et al., 1983). The ESR changes in pregnancy may partly be due to an abnormal 
fibrinogen glycosylation (Ozanne et al., 1983). Fibrin formation by thrombin 
is accelerated when less sialic acids are present on fibrinogen (Galanakis et 
al., 1983; Martinez et al., 1983a; Diaz-Maurino et al., 1982). Others report no 
differences in clotting activity between the glycosylated and non-glycosylated 
forms of fibrinogen (Gilman et al., 1984). 
In liver disease fibrinogen contains more sialylated (Martinez et al., 1983a) 
and more branched glycans (Martinez et al., 1983b). Especially during acquired 
dysfibrinogenemia of liver disease the sialic acid content of fibrinogen is increased 
considerably (Martinez et al., 1983). In liver cirrhosis the modified fibrinogen 
with its higher sialylation shows characteristics similar to those of fetal fibrinogen 
(Narvaiza et al., 1986). Increased sialyltransferase might be at the basis of the 
increased sialic acid content (Francis et al., 1986; Simmonds et al., 1987). 
From this short overview it is concluded that techniques to quantify the different 
glycosylation states of plasma glycoproteins would be helpful in a number of 
instances, both in diagnosis and for monitoring therapy. It is a logical choice 
to develop techniques using lectins: the carbohydrate binding proteins of non-
immune origin. 
1.4 Use oflectins in sandwich EUSA techniques 
In clinical chemistry, a very sensitive and specific assay is the enzyme-linked 
immunosorbent assay (ELISA), first described by van Weemen et al. (1971) 
and Engvall et al. (1972). 
Basically, it consists of an antibody coated solid phase provided by plastic 
tubes, balls or microtiter plates. After incubation with a nonsaturating amount 
of the protein to be measured, a second antibody linked to a marker enzyme 
is added. A standard curve relates the amount of protein present in the sample 
to the amount of enzyme activity bound to the tube. This type of assay is called 
the "sandwich" or two-site ELISA. 
In theory, by replacing either the immobilized antibody or the enzyme-linked 
antibody with a lectin or other carbohydrate-binding protein, it is possible to 
create a heterologous Lectin-Enzyme Immuno-Assay system (LElA) to study 
the glycosylation of a glycoprotein (fig. 1-4). The "sandwich" now consists of 
a lectin and an antibody. Only the protein that meets two conditions is measured; 
type 1 
+>------
• >------
• 
• 
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Figure 1-4. The two types of "sandwich" Lectin Enzyme Immuno-Assay (LEIA) using immobilized 
lectin (type 1) or enzyme-linked lectin (type 2). 
i.e. it must be the right glycoprotein to be bound by the antibody, and it must 
have the right glycan structure to bind the lectin used. The lectin may replace 
either the immobilized or the enzyme-bound antibody. 
In the first type of assay a lectin is immobilized and binds the glycan chain 
of the glycoprotein in question. The amount of protein is subsequently quantitated 
using the enzyme-linked antibody as in the ELISA-technique. This type of assay 
has a potential drawback. The immobilized lectin also binds glycans which are 
connected to other glycoproteins, thus creating a "cross-reactivity" with other 
glycoproteins present in the sample. This could strongly influence the results 
for the glycoprotein under study. 
In the second type of assay the antibody-enzyme conjugate is replaced by 
a lectin-enzyme conjugate. Antibodies to the glycoprotein are immobilized on 
the solid phase as in the ELISA technique. In contrast to the ELISA, saturating 
amounts of the glycoprotein should now be used, after which the lectin reactive 
fraction is quantitated by adding the lectin-enzyme conjugate. The drawback 
of the first type of assay, interference from other glycoproteins in the sample, 
may not be present here, because in theory the immobilized antibodies can only 
bind the glycoprotein against which they were raised. The sensitivity of the 
assay should be better as more glycoprotein material is captured in this system. 
Thus, the second type has an important advantage over the first, because in 
theory, purification of the glycoprotein is not necessary. During the incubation 
of the sample with the immobilized antibody only the specific glycoprotein antigen 
is recognized and bound, and all other proteins remain in solution and are washed 
away. In principle, therefore, this assay should also be able to investigate the 
glycosylation of an individual glycoprotein present in a complex mixture such 
as human plasma. However, as the non-specific binding of enzyme-linked lectin 
to coated antibody immunoglobulins was considered to be a substantial drawback 
to using the type 2 system, the type 1 system was first investigated. 
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1.5 Aim of the study 
The aim of this work is to determine if lectins can be used in "sandwich" 
ELISA techniques so that the glycosylation of specific proteins in mixtures could 
be characterised in a fast and sensitive way without prior purification of the 
protein. Furthermore, the feasability of lectin-enzyme binding assays will be 
explored in various ways to assess the lectin specificity, and to detect the binding 
of lectins to normal plasma glycoproteins and their disease-associated glycoforms. 
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CHAPTER2 
PROSPECTS FOR LECTIN-ENZYME IMMUNOASSAYS 
USING A LECTIN AS THE IMMOBILISED BINDER, 
INVESTIGATED BY LECTIN COLUMN CHROMATOGRAPHY 
OF NORMAL HUMAN PLASMA 
2.1. Introduction 
For the development of enzyme-immunoassays with a lectin as the immobilised 
binder, two criteria must be met. Firstly, under normal conditions, very few 
glycoproteins in plasma must have carbohydrate structures to which the utilised 
lectin can bind. A review of the literature suggested that sialic acid loss from 
glycoproteins with concomittant terminal galactose expression occured in certain 
liver diseases. Thus, it was· reasoned that with galactose-binding lectins as 
immobilised binders in a two-site lectin-immunoassay it would be possible to 
quantitate sialic acid loss from plasma glycoproteins. Ideally the lectin used 
should bind only to the incompletely sialylated plasma glycoprotein in question, 
without binding to other asialo glycoproteins and without binding the normal 
fully sialylated glycoproteins. An enzyme-linked antibody could then simply detect 
and quantitate the amount of (galactose-terminal) glycoprotein bound, as in the 
ELISA-system. As terminal galactose expression in normal plasma seemed to 
be quite low (Byrn et al., 1984) the problem of "cross-reactivity" and inhibition 
by other galacto-glycoproteins present in plasma was expected to be low. 
Secondly, the lectin used must adhere onto plastic tubes or microtiter plates 
and still show its binding characteristics. This was not considered to be a problem 
as many glycoproteins (such as immunoglobulins) adhere to plastic without losing 
their binding affinity or other characterstics. Lectins show quite a peculiar reaction 
pattern with glycoproteins. The precipitation of ten galactose-specific lectins 
with purified plasma asialo glycoproteins in gel diffusion experiments was 
determined by Uhlenbruck et al. (1978) (table 2-1). 
No clear pattern with respect to binding preference can be seen. However, 
the number of glycans linked to the glycoproteins seems to play a role. If the 
results are presented with respect to the estimated number of glycans per protein 
(table 2-2) it becomes clear that this characteristic is important in lectin-
glycoprotein interactions. 
It appears that the more glycans a protein has, the more chance it has to 
overcome spatial restrictions in the binding to lectins that otherwise inhibits 
precipitation in gels. Alternatively, due to the weak interaction of lectin and 
glycan (with a typical Ka of 104 M- 1) it may be a prerequisite for some lectins 
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Table 2-1. Precipitation of asialo glycoproteins by lectins (Uhlenbruck et a!., 1978; Luther et a!., 
1980). 
+ 
++ 
* 
nd 
Serum glycoprotein Precipitating lectins from 
after neurarnindase- Tridacna Tridacna Rutilus Ricinus 
treatment maxima gigas rutilus communis 
Antithrombin III + + 
Haemopexin ++ + + 
Transferrin + 
a 1S-Glycoprotein + 
++ 
Fetuin + ++ 
e2-Glycoprotein ++ + 
++ 
Cholinesterase ++ + ++ ++ 
a 1B-Glycoprotein 
+ + 
3,ls-a2-Glycoprotein 
++ ++ 
a 1-Antitrypsin 
+ ++ 
a 2HS-Glycoprotein 
+ 
a 2-Macroglobulin ++ + 
+ ++ 
a 1 -Antichymotrypsin 
++ + ++ ++ 
8s-a 3-Glycoprotein 
++ ++ ++ + 
e2-"Glycoprotein III 
++ 
Go-Globulin + 
Secretory component ++ + + ++ 
Lactoferrin ++ + + 
Prothrombin ++ + 
Inter-a-trypsininhibitor + ++ ++ 
C3-Activator ++ + ++ 
3,8s-a2-Glycoprotein ++ 
Coeruloplasmin + ++ ++ 
Cl-Inactivator + + ++ ++ 
9, 5S- '\-Glycoprotein ++ ++ 
Haptoglobin ++ + + ++ 
Thyroxin binding ++ + + ++ 
globulin 
IgA + ++ 
IgM + + + + 
IgD + ++ 
IgG + 
IgE ++ ++ + ++ 
no pricipitin reaction 
weak, but good visible precipitin reaction 
strong, sharp precipitation line 
precipitation identical with both native and neuraminidase-treated glycoproteins 
not done 
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Glycine Ononis Axinella Abrus Wistaria Vi scum 
soja spinosa polypoides precatorius floribunda album 
+ + + 
++ ++ + + 
nd + 
+ ++ + + 
+ ++ + + + 
++ ++ ++ ++ + 
++ ++ + ++ + + 
+ nd nd 
+ ++ ++ 
+ 
+ + 
+ ++ ++ ++ + + 
++ ++ ++ + + 
++ ++ ++ + + 
++ ++ ++ nd nd 
+ ++ ++ 
+ + 
+ ++ + + + 
+ + ++ 
+ + 
+ + + + + 
+ ++ ++ + + 
+ ++ + 
++ ++ ++ + + 
+ ++ ++ + 
++ ++ + + 
++ ++ + + 
+ + 
+ 
++ ++ ++ ++ + + 
LECTIN 
AXINELLA POLYPOIDES ++ + 
TRIDACNA GIGAS + + + + + + + 
RUTILUS RUTILUS ++ + + ++ ++ + + 
GLYCINE SOJA ++ + + ++ + + + + ++ 
WISTARIA FLORIBUNDA + + + + + + + + + 
VISCUM ALBUM + + + + + + + + + + 
ONONIS SPINOSA ++ ++ ++ ++ ++ ++ ++ + ++ 
TRIDACNA MAXIMA + ++ ++ + ++ ++ + ++ + + ++ 
ABRUS PRECATORIUS + + ++ + ++ + ++ + + + ++ ++ + + ++ + 
RICINUS COMMUNIS + + + - + ++ ++ ++ + ++ ++ + ++ ++ ++ ++ ++ ++ ++ 
GC TF a2 8 2 AAT AT 3,8S a 1 3 1 lS I Cer IgD 
82 al IgG HS I TBG III C3 a2 Hpx s a2 IgA T Hap 
III B act 
1 1 2 2 2 3 3 3 3 4 4 4 5 5 5 5 6 6 6 6 
Table 2-2. Asialo glycoprotein precipitation by lectins in relation to the number of glycans of the 
glycoproteins (adapted from Uhlenbruck et al., 1978). (·=not done). 
++ + 
+ ++ + 
++ + ++ ++ 
++ ++ + 
+ + + 
+ + + + 
++ ++ ++ 
++ ++ + ~ 
++ ++ ++ 
N 
++ 
++ ++ ++ ++ 
IgE CA 
ACT 9,5S inact 
o.l 
7 10 11 18 
estimated number 
of glycans per 
molecule 
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to have multiple interactions before precipitation occurs. However, the sensitivity 
for the number of glycans differs between lectins. 
To study the terminal galactose expression of plasma glycoproteins and to 
find a lectin with the desired specificity the binding of normal plasma glycoproteins 
and their asialo derivatives to a number of galactose specific lectins was 
determined. We used nine galactose-specific lectins immobilised to Sepharose 
to fractionate plasma glycoproteins according to their galactose expression. Both 
the bound and the unbound fraction were analysed with crossed immuno-
electrophoresis to detect and classify any plasma glycoprotein with affinity for 
the immobilised lectin. A laser nephelometer was used to quantify the con-
centration of the most common proteins in both fractions. 
2.2. Materials and Methods 
The following lectins were used, either immobilised (5 mg /ml gel) by the 
supplier (E.Y. Laboratories, San Mateo, Calif., USA) or in our laboratory (*) 
using CNBr-activated Sepharose (Pharmacia, Uppsala, Sweden): 
* Tridacna squamosa (TSA) 
* Crotalariajuncea (CJA) 
* Bandeira simplicifolia I (BSI) 
Ricinus communis (RCA) Madura pomifera (MPA) 
Abrus precatorius (APA) 
Sophora j aponica (SJ A) 
Arachis hypogaea (PNA) 
* Vi cia villosa (VV A) 
For immobilisation of lectins the following procedure was used: 0.6 gr CNBr-
Sepharose was washed for 15 minutes in 1 mM HCl, then washed with buffer 
A (0.1 M NaHC03 /Na2C03 + 0.5 M NaCl, pH 8.3). Lectin was added (10 
mg in 4 ml buffer A) and incubated for 2 hours at room temperature and for 
16 hours at 4°C. Remaining active groups were blocked with 5 ml 0.1M 
ethanolamine (pH 8.0). The gel was then washed 4x, alternating with buffer 
A and buffer B (0.1 M acetate buffer, pH 4.0). After a final washing with PBS 
(0.1 M phosphate buffer, pH 6.8 with 150 mM NaCl) the gel (2 to 3 ml) was 
allowed to settle in a glass column (internal diameter 7 mm). As a reference 
a column with unconjugated Sepharose was used. Lectin column chromatography: 
0.3 ml of a normal human serum pool, either untreated or neuraminidase treated, 
was brought onto the column and incubated for 30 minutes at room temperature. 
Before and after application of serum the column was washed with 0.1 M Tris 
buffer, pH 8.0, containing 1 mM ca++ and 0.1 mM Mn++. Fractions were 
monitored at 254 nm (Uvicord, LKB Produkter, Bromma, Sweden). Bound 
material was eluted with 5 ml Tris buffer containing 100 mM galactose, after 
which the column was regenerated and washed with 0.1 M acetate buffer, pH 
4.5. 
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Crossed immunoelectrophoresis was run according to standard procedures. 
Briefly, a 1 mm thick 1% agarose gel was used in 37.5 mM veronal buffer, 
pH 8.6 on glass plates (9.4 x 8.2 em). Sample volume was 5 J.tl of the unbound 
or bound fractions. A Multiphor electrophoresis unit (LKB) was used: the first 
dimension was run for 1 hour at 300 Volts, the second dimension for 5 hours 
at 100 Volts (after application on the gel of polyvalent antiserum diluted 1:5 
or 1:1 0). Patterns were interpreted by visual inspection. 
Kinetic immunonephelometry was performed using a Baker 420 laser 
nephelometer (Baker Instruments, Allentown, USA) according to the manufac-
turers instructions. The antisera were obtained from Behringwerke, Marburg, 
Germany. We analysed the unbound and bound fractions and the untreated normal 
serum for their concentrations of transferrin (TF), a 1-acid glycoprotein (AGP), 
haptoglobin (Hp), IgA, IgG and albumin (Alb). Albumin served as an internal 
reference to detect any carry-over during lectin column chromatography from 
the unbound to the bound fraction. As it contains no carbohydrate, it should 
be found in the unbound fraction only. Immobilised neuraminidase (1 U) from 
Vibrio cholerae (Behringwerke) was used to pre12are asialo-serum glycoproteins: 
0.3 ml normal serum was incubated on the column in 0.05 M sodium acetate 
buffer pH 5.5 containing 0.15 M NaCl and 9 mM ca++ for 1 hour at room 
temperature. 
2.3. Results 
Serum glycoproteins did not bind to Sepharose or to Sepharose conjugated 
with any of the following lectins: BSI, SJA, VVA, PNA and TSA. Elution of 
these columns with galactose produced no absorption peak at 254 nm and no 
precipitation arc was found in the crossed immunoelectrophoretic analysis of 
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the "bound" fraction, and no arc was found to be absent using this analysis 
· in the unbound fraction. By contrast, some proteins are bound to the other lectins 
(table 2-3). 
Table 2-3: Analysis of sialo- and asialo glycoproteins from normal serum separated on immobilised galactose-bith..ting 
lee tins 
I Lectin I Crossed immunoelectroP:horesis I Laser ne2helomet!1 
I I I 
I 
I 
I I Present in bound Missing in unbound I Percent of protein present in bound fraction I 
I I fraction fraction I (in parentheses: neuraminidase treated serum) I 1---1 I I I I 
I I I TF I AGP I Hp I IgA I IgG I Alb I 1---1 I 1---1 I I l---1 I I I 
I RCA \ veak a band I I I I I I I 
I I ~e~ee ~ ~ ~:~~ a 2 bands I 0 (100) I o (100) 1 100 (100) I 70 (100) I 10 (10) I 0 (0) I I I I I I I I I l---l I 1 ___ 1 I l---l---l I I I I 
I HPA I y band y band I 0 (0) I 0 (0) I 0 (0) I 70 (100) I 0 (0) I 0 (0) I l---l I l---l I l---l---l I I 
I APA 1 tva veak a -bands I 0 (trace) I 0 (0) I trace I 0 (0) I 0 (0) I 0 (0) I 
I I ' I I I (trace) I I I I \---\ I l---l I l---l---l I I I CJA \ veak band in I 0 (0) I 0 (0) I trace I 0 (0) I 0 (0) I 0 (0) I 
I \ Albumin region I I I (100) I I I I 
I I 
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Although all lectins used are galactose specific (that is: are best inhibited 
by galactose), they displayed large differences in their affinity for (asialo) 
glycoproteins. This observation has been reported earlier for lectin-glycoprotein 
precipitation during "affino-diffusion" in gels using purified neuraminidase-
treated serum glycoproteins (Uhlenbruck et al., 1978). 
Of the lectins tested, Ricinus communis agglutinin binds to the most plasma 
glycoproteins. It binds all haptoglobin and a major portion of IgA from normal 
serum. This could be IgA 1, since the lgA binding galactose-specific lectin 
("Jacalin") from jackfruit (Artocarpus integrifolia) (Roque-Barreira et al., 1985) 
seems to bind only to IgA 1 (Kondoh et a!., 19 86). Besides binding to some 
IgG, possibly IgG3 (Saltvedt eta!., 1975), immunoelectrophoresis showed binding 
to at least two other as yet undefined glycoproteins present in normal serum, 
probably a2-macroglobulin, ceruloplasmin or IgM (Surolia et a!., 1975; Harboe 
eta!., 1975). Using neuraminidase-treated serum the unselective binding of RCA 
to asialo glycoproteins was confirmed: it binds to all of the TF, AGP, Hp and 
IgA present. 
The other lectins are more selective than RCA. MPA binds only IgA. APA 
binds only traces of transferrin and haptoglobin, and CJA binds a trace of 
haptoglobin and binds asialohaptoglobin: 
2.4. Discussion 
The original idea of a galactose-specific lectin as the immobilised binder in 
a lectin enzyme immunoassay for galacto- transferrin was based on the assumption 
that the lectin does not bind normal plasma glycoproteins, whilst still binding 
the glycoprotein under study, which has a loss of sialic acids. However, depending 
on which galactose-specific lectin is chosen for the experiments, both substantial 
binding to other sialoproteins than transferrin and inability to bind to asialo-
transferrin can be observed. 
This means that non-saturating conditions should be used to avoid competition 
in the lectin enzyme immunoassays for the limited number of immobilised lectin 
molecules by other galacto-glycoproteins in plasma. Since we found such extensive 
plasma glycoprotein galactose expression, as measured with a number of galactose 
lectins, this indicated that large dilutions of sample were necessary. Given the 
sensitivity of ELISA techniques, this meant that only massive sialic acid loss 
from transferrin could be detected in a system which makes use of immobilised 
galactose-specific lectins. As shown in table 2-3, there is one combination of 
lectin and (asialo) glycoprotein in which type 1 lectin-enzyme immunoassay 
might work. Crotalariajuncea lectin binds only one (undetermined) normal plasma 
glycoprotein. Of the six major plasma glycoproteins in their asialo form only 
haptoglobin binds. 
The agarose-linked lectins RCA and PNA were used with 1251-labeled anti-
HCG in a lectin-immunoradiometric assay (LIRMA) to quantitate urinary 
desialylated HCG in patients with choriocarcinoma (Imamura et a!., 1987). 
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Significantly elevated levels were found in comparison with normal pregnancy 
or hydatiform mole. The binding of the radio labeled antibody to the immobilised 
lectin was approx. 10% of the maximum signal (highest standard) in the case 
of PNA, and 20% in the case of RCA, just low enough to allow this method 
to be used. Interference from other glycoproteins in urine with terminal galactose 
groups was not investigated. The same approach was taken to detect changes 
in IgG glycosylation. The lectins Con A and PNA were coated onto microtiter 
plates and the amount of bound IgG quantitated with 1251-Protein A or 1251-
anti-IgG (Malaise et al., 1986, 1987). However, the IgG was exhaustively purified 
from plasma before those binding studies. 
2.5 Conclusions 
Application of a lectin as the immobilised binder in lectin enzyme-immuno-
assays is only possible when the lectin does not bind to any of the normal plasma 
glycoproteins, but binds (only) to the aberrantly glycosylated form of the 
glycoprotein under study. It is uncertain whether such a lectin will ever be found 
for the quantification of either galacto-transferrin, or any other abnormal 
glycosylated plasma glycoprotein. The method may be applicable, however, to 
the study of the glycosylation of purified glycoproteins. 
Subsequently, the second type of lectin-enzyme immunoassays is explored, 
consisting of antibody-coated tubes or microtiter plates and using lectin-enzyme 
conjugates as the soluble "second" binder. 
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CHAPTER3 
THE DEVELOPMENT OF A LECTIN-ENZYME 
IMMUNOASSAY FOR TRANSFERRIN GLYCOFORMS 
WITH TERMINAL GALACTOSE GROUPS 
USING IMMOBILISED ANTI-TRANSFERRIN AND 
ENZYME-LABELED GALACTOSE-BINDING LECTIN 
FROM RICINUS COMMUNIS 
3.1. Introduction 
In this chapter a number of experiments are described in chronological order 
leading to the final protocol for lectin-enzyme immunoassays, using immobilised 
antibodies and lectin-enzyme complex. In the following paragraphs the reasons 
are given for the choice of transferrin, Ricinus communis lectin and the 
streptavidin-biotin system in the development of the principles of lectin-enzyme 
imm unoassa ys. 
3.1.1. The choice of transferrin as the model compound 
The following considerations have led to the choice of transferrin as the model 
compound. First, it is a relatively abundant plasma glycoprotein (1.5 - 3.5 g /1), 
and it is easy to isolate milligram quantities. Second, the structures of its two 
N-linked glycan chains are well described. Most transferrin molecules have two 
diantennary side chains terminating in sialic acid residues: 4-sialo transferrin 
is by far the major fraction in humans, followed by the 3-sialo and 5-sialo 
fractions. Also, the glycans of transferrin are relatively simple; neither "inter-
secting" glucosamines nor a 1-2 or a 1-6 fucose residues that may influence 
lectin binding have been described to date. Third, the transferrin sialovariants 
are easily prepared and separated from each other by anion exchange chro-
matography. In this respect transferrin differs from a number of other plasma 
glycoproteins, in which sialic acid groups contribute less to the pi. The change 
in pi of transferrin due to the addition or removal of one sialic acid group 
is approx. 0.15 pH unit, large enough to allow a separation using chromato-
focusing (Pekelharing et al., 1987a) This contrasts to other proteins where the 
difference between the sialovariants is much less than 0.1 pH unit. During this 
work, fast separation methods of the transferrin sialovariants were developed 
using the Pharmacia Fast Liquid Chromatography (FPLC) Mono P chroma-
tofocusing and Mono Q anion-exchange columns (chapter 3.2). 
On the other hand, transferrin as a model compound also has a disadvantage. 
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Not all transferrin molecules are loaded with iron. The iron ions (one or two) 
also contribute considerably to the isoelectric point. This problem was overcome 
by consequently saturating transferrin in all samples with iron, thus eliminating 
charge differences due to differences in iron content. 
3 .1.2. The choice of Ricinus communis agglutinin as the lectin 
In choosing a lectin to develop the principles of the lectin-enzyme immunoassay, 
we limited ourselves to a number of commercially available galactose binding 
lectins. Many others have been described, originating however from rare 
organisms or seeds that are not available in this country. 
We had three reasons to focus on the lectin from the castor bean (Ricinus 
communis). The RCA I (or RCA 120) lectin has a broad binding specificity; 
precipitating with 30 out of 32 asialoglycoproteins prepared from human plasma 
(Uhlenbruck et al., 1978). Nine other galactose specific lectins tested reacted 
with 6 to 27 proteins. RCA I binds to terminal galactose groups. It does bind 
to asialotransferrin. Only three other lectins are known to bind to (fractions 
of) asialotransferrin: the lectins ofViscum album (VAA), Vigna unguiculata (VUA) 
and peanut (PNA) (Uhlenbruck et al., 1978). Moreover, the binding constants 
of RCA I lectin and different glycopeptides has been relatively well established 
(Baenziger et al., 1979). It is unknown to what extent these observations also 
apply to protein-bound glycans. 
A definitive disadvantage of RCA is its extreme toxicity when the material 
also contains the RCA toxin called ricin. This is a galactose specific lectin of · 
60,000 daltons molecular weight (alw called RCA II or RCA 60 lectin), while 
the RCA I galactose lectin present in the Ricinus communis seeds has a molecular 
weight of 120,000 daltons. The toxin is probably the most toxic substance known: 
one molecule may completely block protein synthesis in a cell, leading to cell 
death. A few micrograms are enough to kill a man. This characteristic has been 
used in London in 1978 in the homicide of a Bulgarian dissident (Knight, 1979). 
In practice, the toxicity does not have to be a problem as only very small amounts 
of extremely diluted solutions are used in lectin-enzyme immunoassays. 
3.1.3. The choice of the streptavidin-biotin system 
A vi din is a basic glycoprotein (pi = 1 0.5) with a molecular weight of 68,000 
daltons found in egg-white. It is capable of binding tour biotin molecules with 
very high affinity (Ka = 1015 M- 1). Biotin, a naturally occurring vitamin with 
a molecular weight of244 daltons can easily be coupled via a hydroxy succinimide 
derivative to proteins. The simple addition of avidin to biotinylated proteins 
forms the desired complexes. This technique is now widely employed in 
histochemistry and in ELISA techniques, for the binding of antibodies or lectins 
to enzymes or other marker proteins (Shamsuddin et al., 1983; Takai et al., 
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1987; Plebani et al., 1984; Vilja et al., 1985; Lee et al., 1985; Lin et al., 1984; 
Guesdon et al., 1979; Bonnard et al., 1984; Henke et al., 1984; Wilchek et 
al., 1988). 
The very high isoelectric point of avidin may result in non-specific binding 
due to electrostatic interactions to negatively charged groups such as sialic acids 
linked to glycoproteins or cell membranes (Glass et al., 1981; Bussolati et al., 
1983; Banerjee et al., 1984; Hoffmann et al., 1980). In contrast to streptavidin, 
hen egg-white avidin is a glycoprotein, allowing the interaction with lectins 
binding to its glycans (Green et al., 1970). These disadvantages can be 
circumvented with the use of streptavidin, an extracellular product of Streptomyces 
avidinii. This protein is very similar to avidin, with a molecular weight of 90,000 
dalton consisting of four identical subunits, each containing a single biotin-binding 
site. It has a near neutral isoelectric point (6.5) and it is free of carbohydrate 
side chains. During the course of this work streptavidin-peroxidase (STAP) 
became commercially available and it replaced the individual reagents avidin 
and peroxidase in the subsequent experiments. 
The avidin-biotin amplified ELISA system was chosen in the second type 
of lectin-enzyme immunoassays for three reasons. Firstly, the strength of binding 
oflectins to carbohydrate groups (Ka = approx. 104 M- 1) is less than the antibody-
antigen interaction (Ka = 107 M- 1). This may result in loss of bound lectin, 
for instance during washings of the tubes (Cerven et al., 1981). By complexing 
lectins in such a way that multiple interactions may take place, its was reasoned 
that this problem could be overcome. Indeed, no loss of binding was observed 
in our avidin-biotin based lectin-enzyme immunoassays even after many washings 
(chapter 3.3.11 ), while others report 15-20% loss after each washing (using 
1251-labeled CJA-lectin) (Cerven et al., 1981). Secondly, it was reasoned that 
simple conjugation of enzyme to lectin would provide insufficient signaL The 
fractions to be quantitated with our lectin-enzyme immunoassays may be very 
minor fractions of the glycoprotein; maximum signal amplification is thus 
necessary. The avidin-biotin system provides such an amplification by complexing 
a large number of biotinylated enzyme molecules with avidin or streptavidin, 
especially when using spacer arms (Hofmann et al., 1982; Leary et al., 1983). 
Thirdly, labeling oflectins with radioactive iodine results in alterations of binding 
characteristics (Montelaro et al., 1983; Armstrong et al., 1987). Such alterations 
have not been described for biotin-labeled lectins. ' 
3.1.4. The choice of horseradish peroxidase as the marker enzyme 
Horseradish peroxidase was chosen as the marker enzyme, as it compares 
favourably in ELISA techniques with other enzymes such as alkaline phosphatase 
or ,8-galactosidase (Porstman et al., 1985; Beyzavi et al., 1987; Nugel, 1986). 
The experiments leading to the optimal concentrations of lectin, avidin and 
peroxidase are mentioned only briefly, as in the course of the experiments it 
was decided to use the preformed complexes of streptavidin and peroxidase 
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that came available from Amersham International. These complexes were mixed 
with biotinylated lectin one hour before use. In this way one incubation step 
(of preformed lectin-streptavidin-peroxidase complexes) replaces three subse-
quent incubations (of biotinylated lectin, followed by avidin, and followed by 
biotinylated peroxidase), leading to a substantial decrease of analysis time and 
variations of results. 
During the initial development of lectin-enzyme immunoassays a number of 
difficulties was encountered. High blank values were observed after coating of 
microtiter plates with the IgG fraction of the antiserum, indicating binding of 
the lectin to the immobilised antibody in the absence of sample (results not 
shown). It was therefore decided to use affinity-purified antibodies to raise the 
"signal to noise ratio". 
To establish the relation between the binding of a galactose-specific lectin 
in a lectin-enzyme immunoassay and the number of terminal galactose groups 
of the bound glycoprotein, we choose transferrin as the model compound, as 
discussed above. Most transferrin bears four sialic acid groups, two on each 
glycan. It was reasoned that by means of a short neuraminidase treatment the 
less sialylated glycovariants could be prepared, followed by purification by means 
of a high-resolution focusing or anion-exchange technique. This procedure would 
yield well-defined sialovariants, whose response in the lectin-enzyme immuno-
assay could subsequently be investigated. 
A short incubation time with neuraminidase necessitates a fast removal (or 
inactivation) of the enzyme. Neuraminidase immobilised to Sepharose allows 
a quick removal (by centrifugation or column elution) of the glycoprotein in 
solution. By varying the incubation time one might expect to get differently 
sialylated transferrin variants. Still, each incubation time will probably lead to 
a mixture of sialovariants. 
We preferred the development of Mono P and Mono Q column separation 
methods over other methods such as flat-bed isoelectric focussing in gels, because 
of the fast and preparative character of the column methods. Although the 
resolution obtained with isoelectric focussing, especially in immobilised pH 
gradients, is higher, the resolution of the Mono P and /or Mono Q technique 
was expected to be sufficient for this particular separation. 
We have not considered the isolation and use of transferrin sialovariants present 
in human serum to be used as standards. First, the concentrations of the compounds 
other than 4-sialo transferrin are low, especially the extremely high and low 
sialylated sialovariants. Second, although their N-acetylneuraminic acid content 
may be deduced from their eluting position from Mono P or Mono Q columns, 
the terminal galactose expression is essentially unknown. Probably, even the 
sialovariants are complex mixtures, making them unsuitable for use as standards 
in the lectin-enzyme immunoassay. Moreover, if sulphate or phosphate is present, 
even the sialic acid content is uncertain. 
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3.2.1. Materials 
The chemicals used were from Merck (Darmstadt, Germany) unless stated 
otherwise. OPD was obtained from Sigma (St. Louis, USA). RCA lectin and 
HRP (horseradish peroxidase) were from Boehringer (Mannheim, Germany). 
RCA-Agarose was from E.Y. Laboratories (San Mateo, USA). LCA-Sepharose 
and CNBr-activated Sepharose were from Pharmacia (Uppsala, Sweden). The 
proteins AAT, AGP, BG III, GC and TF and their antibodies were a gift from 
Behringwerke (Marburg, Germany). Goat-anti-Rabbit-IgG and its F(ab')2 frag-
ments were from Pel-Freez (Rogers, USA). N-hydroxysuccinimidobiotin, egg 
white avidin and pepsin were from Sigma. Streptavidin-biotinylated-peroxidase 
complexes were from Amersham Int. (Amersham, England). Polystyrene mi-
crotiter plates were obtained from Greiner (Langental, Switzerland). Antitrans-
ferrin was from Dako (Glostrup, Denmark). 
Human transferrin was obtained from Sigma (St. Louis, USA), and saturated 
with iron in a bicarbonate solution at pH 8.0 for 24 hours. Bis-tris and bis-
tris-propane were also from Sigma. Neuraminidase (from Clostridium perfringens) 
was obtained from Behringwerke (Marburg, Germany). CNBr-activated Sepha-
rose 4B and polybuffer 74 were purchased from Pharmacia (Uppsala, Sweden). 
The chromatographic experiments were performed using a FPLC apparatus (Fast 
Protein Liquid Chromatography), also from Pharmacia. 
3.2.2. Methods 
Desialylation of transferrin 
Neuraminidase (1 U) was coupled to CNBr-activated Sepharose 4B according 
to the procedures as described by the manufacturer. 2 ml of Sepharose-coupled 
neuraminidase was equilibrated with 50 mM sodium acetate buffer pH 5.5, 
containing 1 mM CaC12 and 150 mM NaCL 10 mg iron-saturated transferrin 
in 250 11l of the same buffer was incubated for different lengths of time on 
the column and eluted with PBS, pH 7.4. The incubation times were 1 minute, 
5 minutes, 1 hour and 20 hours at room temperature. The resulting fractions, 
containing transferrin in an increasing degree of desialylation, were then pooled 
in such a way that a "standard" mixture was obtained containing roughly equal 
amounts of the five sialovariants of transferrin. 
Chromatofocusing on Mono P 
The Mono P 5 /20 column (0.5 em diameter, 20 em long) was equilibrated 
with starting buffer (1 ml/min of 25 mM bis-tris, pH 6.65, containing 10 mM 
NaCl and 311M FeC13). 500111 "standard" mixture with a transferrin concentration 
of 1 mg /ml was applied to the column. After washing with starting buffer the 
pH-gradient was formed by elution with polybuffer 74 (diluted 1:10, containing 
10 mM NaCl and 3 11M FeC13, pH 5.2). The pH of the eluting fractions was 
determined using a pH-meter. 
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Anion-exchange chromatography on Mono Q 
100 J.d of the "standard" mixture is brought onto the Mono Q 5 /5 column 
(0.5 em diameter, 5 em long). The starting buffer was 20 mM bis-tris-propane, 
pH 7.0, containing 3 JLM FeC13• The salt gradient was formed with 300 mM 
NaCl in starting buffer. Flow rate was 1 ml /min. 
Carbohydrate analysis 
Transferrin and asialo-transferrin were subjected to methanolysis (1.0 M 
methanolic HCl, 24 h at 85°C) followed by gas-liquid chromatography of the 
trimethylsilylated (N-reacetylated) methyl glycosides on a capillary CPsil5 
WCOT fused silica column (0.34 mm x 25 m) (Chrompack, Middelburg, The 
Netherlands) (Kamerling et al., 1982). 
Preparation ofF (ab')2 fragments 
A few ml antibody solution was acidified with 1 M HCl to pH 3.8. Then 
0.02 mg pepsin was dissolved per mg protein, and the mixture was incubated 
for 20 hours at 37°C. Any precipitate was removed by centrifugation, the mixture 
was made alkaline (pH = 8.0) with 1 M NaOH, followed by dialysis against 
0.1 M NaCl containing 15 mM NaN3. 
Biotinylation 
Antibody was diluted in PBS to a concentration of 10 mg /ml. A N-
hydroxysuccinimido-biotin derivative was dissolved in DMSO to a concentration 
of 1 mg /ml. 250 JLl antibody-solution and 250 JLl biotin-DMSO solution were 
added to 750 JLl of a 0.1 M carbonate-buffer pH 9.2 and 3.5 ml PBS. The 
reaction was allowed to take place for three hours at room temperature. 
Subsequently, the solution was dialysed for three days at 4°C against PBS with 
6 buffer exchanges, or alternatively desalted on G-25 or PD-10 gel filtration 
columns. 
Immobilisation of proteins on Sepharose 
The immobilisation of proteins on CNBr-activated Sepharose was done as 
described by the manufacturer (Pharmacia, Uppsala, Sweden). 
Affinity purification of antiserum 
The antigen column was eluted until a stable base line was obtained, first 
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with PBS, then with 0.1 M glycine buffer pH 3.0 containing 1 M NaCl, followed 
by PBS. Sample was applied onto the column and allowed to interact for 30 
minutes. All unbound proteins were eluted with PBS and discarded. The specific 
antibody was eluted with 0.1 M glycine buffer pH 2.8, and collected in 0.25 
M verona! buffer pH 9.5. 
Antibody coating of microtiterplates 
Microtiter plates were coated with a predetermined dilution of antitransferrin 
or its F(ab')2 fragments just giving maximum results, for various lengths of 
time. Coating appeared to be complete within 1 0 minutes, but overnight coating 
was used as a routine. 
3.3. Experiments and Results 
The carbohydrate analysis of transferrin and asialo transferrin is given in table 
3-l. It indicates complete removal of the four sialic acids by immobilised 
neuraminidase. 
Table 3-1. Carbohydrate analysis of transferrin and asialotransferrin, expressed as mol /3 man 
Transferrin Asialotransferrin 
Man 3 3 
Gal 2.0 1.7 
GlcNAc 3.9 3.8 
NeuAc 2.0 0· 
Figure 3-lA shows the Mono P elution patterns of the five human transferrin 
sialovariants prepared in vitro. The pH values of the eluting fractions are as 
follows: asialo 5.85, monosialo 5.70, disialo 5.54, trisialo 5.37 and tetrasialo 
5.21. Figure 3-lB shows the Mono Q elution pattern of the same sialovariants. 
pH 
6.0 
5.8 
5.6 
5.4 
5.2 
5.0 
A 
1.0 
0.8 ~ 
0 
"' '·, ________ ,til_ ::: ~ 
~ ~.... ~ 
'.,___ 0.2 ~ 
--. .0 
<( 0- 1- 2- 3- 4- 0.0 
-Sialo-Transferrin 
B 
50 
40 co 
30 iii 
4-
4-
20 .E 
/ 0- 1- 2- 3- 4- 0 
-Sialo-Transferrin 
Figure 3-1. Separation of transferrin sialovariants on Mono P column (A) or Mono Q column (B). 
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The fractions elute at the following buffer B percentages: asialo 11, monosialo 
15, disialo 19, trisialo 24 and tetrasialo 28. 
3.3.1. Determination of optimal avidin, lectin and peroxidase concentrations 
A number of experiments were done with subsequent incubations of RCA-
biotin, avidin and peroxidase-biotin (always with four washings between each 
step) to determine the combination of concentrations that would give maximum 
enzyme activities. These experiments led to the following protocol: 
1. Incubate antibody coated plates (50 ~d, 16 h) with 50 J.tl sample for 2 hours. 
2. Incubate with 50 J.tl RCA-biotin (20 }Lg /ml) for 1 hour. 
3. Incubate with 50 J.tl avidin (10 }Lg /ml) for 1 hour. 
4. Incubate with 50 J.tl peroxidase-biotin (7 }Lg /ml) for 1 hour. 
5. Peroxidase reaction. 
This protocol applied to transferrin samples gives a standard curve of asialo 
transferrin (figure 3-2). 
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Figure 3-2. ELISA and LElA standard curve of asialotransferrin. 
3.3.2. Premixing of reagents 
To diminish the large number of incubations and wash steps, it was decided 
to use preformed complexes by premixing the reagents. RCA-biotin and HRP-
biotin were added to the microtiter wells, followed by a simple addition of avidin 
to complex the compounds. The following protocol was used: 
1. Incubate antibody coated plates (50 J.tl, 16 h) with 100 J.tl asialo-transferrin 
for 2 hours. 
2. Incubate with 30 J.tl RCA-biotin; 20, 10 or 5 JLg /ml, and 30 J.tl HRP-biotin; 
20, 4 or 1 }Lg /ml for 1.5 hours. 
3. Add avidin; 60, 20, 6 or 2 }Lg /ml in 50 J.tl and allow to react for 1.5 hours. 
4. Peroxidase reaction. 
The results are shown in figures 3-3, 3-4 and 3-5 for 10 JLg /ml RCA (the 
other RCA concentrations gave comparable results). 
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3.3.3. Premixing of reagents with lower concentrations of avidin 
1. Incubate antibody coated plates (50 ,ul, 16h) with 100 ,ul asialo-transferrin 
for 2 hours. 
2. Incubate with 30 ,ul RCA-biotin; 20, 10 or 5 ,ug /ml, and 30 ,ul HRP-biotin; 
20, 4 or 1 ,ug /ml for 1,5 hours. 
3. Add 60 ,ul avidin; 10, 5, 2.5, 1.25, 0.63, 0.31, 0.16, 0.8 ,uglml and incubate 
for 1.5 hours. 
4. Peroxidase reaction. 
Figures 3-6 and 3-7 show the results. A standard curve of asialo transferrin 
was produced with this method. The curve is presented in figure 3-8. 
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Figure 3-7. 
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Figures 3-3 through 3-7. RCA binding in LEIA without intermediate washings as a function of 
RCA, avidin and peroxidase concentrations. 
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Figure 3-8. LEIA standard curve in the direct addition method. 
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3.3.4. Influence of rheumatoid factor (RF) 
At this stage the performance of the lectin-enzyme immunoassay was chal-
lenged with plasma samples, the medium for which the assay was ultimately 
developed. Experiments with plasma samples from patients with rheumatoid 
arthritis indicated that very high results may be obtained, exceeding the highest 
standard, probably caused by IgM-RF binding to the coating and subsequent 
binding of RCA binding to IgM (Saltvedt et al., 1975). This was also shown 
using pre-immune IgG coated plates. RF also interferes in classical ELISA systems. 
It was decided to use F(ab')2 coated wells, since most RF's bind to the Fc-
fragments of immunoglobulins. The elimination of IgM-RF was checked using 
2 microtiter plates coated with anti-transferrin and with F(ab')2 anti-transferrin, 
respectively. 
1. Coat with 50 J.Ll anti-transferrin IgG or F(ab')2. 
2. Incubate with 100 ,ul plasma, diluted 1:100 with PBS for 2 hours. 
3. Incubate with 50 ,ul diluted anti-IgM-peroxidase complex for 2 hours. 
4. Peroxidase reaction. 
Table 3-2 gives the results. 
Table 3-2. Extinctions in LElA with RA samples (R) and tumor samples (T) in wells coated with 
antitransferrin IgG (left) or F(ab')2 (right). 
====================================== 
R 22 3151 31 
R -J -=· "-·-' 2251 48 
R 24 2086 153 
R 25 2155 40 
R -J ' L....C• 2713 109 
R 27 1384 61 
R 28 160 32 
R 29 163~· 42 
R 30 652 20 
T 5 434 79 
T 6 379 63 
T 17 121 36 
T 21 1804 Ol 
====================================== 
3.3.5. Preformed lectin-streptavidin-peroxidase complexes 
The availability of stable complexes of streptavidin with peroxidase-biotin (STAP) 
(Amersham) opened the way of reproducible premixing of reagents. The minimal 
RCA-biotin concentration was determined as follows. 
1. Coat with F(ab')2 anti-transferrin (50 ,ul, 16 h). 
2. Incubate with 50 ,ul asialo-transferrin for 2 hours. 
3. Incubate with a 1 hour premix of STAP diluted 1:1250 or more and RCA-
biotin; 0.32 - 20 ,ug /mi. 
Results are represented by figures 3-9 and 3-10. 
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2 4 6 8 10 12 14 16 18 20 Jlg/ml RCA 
a: Transferrin 3260 ng/ml 
b: Transferrin 1090 ng/ml 
c: Transferrin 121 ng/ml 
3 4 5 6 7 
a: Transferrin 3260 ng /ml 
b: Transferrin 360 ng/ml 
c: Transferrin 40 ng /ml 
8 9 10 STAP dilutict~ (x) 
Figure 3-9 (top) and 3-10. LEIA response as a function of RCA and STAP concentrations. 
3.3.6. Influence of incubation time 
The binding of RCA-STAP complex as a function of the incubation time 
was investigated as in 3.3.5. Incubation times ranged from 10 to 180 minutes. 
RCA: 1,ug/ml,STAP 1:2500.Figure3-ll showstheresult. 
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3.3.7. Influence of preincubation time 
To determine the length of time needed to form complexes between RCA 
and STAP, the pre-mixing time was investigated between 15 and 120 minutes. 
The extinctions measured are shown in figure 3-12. Reaction conditions as in 
3.3.6. 
a 
b 
c .---~---.·--~·~------~·~_______. 
d 
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a: Transferrin 3270 ng/ml 
b: Transferrin 360 ng/ml 
c: Transferrin 121 ng/ml 
1200 minutes 
Figure 3-12. LElA response as a function of RCA /STAP preincubation time. 
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3.3.8. Influence of the number of washings 
1. Coat with 50 Ml F(ab')2 anti-transferrin for 16 hours. 
2. Incubate with 50 Ml asialo transferrin for 2 hours. 
3. Incubate with an 1 hour premix of 1 Mg /ml RCA-biotin and STAP 1:2500 
for 1.5 hours. 
4. Wash x times (0-6). 
5. Peroxidase reaction. 
3.3.9. Standard curves of asialo a 1-antitrypsin, ,82-glycoprotein III and 
Gc-globulin. 
Microtiterplates were coated with F(ab')2 fragments of affinity purified an-
tibodies against these proteins (50 Ml, 16 h). Other reaction conditions as in 
5.3.8. The standard curves obtained with a 1-antitrypsin and ,82-glycoprotein III 
are given in figures 3-13 and 3-14. 
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Figure 3-13 (top) and 3-14 (bottom). LElA standard curves with RCA for ATT and BGIII. 
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3.3.1 0. Response of transferrin sialovariants 
Transferrin sialovariants were prepared and separated as described in chapter 
4. They were diluted to a concentration of 10 J.lg /ml before incubation in F(ab')2 
coated plates. Other reaction conditions as in experiment 3.3.8. The response 
of the five sialovariants is given in figure 3-15. 
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Figure 3-15. ELISA of five transferrin sialovariants and LElA response with RCA lectin. 
3.3.11. Influence of the number of washing steps on RCA-STAP binding to the 
various transferrin sialovariants 
Plates were rinsed 3, 4, 5, and 6 times to detect any galactose-density dependent 
loss of RCA-STAP binding. Experimental conditions as in 3.3.8. Figure 3-16 
shows the results. 
3.3 .12. Dilution of transferrin sialovariants 
To investigate the influence of surface galactose density on the binding of 
lectin-STAP complex, an experiment was done with dilutions of the F(ab')2 
coating. If the surface galactose density has a different influence on the binding 
of RCA to each of the transferrin sialovariants, this experiment should show 
it. Coating: F(ab')2 fragments, 50 J.ll, 16 h, diluted 2, 4, 8, 16, 32 and 64 times. 
Other reaction conditions as in 3.3.8. Figure 3-17 shows the response of the 
five sialovariants. 
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Figure 3-16. Influence of wash cycles on LElA response as a function of terminal galactose groups. 
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Figure 3-17. Effect of diluting the coating antibody on the results of the lectin-enzyme immunoassay 
for the five transferrin sialovariants. 
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3.3.13. Response of LCA-binding transferrin in the lectin-enzyme immunoassay 
The standard curve is shown in figure 3-18. The influence of the LCA 
concentration on the response of the various standards is given by figure 3-
19. 
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Figure 3-18. LEIA standard curve ofLCA binding transferrin. 
a: Transferrin 9960 ng/ml 
b: Transferrin 3320 ng/ml 
c: Transferrin 1110 ng/ml 
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Figure 3-19. LEIA response as a function ofLCA concentration. 
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3.4. Overview and discussion of the results 
As can be seen in figure 3-lA and figure 3-lB the resolving power of Mono 
P and Mono Q are roughly equal. The latter technique however, has a few 
distinct advantages. Firstly, the anion-exchange chromatography takes consi-
derably less time. Secondly, as no ampholytes are involved, the Mono Q separation 
produces pure transferrin sialovariants ready for use in other experiments. Thirdly, 
the pH used in the Mono Q separation bears less risk of sialic acid loss from 
the glycan. Most sialic acid groups are sensitive to hydrolysis in an acid 
environment. And fourthly, the Mono Q separation is cheaper as it employs 
no ampholytes. 
It is unknown why the separation of transferrin sialovariants can be obtained 
(either with Mono P or Mono Q), while most other glycoprotein sialovariants 
elute much closer to each other, not allowing complete separation. Possibly the 
distribution of the glycans on the surface of the molecule is of importance. 
The stepwise incubations of asialo transferrin immobilised to a solid phase 
with biotinylated RCA, avidin and biotinylated peroxidase (experiment 3.3.1) 
indicate that in principle this approach is suitable to detect asialo transferrin 
in a lectin-enzyme immunoassay (fig. 3-2). However, large variations between 
individual results were obtained (not shown), suggesting that the number of 
incubations and wash steps (twelve in all) should be decreased. 
This could be achieved by adding simultaneously biotinylated RCA and bio-
tinylated peroxidase, followed without washing by the addition of avidin which 
forms the desired complexes (experiments 3.3.2. and 3.3.3.). 
As experiment 3.3.2 shows (figures 3-3, 3-4 and 3-5) this approach also works 
well, as long as the HRP-biotin concentration is above 20 J.lg /ml. Lower HRP 
concentrations lead to very low extinctions. The avidin concentrations used were 
considered to be too high, given the response shown by figure 3-4. In a second 
experiment (3.3.3) avidin concentrations between 10 and 0.8 J.lg /ml were used. 
Figures 3-6 and 3-7 show the dose-response curves for 5 and 10 J.lg /ml HRP, 
respectively, and for 5, 10 and 20 J.lg /ml RCA as a function of the avidin 
concentration. The avidin concentration of 5 J.lg /ml and the RCA concentration 
of 20 J.lg /ml were suitable for further use. The amount of HRP is not critical: 
more HRP leads to higher extinctions. 
Figure 3-8 shows the dose-response curve with this method as a function of 
the asialo transferrin concentration. The very low slope indicates that the method 
in this form is not suitable for use in a lectin-enzyme immunoassay. 
Another problem appeared to be the high background signal caused by 
rheumatoid factors. These antibodies to IgG may bind to the coated IgG. If 
they are of the IgG3, IgM or IgA class, they may bind RCA. Most RF's are 
IgM. Thus, serum samples containing RF will show falsely elevated values in 
the lectin-enzyme immunoassay for galacto-transferrin, even without any trans-
ferrin present. Experiment 3.3.4 indicates the interference from RF's (table 3-
2). Use ofF(ab')2 coating is recommended. 
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At this stage, the preformed streptavidin-biotinylated peroxidase (STAP) 
complexes became commercially available. When biotinylated lectin is mixed 
with STAP before use, only one incubation step is needed for the three components. 
Besides, the premixing leads to multiple lectins complexed to each other, which 
may be advantageous in view of the low association constant of most lectins. 
The advantages of streptavidin over avidin (its neutral pi (6.5 vs 10.5) and its 
lack of carbohydrate side chains) are of less importance here. 
To determine the best proportions of RCA and STAP experiment 3.3.5 was 
conducted. Any RCA concentration above 1 p,g /ml worked well (figure 3-9). 
A STAP dilution experiment showed that dilutions further than 1:2500 lead 
to low absorbance values (figure 3-1 0). 
In chapter 4 a new fast method is described making use of avidin coated plates 
to find the optimallectin-streptavidin-peroxidase complex composition without 
using the lectin binding function. 
As the reagents are premixed, complex formation may take place during the 
incubation steps. This was investigated in experiment 3.3.6. As can be seen 
in figure 3-11 the measured extinction continues to rise for at least three hours. 
90 minutes was arbitrarily chosen for the subsequent experiments. 
Experiment 3.3.7 (figure 3-12) indicates that complex formation occurs within 
15 minutes after premixing ofRCA-biotin and STAP. We selected a pre-incubation 
time of 60 minutes, but this is not critical. 
The relatively low binding constant of lectin-glycan interaction might cause 
loss of bound lectin during the washing steps. This has been observed for 125I-
labeled Crotalaria juncea lectin (CJA) binding to galacto-transferrin (Cerven 
et al., 1981) where each washing induces a loss of signal of approx. 20%. In 
that system, however, lectins were not complexed with STAP. The use of lectin-
STAP complexes may reduce the liberation of lectin bound to the captured 
glycoprotein. No dependence was found in our system on the number of wash 
steps, indicating that the lectin-STAP complex is firmly bound to the captured 
transferrin having four terminal galactose groups (experiment 3.3.8.; results not 
shown) or less (figure 3-16). The antibody-antigen interaction too is apparently 
not disrupted. 
It is concluded that lectins complexed with peroxidase by the avidin-biotin 
system and bound to the captured glycoprotein are not dissolved again by the 
washing procedure, in contrast to uncomplexed lectin. This finding supports the 
choice of the avidin-biotin system versus direct enzyme-conjugated or radio-
iodinated lectin. 
The experiments described in paragraph 3.3.9 indicate that the concept of 
lectin-enzyme immunoassay may also work for galacto-a !-antitrypsin (figure 
3-13), but not (with RCA as the galactose specific lectin) for BG III (figure 
3-14) or Gc (not shown). The reason for this discrepancy is not known. AAT 
contains three N-linked glycans but the structures of BG III and Gc are not 
known. In any case they contain only little carbohydrate (table 1-1). If they 
contain 0-linked chains to which RCA does not bind, or if their structures are 
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resistant to neuraminidase these observations could be explained. Neuraminidase-
treated BG III is not precipitated by RCA but Gc-globulin is (Uhlenbruck et 
al., 1978). On the other hand, N-acetylgalactosamine has been demonstrated 
in BG III but not in Gc-globulin, while Gc-globulin does not contain sialic acids 
while BG III does (Uhlenbruck et al., 1979). 
The response of the five purified transferrin sialovariants in the lectin-enzyme 
immunoassay (experiment 3.3.10) is given in figure 3-15. 
Two conclusions may be drawn. First, it is noted that the number of sialic 
acid groups does not have any influence on the response of the ELISA. The 
amount of each sialovariant bound to the coated antibodies is thus the same. 
Second, the RCA-STAP binding was found to be dependent on the number 
of galactose groups present on the transferrin molecule. 
As the strength of binding to RCA lectin depends on the number of terminal 
galactose groups (Kornfeld et al., 1981; Baenziger et al., 1979), it could be 
reasoned that a preferential loss during wash cycles may occur of RCA-STAP 
complex from the higher sialylated transferrin sialovariants. The experiment 
described in 3.3.11. indicates that no liberation occurs from any of the transferrin 
sialovariants (figure 3-16). If lectin-STAP complexes are preferentially washed 
away from those glycoprotein glycovariants having less carbohydrate structures 
recognised by the lectin, the concept of lectin-enzyme binding assay would be 
without a firm basis. 
The experiments described in paragraph 3.3.12 were performed to investigate 
the influence of the coating density on the binding of complexed lectins. It could 
be argued that the lectin-enzyme binding is a function of the galactose density 
in the coated microtiter plates. Figure 3-17 shows that this is not the case. 
The parallel lines indicate that the response remains a function of the number 
of terminal galactose groups per transferrin molecule, whatever the coating 
density. 
As figure 3-17 shows, the density of the coating antibody does not influence 
preferentially any of the sialovariants. This may mean that the average coating 
distance between antibodies is larger than the average lectin-STAP complex. 
To investigate the application of another lectin in the lectin-enzyme immu-
noassay we investigated the binding of the lectin from Lens culinaris (LCA), 
known to bind a 1-6 fucosylated diantennary glycans (experiment 3.3.13). To 
obtain transferrin that binds to the lectin in the assay, a column of immobilised 
LCA was used to extract the binding fraction from commercially available 
transferrin. This approach is essentially different from the RCA binding fractions, 
where enzymatic (i.e. neuraminidase) treatment of the glycoprotein yields the 
standard material. In the case of LCA, and possibly a number of other lectins 
as well, the standard material must be isolated from the purified glycoprotein 
by lectin column chromatography using the same lectin as in the lectin-enzyme 
immunoassay. The standard curve obtained with the LCA binding transferrin 
thus isolated is shown in figure 3-18. Variation of the LCA-biotin concentration 
affected the results only slightly (figure 3-19). The same has been found for 
RCA-biotin. The LCA non-binding fraction, diluted to 10 ,ug /ml, did not show 
binding ofLCA-STAP complex in the assay. 
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3.5. Discussion 
The lectin-enzyme immunoassay described here is a new tool to investigate 
protein glycosylation and its modifications. It has a number of distinct advantages, 
such as speed, sensitivity, specificity and simplicity, and when using microtiter 
plates it is easily automated. In theory, purification of the glycoprotein being 
studied is not necessary. Since the assay was developed with purified transferrin 
sialovariants, it remains to be established to which extend the presence of other 
glycoproteins has an influence on the analysis. 
In general, the standards used in the LElA differ from those used in the ELISA, 
as they consist of subfractions of a glycoprotein. This means that enzymatic 
removal of sugar groups may be necessary to obtain the standard. We used 
neuraminidase to prepare the asialo-transferrin standard. In other cases (i.e. LCA-
reactive glycoprotein) the standard material must be purified by isolating the 
subfraction in question with an immobilized lectin, the same as that used in 
the LElA. The material probably does not have to be very pure with respect 
to contamination with other glycoproteins, but it must be pure with respect to 
its glycosylation. 
The standard curve of the assay was constructed with compounds bearing 
whole integers of galactose groups. The result of an unknown sample, however, 
may lead to fractions; the average of a large number of differently galactosylated 
molecules. This means that the unit of expression of the lectin-enzyme 
immunoassay should be "average molar number of terminal galactose units". 
The sensitivity of the LElA has to be high when the subfractions to be 
quantitated make up only a small portion of the glycoprotein. This was achieved 
by two measures. Firstly, antibodies that were affinity purified over an immobilized 
antigen column were used as the coating material. This will increase the lectin 
binding to the captured glycoprotein by increasing the density of the coated 
specific immunoglobulin. Secondly, we used biotin-labeled lectin bridged by 
streptavidin to biotin-labeled peroxidase to increase the number of marker enzyme 
molecules bound per lectin molecule. This amplification system also increases 
the sensitivity of the LElA. It also increases the binding affinity of the complexed 
lectin molecules to the captured glycoprotein molecules. In contrast, by using 
single lectin molecules one may observe loss of binding during each washing 
step (Cerven et al., 1981). This was not observed in our assay. 
Recently three enzyme-linked and one radio-labeled lectin binding assay have 
been described (Molin et al., 1986; Van der Schaal et al., 1984; McCoy et al., 
1983; Cerven et al., 1981) Our assay is distinct in several respects. Both the 
enzyme-linked lectin binding assay (ELBA) described by Van der Schaal et al. 
and the enzyme-linked lectin assay (ELLA) described by McCoy et al. used 
passive adsorption of a glycoprotein to polystyrene. The ELBA method was 
used to determine the lectin affinity of the Pea lectin by inhibition of the binding 
by mono- and polysaccharides. The ELLA method was used to study the 
expression of a-D-galactopyranosyl end groups of natural and synthetic gly-
coproteins using the Bandeira (Griffonia) simplicifolia I B4 isolectin. These 
methods work well with pure glycoproteins or glycolipids. 
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The binding oflectins to glycosphingolipids was investigated in a lectin-enzyme 
binding assay (Molin et al., 1986). The lipids were adsorbed in microtiter plates 
by evaporation of the methanol solvent from the cholesterol, lecithin and lipid 
mixture. Biotinylated lectins were allowed to bind, and after washing, a solution 
of avidin-peroxidase conjugate was added. With this system, the affinity of the 
lectins PNA, WGA and UEA-I for a number oflipids was characterised. 
In our assay an antibody-coated solid phase was used. This has the advantage 
of specificity with respect to the glycoprotein under study when it is present 
in a complex mixture. Passive adsorption can be used only when purified 
glycoprotein is available. However, not all proteins bind very well to polystyrene 
surfaces. Because immunoglobulin G binds strongly, such proteins can also be 
analysed if antibodies are available. 
The radiolectin immunoassay technique (RLIA) described by Cerven et al., 
was used to study the glycosylation of transferrin sialovariants with a 1251-labeled 
galactose-binding lectin isolated from Crotalaria juncea seeds and with the 1251-
labeled sialic acid-binding lectin from Limulus polyphemus. CNBr-Sepharose-
bound anti-transferrin served as the solid phase. Increased desialotransferrin (pi 
5.7) concentrations were found in serum from alcoholics, in agreement with 
other reports (Stibler et al., 1981; 1986). However, loss of binding occurred 
due to the relatively weak lectin-glycan interaction. 
An alternative immunoassay was subsequently developed by the authors to 
avoid the problems associated with the loss of bound radiolabeled lectin during 
wash steps. They investigated the feasability of radiolabeling the sialic acid groups 
of transferrin bound by the immunoadsorbent, by oxidation with sodium me-
taperiodate followed by introduction of the label with sodium borotritide. The 
method exhibited high background values due to binding of the tritium label 
to the immunoadsorbent gel and to other sugars then sialic acid. Moreover, 
measurement of a small decrease in sialic acid content of transferrin such as 
occurs in alcoholics is quite difficult to quantitate in this way. The labeling 
immunoassay might have certain potentials if the terminal galactose groups were 
labeled (for instance with galactose oxidase followed by the sodium borotritide 
reductive labeling), as terminal galactose groups are sparse on human sera-
transferrin. 
Our lectin-enzyme immunoassay (LElA) has a number of advantages in 
comparison with the RLIA procedure. It uses the RCA lectin, which has been 
shown to bind to asioalotransferrin (Uhlenbruck et al., 1978) but which does 
not bind to immunoglobulin G except for the minor fraction IgG3 (Saltvedt 
et al., 1975). It does not use 1251-labeled lectins, which are shown to have altered 
carbohydrate-binding properties (Shimoda et al., 1985). The binding of the lectin 
is independent of the number of washing steps, while in the RLIA procedure 
15-20% loss occurs during each wash cycle, probably due to a lower binding 
constant of single 1251-CJA lectin molecules compared with biotin-streptavidin 
complexed RCA lectin molecules. 
A theoretical disadvantage of our LElA technique, i.e., the binding of the 
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lectin to the antibody coating, may occur. The use of affinity-purified antibodies 
increases the density of the captured glycoprotein and the lectin binding to it, 
probably without having an influence on the "aspecific" binding of lectin to 
the immunoglobulin coating ("aspecific" is written in quotation marks because 
of course the lectin binding to the immunoglobulin glycans is carbohydrate 
specific, but to the wrong molecules). The use of the F(ab')2 fraction may further 
lower the background binding because most immunoglobulin glycans are Fc-
linked (Taniguchi et al., 1985). If necessary, other measures can be taken to 
suppress background binding, such as affinity purification of the immunoglobulins 
on a column of an immobilized lectin (the same one as used in the LElA). 
Although RCA column chromatography of the coating antibodies does increase 
the "signal to noise ratio" it does not completely eliminate the binding of enzyme-
labeled RCA lectin to the coated immunoglobulins. Complete elimination of 
this background binding can probably only be achieved by removal of the lg 
glycans by N-glycanase treatment, or by removal of galactose groups by sequential 
neuraminidase and ,8-galactosidase treatment. Preliminary experiments to reach 
this goal proved to be unsuccessful, probably due to the resistance of RCA 
binding lg glycans to N-glycanase and galactosidase (data not shown). The right 
conditions to prepare aglyco- or agalacto immunoglobulins remain to be 
established. 
Unexpectedly, the LElA standard curve of the number of terminal galactose 
units plotted against the percentage of maximum enzyme activity bound 
consistently produces a straight line. As the form of the curve is determined 
by binding constants, size of the RCA-complexes, glycoprotein glycan exposition, 
etc. such a straight line is not necessarily expected. 
With LElA technique it is possible to study the glycosylation of very small 
amounts of a glycoprotein. The amount of carbohydrate present per well 
(calculated from the saturating amount of transferrin (200 ng) and given the 
5% carbohydrate in transferrin) is approx. 10 nanograms. This indicates a very 
high sensitivity compared with other techniques. 
One application is the investigation of the glycosylation of small amounts 
of glycoproteins produced by recombinant techniques and tissue cultures. Another 
is the change in plasma glycoprotein glycosylation in disease. 
3.6. Conclusions 
The experiments described in this chapter have led to a protocol for lectin-
enzyme immunoassays. Although it was developed for the RCA lectin, the 
successful application of the LCA lectin shows that it is also applicable for 
other biotinylated lectins. 
Methods using stepwise addition of lectin, avidin and enzyme are considered 
inferior compared with the one-step addition of premixed and complexed lectin-
streptavidin peroxidase. Binding stability increases, and the number of incubation 
steps involved is reduced. 
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CHAPTER4 
LECTIN-ENZYME BINDING ASSAYS FOR THE 
CHARACTERISATION OF THE LECTIN SPECIFICITY 
AND FOR THE DETERMINATION OF EQUIVALENCY 
BETWEEN LECTIN-BIOTIN 
AND STREPTAVIDIN-PEROXIDASE 
4.1. Introduction 
It is at present not possible to predict which lectin is most suitable to detect 
disease-associated changes of a certain plasma glycoprotein. Increased branching, 
increased or absent sialylation, decreased galactosylation and increased fuco-
sylation have all been described (Endo et al., 1987; Pekelharing et al., 1988; 
Thompson et al., 1987). On the other hand, the detailed binding specificities 
of most lectins have not yet been elucidated. Thus, both the glycan changes 
in disease of most plasma glycoproteins and the specificity of our "tools" remain 
obscure. This means that to find a fruitful combination of lectin and glycoprotein, 
a trial and error approach should be taken. Thus, a fast way to prepare lectin-
STAP complexes without using the lectin binding function is a necessity. This 
chapter describes such a method. 
The lectin-enzyme binding assay may be used to gain insight in the 
carbohydrate specificity of lectins. Inhibition studies using simple sugars as well 
as binding studies to immobilised neoglycoconjugates will lead to a more detailed 
description of the carbohydrate structures for which the lectin has affinity. 
To be able to detect small subfractions of a glycoprotein, the lectin should 
not bind to the glycoprotein from healthy persons plasma. This may also be 
investigated by lectin-enzyme binding studies, using immobilised purified plasma 
glycoproteins. 
4.2.1. A lectin-enzyme binding inhibition assay in glycoprotein-coated microtiter 
plates to determine the lectin binding specificity 
Since the early days of 1888 when Stillmark discovered the "phyto-
hemagglutinins", lectins are detected by their capacity to agglutinate red blood 
cells. Watkins and Morgan (1952) found that simple sugars are capable of 
inhibiting the hemagglutination. The hemagglutination inhibition system to 
investigate the lectin specificity has the advantage of being sensitive and very 
easy to perform: the hemagglutination is readily visualized in a test tube. On 
the other hand, the red blood cells contain a very large variety of structurally 
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different glycoproteins and glycolipids, each contributing to a different extent 
to the binding of the lectin used. Quantitation of the observed agglutination 
is also a problem. 
A more defined system would be the inhibition by simple sugars of the binding 
of the lectin to a purified glycoprotein with well-known glycan structures. In 
such an assay, however, no red cells are available to serve as the detector system. 
The use of radioactive groups introduced in the lectin molecules would be a 
possibility, but 1251-labeling may change the binding characteristics of lectins 
(Montelaro et al., 1983, Shimoda et al., 1985). Biotin labeling has the advantage 
of being relatively inert. The amount of bound biotinylated lectin may be 
quantitated using enzyme-labeled (strept-)avidin. 
In the method that we developed we used a glycoprotein coated to a solid 
phase provided by a microtiter plate, to which the lectin-streptavidin-peroxidase 
complex may bind. The glycoprotein used is asialo transferrin, the lectin is Ricinus 
communis agglutinin I (RCA) and the enzyme is horseradish peroxidase. By 
inhibiting the binding of the lectin-enzyme complex to immobilized asialo 
transferrin with a number of simple sugars in various dilutions the lectin specificity 
is characterised. 
4.2.2. Materials and Methods 
All experiments were performed in 96 well microtiter plates from Greiner 
(Langental, Switzerland). Ricinus communis 120 lectin was obtained from 
Boehringer (Mannheim, Germany). Asialotransferrin was prepared by incubating 
10 mg transferrin (Kabi, Stockholm, Sweden) for 24 hours at room temperature 
in 0.1 M acetate buffer, pH 6.8, containing 10 mM Ca2+ with 2 ml CNBr-
activated agarose gel to which 1 U neuraminidase (Boehringer) has been 
covalently linked. Transferrin concentrations were determined by radial immu-
nodiffusion. Streptavidin-biotinylated peroxidase complexes were obtained from 
Amersham (Amersham, England). Ricinus communis lectin was biotinylated by 
dissolving 10 mg of the lectin in 1.6 ml PBS buffer to which is added 1 mg 
N-hydroxysuccinimidobiotin (Sigma, St. Louis, USA), dissolved in 1 ml dimethyl-
sulfoxide and 3 ml 0.2 M carbonate buffer, pH 9.2. After 3 hours incubation 
at 25°C the reaction mixture is dialyzed against 0.9% NaCl. The NaCl solution 
is changed six times. The biotinylated lectin is stored in 0.5 ml portions at -20°C. 
The microtiter plates were coated with asialotransferrin by incubating each well 
with 50 J.Ll asialotransferrin in PBS (10 Jlg /ml) at 4°C. 
After 16 h the plates were washed four times with PBS pH 7 .4, containing 
0.1% Tween 20. The wells were incubated at 25°C with 100 J.Ll PBS-Tween, 
containing the competing sugar, Ricinus communis lectin (1.25 }lg /ml) and the 
streptavidin peroxidase complex in a final dilution of 1:2500. After 70 minutes 
the plates were washed four times and the peroxidase activity was measured 
by incubating the wells with 100 J.Ll 0.08 M Na2HP04 /citric-acid buffer with 
4.4 mM a-phenylenediamine and 3.5 mM H20 2• After 14 minutes the reaction 
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was stopped with 50 ,u.l 2 M H2S04. The absorbance was measured at 492 
nm with a Titertek Multiskan Elisa reader. 
4.2.3. Results 
The kinetics of the adsorbance of asialo-transferrin coating to the plastic 
cuvettes of the microtiter plate shown in figure 4-1. We used overnight coating 
at 4°C as a routine, although 10 minutes at room temperature is sufficient. 
Figure 4-2 shows the increase with time in the binding ofthe lectin-streptavidin-
enzyme complex to the coated asialo-transferrin. After three hours 95% of the 
maximum signal was reached. 
The inhibition by various sugars of RCA binding to asialo-transferrin is shown 
in figure 4-3. The 50% inhibition concentrations for the various sugars are given 
in table 4-lA. 
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Figure 4-3. Inhibition by simple sugars of RCA-STAP binding to immobilized asialo transferrin. 
Table 4-lA. 50% inhibition concentrations of RCA-STAP binding to immobilized asialo transferrin. 
~ ONP-e-D-galactose 
IIIII a-D-lactose 
~ ONP-a-D-galactose 
~ a-D-stachyose 
0 D-galactose 
[] a-D-melibiose 
8 D-galactosamine 
Glucose 
Mannose 
Fucose 
4.2.4. Discussion and Conclusions 
50% inhibition concentration 
0.09 mM 
0.15 mM 
0.39 mM 
0.46 mM 
0.61 mM 
0.68 mM 
4.7 mM 
> 200 mM 
> 200 mM 
> 200 mM 
The results of hemagglutination inhibition tests are often expressed in terms 
of "relative inhibitory potency" arbitrarily taking one of the most inhibiting 
saccharides as 1.0. As hemagglutination assays are not easily quantitated, the 
results obtained remain an approximation. The assay described above allows 
the precise determination of the 50% inhibition concentration. In this way, small 
differences in inhibitory potency between sugars are readily established. 
The assay was developed using asialotransferrin as the coated glycoprotein 
and RCA as the lectin. The results are comparable to those obtained with 
precipitation-inhibition or hemagglutination-inhibition assays (Goldstein et al., 
1978). A major difference is the inability of fucose to inhibit binding in the 
assay, while it inhibits the turbidity resulting from the lectin-galactomannan 
reaction. A possible explanation might be found in the purity of the mono-
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saccharides used: a slight contamination of a non-inhibiting sugar (i.e. fucose) 
with an inhibiting sugar (i.e. galactose) renders the material used inhibitory. 
Another explanation could be the presence of fucose-containing structures on 
the erythrocytes used to which the lectin binds in the absence of free fucose. 
The asialotransferrin used in our assay contains no fucose groups. 
In principle our system is also suitable to characterise the binding of univalent 
lectins that are unable to induce hemagglutination. As hemagglutination is most 
often used to detect lectins, the existence of univalent lectins is still uncertain. 
The lectin-associated toxins that were once thought to be univalent may appear 
to have multiple binding sites (Housten et al., 1982). 
In conclusion, our lectin-enzyme binding inhibition assay may be used to 
get a quick impression of the lectin-enzyme binding specificity of new lectins. 
Extending the number of inhibiting saccharides increases the correctness of the 
description. 
4.3.1. The determination of equivalency between lectin-biotin and streptavidin-
peroxidase without u:sing the lectin binding function 
The very high affinity of avidin or streptavidin for biotin and the simplicity 
of protein biotinylation have resulted in the widespread use of the avidin-biotin 
amplification system in histochemistry, cytochemistry and immunochemistry. The 
system employs in its basic form a complex of biotinylated binding protein (i.e. 
an antibody, a lectin, protein A, etc.), avidin or streptavidin, and biotinylated 
enzyme (i.e. peroxidase), or chemically conjugated avidin and enzyme. This 
complex may be prepared before use, and it is added in a single incubation 
step to the tissue, the cells or the immunoassay tubes in question. 
The use of the avidin-biotin interaction in lectin binding studies has a few 
advantages. Labelling of lectins by radioactive iodine is circumvented. The 
introduction of the relatively large iodine molecules into the lectin protein induces 
changes in the binding characteristics (Shimoda et al., 1985). In comparison, 
the coupling of biotin molecules through a spacer arm to the lectin protein 
is a relatively inert modification: no changes in lectin binding affinity have been 
described. 
Moreover, the biotinylation of the lectin and the use of avidin or streptavidin 
with four biotin binding sites allows the formation of large complexes. This 
may be advantageous in view of the relatively low association constant of lectin 
monomers, which may be overcome by creating multiple interactions between 
glycoprotein or cell membrane and lectin aggregates. It also provides an 
amplification which is a necessity when small amounts or subgroups of a 
glycoprotein or glycolipid are to be detected. 
The use of streptavidin has a few advantages over avidin. Streptavidin has 
no carbohydrate groups to which lectins may bind. Moreover, its isoelectric point 
is 6.5 compared with 10.5 for avidin, leading to less nonspecific interactions 
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with negatively charged groups such as sialic acids. Both proteins possess four 
biotin binding sites (avidin groups). 
Complexes of streptavidin and enzyme, either linked chemically or by virtue 
ofbiotinylation of the enzyme, are commercially available, and biotinylated lectin 
has only to be added in equivalent amounts to prepare the desired complexes. 
However, this point of equivalency is not easily found. 
In a sense, complexes of streptavidin-peroxidase (STAP) and lectin-biotin may 
be compared with antigen-antibody complexes where antigen excess, equivalence, 
and antibody excess are distinguished. Thus, in situations of STAP excess, the 
complexes formed will still have vacant avidin groups able to bind to biotin. 
In situations of lectin-biotin excess, the avidin groups will be saturated with 
lectin-biotin which will also be present in solution in free form. In situations 
of equivalence, all STAP avidin groups will be occupied by lectin-biotin, but 
no excess of either lectin-biotin or STAP will be present in solution. For lectin-
enzyme binding assays this is the desired situation giving the largest complexes 
and giving the maximum color development. 
An excess of free (biotinylated) lectin will effectively compete with lectin-
STAP complexes for the available carbohydrate structures of the glycoprotein 
or glycolipid, leading to a loss of enzyme signal. An excess of free STAP on 
the other hand may increase the nonspecific binding or it may decrease the 
sensitivity due to a shortage of lectin-STAP complexes. Until now, no method 
has been described to provide a fast means of finding the point of equivalency 
where neither lectin nor STAP exists in excess. 
Many lectins bind to only a few purified (and immobilised) glycoproteins, 
for instance from plasma. If no binding occurs the formation of optimallectin-
streptavidin-peroxidase complexes cannot be determined in a system based on 
the lectin binding function. Alternative and generally applicable methods must 
be sought to establish the optimal lectin-STAP complex composition for any 
lectin, independent of the lectin binding specificity. 
It was reasoned that complexes formed in STAP excess.will bind to a biotinylated 
solid phase, such as albumin-biotin coated to microtiter plates (figure 4-4). 
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At lectin-biotin excess on the other hand, not much STAP will be able to 
bind to albumin-biotin because all avidin groups on STAP are occupied by lectin-
biotin. At equivalence, some binding of STAP complexes will occur due to the 
presence of a few STAP or lectin-STAP complexes possessing avidin groups 
that are left unoccupied. The optimal amounts of lectin-biotin and STAP may 
thus be approached in this way, for instance by searching for the half-maximal 
peroxidase enzyme activity bound to immobilised albumin-biotin. 
By contrast, when using avidin coated plates quite different results are expected. 
In situations of STAP excess, as figure 4-5 shows, no binding will occur due 
to the absence of available biotin groups on the STAP complexes. In situations 
of lectin-biotin excess no binding of STAP will occur either because all 
immobilised avidin groups will be occupied with lectin-biotin. However, at 
equivalence some binding is to be expected due to the presence of available 
biotin groups on the lectin-biotin molecules bound to the STAP complexes, 
assuming more than one biotin group per lectin molecule. 
We thought that it might be possible to determine the best STAP and lectin-
biotin dilutions, for any biotinylated lectin, by using avidin coated microtiter 
plates. To investigate the feasability of this method the binding of preformed 
lectin-biotin-STAP complexes of different compositions was determined, both 
to avidin and to albumin-biotin coated microtiter plates, as well as to reference 
plates coated with a glycoprotein for which the lectin has affinity (figure 4-
6). We thus used the combination of desialo-a 1-acid glycoprotein (desialo-AGP) 
coated plates and the lectin from Ricinus communis (RCA) which binds to desialo-
AGP to determine if optimal binding in the desialo-AGP coated plates correlates 
with results obtained with avidin coated plates. If so, avidin (or streptavidin) 
coated microtiter plates may serve as a general tool to determine the best 
composition of complexes of STAP and biotinylated lectin (or other (binding) 
proteins such as antibody or protein A) without using the lectin binding function. 
4.3.2. Materials and methods 
4.3.2.1. Avidin coating of microtiter plates 
Hen egg white avidin (Sigma Chemical Company, St. Louis, USA) was 
dissolved in PBS to a concentration of 5 J.Lg /mi. 50 J.Ll was transferred to each 
well of a microtiter plate (Flow laboratories, Irvine, Scotland). One row was 
left uncoated. After 1 hour at room temperature the plates were washed four 
times with PBS containing 0.05% Tween-20, tapped empty on paper tissue and 
allowed to dry. Plates were wrapped in aluminium foil and stored in -20°C 
until use. 
4.3.2.2. Preparation of microtiter plates coated with perchloric acid soluble AGP 
To human plasma an equal volume of cold 0.6 M perchloric acid was added. 
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Figure 4-6. 
/ 
/ / 
Figure 4-4, 4-5 and 4-6: Schematic representation of (RCA)-STAP binding to microtiter plate wells 
coated with albumin-biotin, avidin or glycoprotein, respectively, as a function of RCA-biotin dilutions 
(left to right) and STAP dilutions (top to bottom). 
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The precipitate was removed by centrifugation. The supernatant was dialysed 
against PBS. It consists mainly of AGP with diminished sialic acid content due 
to the acid treatment, together with traces of other proteins. The solution was 
diluted to 50 J.Lg /ml. For coating the plates were treated as described above. 
4.3.2.3. Preparation of albumin-biotin coated microtiter plates 
Human albumin (KabiVitrum, Stockholm, Sweden) was biotinylated as 
described below for the lectins. The biotinylated albumin was diluted to a 
concentration of 5 J.Lg /ml, and coating was proceeded as described above. 
4.3.2.4. Biotinylation of lectin 
The lectin from Ricinus communis was obtained from E.Y. Laboratories, 
San Mateo (Calif., USA). This and other lectins were dissolved in 0.1 M carbonate 
buffer pH 9.5 at a concentration of 10 mg /ml. 200 J.Ll 0.1 M NHS-LC-Biotin 
(Pierce Chemical Company, Rockford, Illinois, USA) in 0.1 M carbonate buffer 
was added. After one hour at room temperature the mixture was applied on 
a 10 x 1.5 em (length x diameter) gel filtration column containing polyacrylamide 
gel (Desalting Bio-Gel, Biorad, Richmond, USA) to remove the excess free biotin. 
The column separation procedure was standardized with a mixture of albumin 
(11 mg /ml) and tryptophan (1 mg /ml). The biotinylated lectin was stored in 
200 J.Ll aliquots in -20°C until use. 
4.3.2.5. Preparation of lectin-STAP complexes 
In an uncoated microtiter plate ten stepwise dilutions (1 + 1 in PBS) of 
the biotinylated lectin which were made separately in glass tubes were added 
in one direction ("horizontal") to six stepwise dilutions (1 + 1 in PBS) of STAP 
(Amersham International, Amersham, England), made separately, in the other 
direction ("vertical"). The complexes were allowed to form for 1 hour before 
transferring 50 J.Ll of each complex to the corresponding well of each of the 
three microtiter plates coated with albumin-biotin, desialo-AGP and avidin, 
respectively. After incubation for 1 hour at 37°C the plates were washed four 
times with PBS-Tween and tapped empty on paper tissue. 160 J.Ll of a freshly 
prepared chromogen solution of OPD and H202 in 30 mM citric acid, pH 5.5 
was added. 
Color development was allowed to take place for 20 minutes, after which 
the enzyme reaction was stopped by adding 40 J.Ll 2.5 M H2SO4• Absorbance 
was read at 492 nm using a Titertek multiscan plate reader. 
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4.3.3. Results 
The color development due to the bound peroxidase activity in the albumin-
biotin coated microtiter plate is shown in figure 4-7. At high concentrations 
of biotinylated lectin no binding of STAP occurs. The extinctions are presented 
graphically in figure 4-8. 
Figures 4-9 and 4-10 show the enzyme activity in the microtiter plate coated 
with desialo-AGP. Both lectin-biotin excess and STAP excess lead to less 
peroxidase binding. 
The binding of lectin-STAP complexes to an avidin coated microtiter plate 
is shown in figure 4-11. Color development is only found at a fixed dilution 
ratio between biotinylated lectin and STAP. The extinctions are shown graphically 
in figure 4-12. 
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Figure 4-7 (top), 4-9 and 4-11 (bottom). Color development as a function of STAP and RCA-
biotin dilutions in microtiter plates coated with albumin-biotin, avidin and desialo AGP, respectively. 
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Figures 4-8 (top), 4-10 and 4-12. Graphic representation of the binding of RCA-STAP complexes 
to microtiter plate wells coated with albumin-biotin (top), avidin or desialo AGP (bottom) as a 
function of STAP and RCA-biotin dilutions. 
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4.3.4. Discussion and conclusions 
In the microtiter plate coated with desialo-AGP the RCA-lectin is the only 
constituent that binds, as neither streptavidin nor peroxidase have affinity for 
AGP. As the streptavidin-peroxidase complex is the only constituent with 
peroxidase activity, the binding of peroxidase to the plate can only be the result 
of complex formation between lectin and STAP, followed by binding of the 
complex through the lectin function. The results obtained with the glycoprotein 
coated plate indicate that the lectin dilution is not very critical. This is probably 
due to the stronger binding interaction of lectin molecules complexed by 
streptavidin, allowing multiple interactions with the coated glycoprotein, in 
comparison with the free lectin molecules that exist in solution in the case of 
lectin excess. 
In the avidin coated plate the situation is slightly different. Here, too, free 
STAP will not be bound. Free lectin may bind to the avidin glycans but this 
does not lead to bound enzyme activity. Color development only takes place 
after binding of the lectin-STAP complex, either through the lectin which may 
bind to the carbohydrate chains of avidin, or through the excess biotin groups 
located on the lectin molecules in the lectin-STAP complex leading to recognition 
by the coated avidin. In the avidin coated plate the dilutions of lectin and STAP 
are more critical. This is expected as due to the extremely high association 
constant of the avidin-biotin interaction the biotinylated free lectin molecules 
that exist in lectin excess will in this case quite effectively compete with lectin-
STAP complexes for the available avidin binding sites. Thus, a small amount 
of lectin excess can be tolerated in the glycoprotein coated plate, although it 
will lead to less binding in the avidin coated plate. 
In the albumin-biotin coated plate effective binding of STAP is observed, as 
expected. Biotinylated lectin occupies the available biotin binding sites on STAP 
leading to a gradual loss of STAP binding to the coated albumin-biotin at 
increasing lectin-biotin concentrations. 
For a few lectins the picture may be more complicated than as described 
above. In these cases the lectin binds to the carbohydrate groups of the peroxidase 
molecules in STAP. This interaction may have two results. First, the lectin may 
increase the process of multimerisation of STAP complexes due to its multivalency 
(most lectins are di- or tetravalent). This process adds to the complex formation 
already mediated by the multiple biotin groups on the lectin to which STAP 
complexes may bind, but the interaction is much weaker: Ka = 104 vs 1015 
M- 1. Second, the binding of the STAP complex to the glycan of the immobilised 
glycoprotein may also be mediated through interaction of the lectin with the 
carbohydrate groups of peroxidase. In such cases the biotinylation of the lectin 
may not be necessary at all. 
If one wishes to avoid this situation one might think of using a nonglycosylated 
marker enzyme, such as lactate dehydrogenase or E. coli alkaline phosphatase. 
However, the indicated interactions are probably not at all a disadvantage. It 
should be noted that this system only works when the lectin molecules contain 
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two or more biotin groups. Commercially available lectins contain on the average 
3-8 biotin molecules. 
The optimal ratios of lectin and STAP are those leading to high peroxidase 
activity in the avidin coated plates, and leading to a low peroxidase activity 
in the albumin-biotin coated plates. Given the results from the AGP coated 
plates we prefer to usc in our subsequent experiments a two-fold or four-fold 
excess of lectin-biotin. After establishment of the ratio of lectin solution and 
STAP solution, the concentration of the formed lectin-STAP complex is sub-
sequently chosen in such a way that an extinction of 1.0 is reached in 20 minutes. 
At higher STAP dilutions, the ratio becomes less critical. For most lectins we 
used 1:500 diluted biotinylated lectin solution (of0.25 mg /ml) and 1:1000 diluted 
STAP, which equals roughly 0.5 p,g of lectin per ml of 1:1000 diluted STAP. 
Thus, per well 25 ng of biotinylated lectin is used. 1 mg of biotinylated lectin 
suffices for 400 microtiter plates. 
We also compared avidin and streptavidin coating of microtiter plates (results 
not shown). A vi din coated plates yielded more color development, possibly due 
to a more efficient coating of avidin with its high pi compared with streptavidin. 
A vi din also has the advantage of being readily avialable. Thus, in practice the 
right dilutions of biotinylated lectin and of STAP are found on the "diagonal" 
line linking points of equal lectin /STAP ratio in the avidin coated plate as shown 
in figure 4-5, a line which corresponds with the decreased binding of STAP 
in the albumin-biotin coated plate as shown in figure 4-4. We have now 
successfully used this method with more than thirty lectins. 
In conclusion, the use of microtiter plates precoated with avidin and albumin-
biotin allows the fast determination of the equivalent amounts of biotinylated 
lectin and streptavidin-peroxidase as well as the optimal dilution of the complex 
formed, without using the lectin binding function. The method may also be used 
with other biotinylated binding proteins, such as antibodies or protein A. The 
method will be applicable in histochemistry, cytochemistry and immunochemistry. 
4.4.1 Determination of lectin specificity by investigating the lectin-enzyme 
binding to various neoglycoproteins absorbed in microtiter vlate wells. 
Lectins are detected by their capacity to agglutinate red blood cells. In most 
cases the structures of the sugar groups on the erythrocyte membrane to which 
they bind are not known. Inhibition studies with simple sugars, such as described 
in chapter 4.2 may give an indication with respect to the binding specificity 
of the lectin. However, while some lectins bind specifically to certain terminal 
monosaccharides, most lectins show higher affinities to complex structures, often 
extending to three or more sugar sequences. It is also important to note that 
the oligosaccharide structure involved in the binding of a lectin may be quite 
different from the best monosaccharide inhibitor. 
Given the large diversity of the erythrocyte glycolipids and glycoproteins, it 
is reasonable to assume that most lectins will bind to a number of such structures, 
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with each interaction having its own assoc1at10n constant. When adding a 
competing saccharide the weak interactions will be inhibited first. Hemagglu-
tination inhibition studies are thus only leading to an approximation of the binding 
specificity of the lectins. The bound structures are known only in the case of 
blood-group specific lectins. 
A second method to investigate the binding specificity is to use lectins 
immobilised on the solid phase of a chromatography column. Radioactively 
labelled carbohydrates or glycopeptides are chroma to graphed and their retention 
times compared (Narasimhan et al., 1985; Osawa et al., 1987). 
The second method has the advantage of using well-defined saccharides 
interacting with the immobilised lectins. However, the use of radioactive isotopes 
is a disadvantage. Beside~, the lectin-column chromatography experiments are 
very time consuming. They also need a relatively large amount of lectin to 
be immobilised. These large amounts are not always available, as is the case 
of human membrane lectins. 
In principle, lectin-enzyme binding studies do not have the drawbacks described 
above. If well-defined gycoconjugates are immobilised, a fast and unequivocal 
determination of the lectin binding specificity is possible. The amounts of material 
involved would be in the microgram range. 
In this chapter experiments are described in which a number of well-defined 
BSA-glycoconjugates are adsorbed to microtiter plates. A large number of lectin-
STAP complexes were allowed to bind. Subsequently, the amount of bound 
peroxidase activity was quantitated. 
4.4.2. Materials and methods 
The lectins used were selected from table 4-1. 
The following BSA-glycoconjugates were obtained from Janssen Pharmaceutica 
(Beerse, Belgium) (table 4-2). 
The BSA-glycoconjugates were dissolved in PBS. After measurement of the 
optical density at 280 nm they were further diluted to a final concentration 
of 5 11g /ml, assuming for all BSA-glycoconjugates an extinction of 0.53 for 
a 1.0 mg /ml solution. One lane was coated with avidin (Sigma, St. Louis, USA) 
at a concentration of 5 11g /ml. One lane was coated with biotinylated albumin 
at a concentration of 5 11g /ml. 
Coating was allowed to take place in flexible PVC microtiter plates (Flow 
laboratories, Irvine, Scotland) for 1 hour. Subsequently, plates were washed five 
times with PBS containing 0.05% Tween 20, followed by a short incubation 
with PBS-Tween containing 5 11g /ml human albumin (Biomerieux, Lyon, France) 
and 0.05% v /v Triton X -100 (Technicon, Tarrytown, USA). Plates were tapped 
empty on paper tissue and allowed to dry. They were stored in -20°C wrapped 
in aluminium foil. The lectin-STAP binding protocol used is given in chapter 
4.3. 
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Table 4-1. Lectins available for use in lectin-enzyme binding studies. 
Lectins Abbrev. Cat no Footnote 
- Limulus polyphemus LPA L-1501 (a) 
- Lotus tetragonolobus Lotus L-601 (a) 
- Bauhinia purpurea BPA L-2501 (a) 
- Madura pomifera MPA L-3901 (a) 
- Euonymus europaeus EEA L-4201 (a) 
- Datura stramonium DSA L-5701 (a) 
- Ulex europaeus I UEA-I L-2201 (a) 
- Ulex europaeus II UEA-11 L-2202 (a) 
- Vicia villosa VVA L-4601 (a) 
- Erythrina cristagalli ECA (b) 
- Erythrina corallodendrum ECO (b) 
- Tridacna maxima TMA (c) 
- Solanum tuberosum STA (c) 
- Crotalaria juncea CJA (c) 
- Pisum sativum PSA L5380 (d) 
- Phaseolus vulgaris 
Leucoagglutinin PHA.L L8504 (d) 
- Phaseolus vulgaris 
eryagglutinin PHA.E L8629 (d) 
- Lens culinaris LCA L5880 (d) 
- Arachis hypogaea PNA L0881 (d) 
- Ricinus communis I RCA L8508 (d) 
- Bandeiraea simplicifo1ia II BSII L7508 (d) 
- Concanavalin A Con A 17-0450-01 (e) 
- Triticum vulgaris WGA 17-0750-01 (e) 
- Aleuria aurantia AAL (f) 
- Limax Flavus Lim ax (g) 
- Abrus precatorius APA (d) 
- Artocarpus integrifolia AlA (Jacalin) (d) 
- Anguila anguila AAA (d) 
- Phylodendron californium PCA (h) 
- Artocarpus communis ACA (i) 
Sources: 
a. Gift from E.Y. laboratories, San Mateo, California. USA. 
b. Gift from Prof. N. Sharon, Department of Biophysics, The Weizmann Institute of Science, Rehovot, 
Israel. 
c. Gift from Prof. G. Uhlenbruck, University of K6ln, West-Germany. 
d. Obtained from Sigma Chemical Company, St. Louis, USA. 
e. Obtained from Pharmacia, Uppsala, Sweden. 
f. Gift from Dr. H. Debray, Universite de Lille, Lille, France. 
g. Gift from Prof. J. Angeray, Universite de Paris Sud, Paris, France. 
h. Gift from Prof. H. Franz, Staatliches Institut fiir Immunprliparate und Nahrmedien. 
i. Gift from T. Animashaun, MRC, London, England. 
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Table 4-2. Available BSA-glycoconjugates. 
Cat. Molar Structure 
nr chain ratio 
B-1000 30-40 CHr 
B-1001 20- 30 Glc,B-
B-1002 30- 40 Gal,B-
B-1003 30-40 Mana-
B-1004 20- 30 Galf31-4Glcf3-
B-1005 20- 30 Galf31-4GlcNac{3-
B-1006 30-40 Gala l-4Galf3-
B-1007 10-20 Olea l-6Glca l-4Glca l-4Glcf3-
B-1008 10- 30 GlcNAca l-4{Fuca l-6}GlcNAc[3-
B-1009 15- 30 Gala l-4Galf31-4Glcf3-
B-1010 20-40 Gala l-4Gal[31-4GlcNAc[3-
B-1011 10- 20 Galf3l-3GalNAc[3-
B-1012 25- 35 Gal{31-3GlcNAc[3-
B-1013 30- 40 GlcNAc,B-
B-1014 20- 30 GalNAc,B-
4.4. 3. Results 
The peroxidase enzyme activity found in the glycoconjugate-coated wells is 
compared with the activity found in the avidin-coated wells. This latter activity 
is taken as 100%, and expressed in table 4-3 as++. Higher activities are+++. 
Between 20% and 100% of the avidin signal is given +, and between 10% 
and 20% is given ±. Below 10% is considered negative: -. 
4.4.4. Discussion and conclusions 
The method described in this chapter allows the fast and detailed determination 
of the binding specificity of the lectin used. The lectin-STAP complex is simply 
added to all wells, and within a few hours the results are available. The plates 
coated with the BSA-glycoconjugates are stored in the freezer. We observed 
no loss in binding of any of the lectins, indicating stability of the coated and 
dried plates. This allows the coating at one time of a large number of plates 
for later use, thus contributing to the efficiency of the method described. For 
RCA, representation of the results as follows leads to a few new findings. 
From these results it may be concluded that RCA may bind slightly to 
innerchain -4Gal,81-4Glc(NAc),8-structures. The addition of terminal a 1-4 
galactose has a much larger influence on the binding to the lactosamine group 
than to the binding to the lactose group. It is also apparent that the introduction 
of a glucose group between the terminal ,8-galactose and the carrier protein 
slightly inhibits binding of RCA, but that a subsequent addition of an N-Acetyl 
group to the glucose increases the binding to higher than original values. 
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Table 4-4. RCA-STAP binding to some BSA-glycoconjugates. 
Sugar 
Gal,B-
+++ 
Gal,B I - 4Glc,B -
++ 
Gal,B I - 4GicNAc,B -
++++ 
Gala I - 4Gal,B I - 4Gic,B -
+ 
Gala I - 4Gal,B I - 4GlcNAc,B-
+ 
Gala I - 4Gal,B-
0 
Molar BSA /glycan ratio 
30-40 
20- 30 
20- 30 
15- 30 
20-40 
20-40 
Not all BSA-glycoconjugates carry exactly the same number of saccharide 
chains per BSA molecule. It is not expected, though, that this number has a 
significant influence on the results, as the BSA-glycoconjugate can only acco-
modate a few lectin-STAP complexes at the most. The molar glycan ratio will 
therefore be effectively in excess in all cases. 
The method is validated by the fact that lectins with known indentical 
specificities show exactly the same binding pattern in BSA-glycoconjugate coated 
microtiter plates. For instance, the lectin called Jacalin from the jackfruit 
(Artocarpus integrifolia) from Venezuelan sources shows the same binding pattern 
as the lectin from the breadnut (Artocarpus communis) from Nigerian sources, 
although no doubt the plant species, the isolation procedures and purity are 
different. The lectins LCA and PSA with slightly different binding specificities 
(Kornfeld et al., 1981) both bind to none of the BSA-glycoconjugates. ECA 
and ECO, isolated from different Erythrina species, bind only to Gal,B1-4GlcNAc,B 
structures. For the other lectins, the known binding specificities (Goldstein et 
al., 1978; Liener et al., 1986) are confirmed by our assays. However, in a number 
of instances new or extended affinities are found. For example, the binding of 
Jacalin and ACA, known to be Gal /GalNAc specific, to Mannose and (Glc)4 
as well as to GlcNAc,B1-4 (Fuc a1-6) GlcNAc,B is a new finding. It appears 
that our assay is more sensitive than other techniques leading to the detection 
of weak interactions not found by hemagglutination or lectin-column chroma-
tographic techniques. 
A similar approach has been used for studying the lectin binding specificity 
to glycosphingolipids (Molin et al., 1986). The lipids were coated onto microtiter 
Table 4-3. Binding of 30 lectin-STAP complexes to 14 immobilized BSA-neoglycoconjugates. 
I I I I I I I I I I Lima x I I I I I I 
I OSA I RCA I WGA 1· ECA I ECO I LCA I PNA I THA I AAA I flavus I APA I WA I Lotus I ACA I BSA I 
_____________ l __ , __ , __ , __ , __ l __ , __ , __ , __ , __ , __ l __ l __ l __ , __ , 
B-1000 = CH l-1-1-l-l-1-1-l-l-l- 1-1-1-1-1-1 
--------.,---------'--'--'--'--'--'--'--'--'--'--'--'--'--'--'--' a-1001 = Glc~ I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
--------.,---------'--'--'--'--'--'--'--'--'--'--'--'--'--'--'--' a-1002 = Gal~ I - I ••• I - I - I - I - I - I - I - I - I ••• I - I - I - I - I 
_____________ l __ , __ , __ , __ , __ l __ l __ , __ , __ , __ l __ l __ l __ l __ , __ l 
B-1003 = Han« l-1-l-1-1-l-l-1-l-l- 1-1-1-1•1-1 
_____________ I __ J __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I 
B-1004 = Gal~ 1-4Glc~ I - I ++ I - I - I - I - I - I - I - I - I ++• I - I - I - I - I 
_____________ l __ , __ , __ , __ , __ l __ , __ , __ , __ , __ , __ l __ l __ l __ , __ , 
B-1005 = Gal~ 1-4GlcNac~ I •· I ••• I ••• I ••• I • I - I - I - I - I - I ••• I - I - I - I - I 
_____________ , __ , __ , __ , __ , __ , __ , __ , __ , __ , __ , __ , __ , __ , __ , __ , 
B-1006 = Gal« 1-4Gal~ 1-1-1-1-l-1-1-l-1-1- 1-1-1-1-1-1 
_____________ , __ , __ , __ , __ , __ l __ , __ , __ , __ , __ l __ l __ , __ l __ , __ l 
B-1007 = Glc« 1-6GlC« 1-4Glc« 1-4Glc~ 1-1-l-1-1-1-1-l-1-1- 1-1-l-l.!:.l-1 
-----------,--,----:-'--'--'--'--'--'--'-'--'--'--'--'--'--1--1--1 a-1ooe = GlcNac~ 1-4fFuc« 1-6lGlcNac~ I - I - I ••• I - I - I - I - I - I • I - I - I - I - I .!:. I • I 
_____________ l __ l__l __ l __ l __ l __ l __ l_. _l __ l __ l __ l __ , __ , __ l __ l 
B-1009 = Gal« 1-4Gal~ 1-4Glc~ I - I • I .!:. I - I - I - I - I - I - I - I ••• I - I - I - I - I 
_____________ , __ l __ l __ l __ l __ , __ l __ l __ l __ l __ , __ , __ l __ l __ l __ l 
a-1010 = Gal« 1-4Gal~ 1-4GlcNac~ I .!:. I • I ••• I - I - I - I - I - I - I - I •• I - I - I - I - I 
_____________ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I __ I_._J __ I 
a-1011 =Gal~ 1-3Ga1Nac~ I - I •• I .!:. I - I - I - I •• I - I - I - I ••• I .!:. I - I •• I - I 
_____________ l __ l __ l __ , __ l __ l __ l __ l __ , __ l __ l __ l __ l __ l __ l __ l 
B-1012 = Gal~ 1-3GlcNac~ I - I + I - I - I - I - I - I - I - I - I +++ I - I - I NT I NT I 
_____________ l __ l __ l __ l __ l __ , __ , __ , __ l __ l __ l __ l __ l __ l __ l __ l 
B-1013 = GlcNacp I - I - I +++ I - I - I - I - I - I - I - I - I - I - I - I • I 
_____________ I __ I __ I __ I __ I __ I __ I __ I __ J __ I __ I __ I __ I __ I __ J __ I 
B-1018 = GalNacp 1-l-1-l-1-l-1-l-l-l- 1-1-1•1•1-1 
00 
0 
I I I I I I I I I I I I I Jaca I 
I LPA I PSA IPHA-LI STA I BPA I HPA I EEA IPHA-EICon-AI CIA IUlex-1IUlex-21 lin I AAL I PCA I 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1000 = CH l-l-1-l-l-l-1-1-l-1-1- 1-1-1-1-1 
_____________ l __ l __ l __ l __ l __ l __ . l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1001 = Glc~ 1-1-l-1-l-l-l-1-l-1-l- 1-1-1-1-1 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1002 = Gal~ l-l-1-1-l.tl-l-1-l-1-l- 1- 1-1-1>+1 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
s-1oo3 = Hana I - I - I - I - I - I - I - I - I +++ I - I - I - I + I - I - I 
. l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1004 = GalP 1-4GlcP I - I - I - I - I - I - I - I - I - I + I - I - I - I - I + I 
--------,-------l __ l __ l __ l __ l __ l __ l __ l_· _l __ l __ l __ l __ l __ l __ l __ l 
B-1005 = GalP 1-4GlcNacP I - I - I - I - I .t I - I - I - I - I ++ I - I - I - I - I +++ I 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1006 = Gala 1-4Gal~ 1-l-1-1-l-1-1-1-l-1-1- 1-1-1-1-1 
-------,-------,---1-_l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l ___ l __ l __ l __ l 
B-1007 = Glca 1-SGlca 1-4Glca 1-4GlcP I - I - I - I - I - I - I - I - I ++ I - I - I - I .t I - I - I 
-----------,----1-_l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1008 = GlcNacp 1-4(Fuca 1-S)GlcNacp I - I - I - I - I - I - I - I - I - I - I - I - I .t I +++ I - I 
_____________ l __ l_~l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1009 = Gala 1-4GalP 1-4GlcP I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
e-1010 = Gala 1-4GalP 1-4GlcNacP I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
s-1011 = GalP 1-3GalNacP I - I - I - I - I +++ I - I - I - I - I - I - I - I ++ I - I - I 
_____________ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1012 = Gal~ 1-3GlcNac~ I - I - I - I - I .. I - I - I - I - I NT I NT I NT I NT I NT I NT I 
-------:--------1-_l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1013 = GlcNacP I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
-------:--------1-_l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l __ l 
B-1018 = GalNacP I - I - I - I - I - I " I - I - I - I - I - I - I - I - I - I 
00 
>-' 
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plates by evaporating the solvent from a cholesterol-lecithin-lipid solution. 
Biotinylated lectins were allowed to bind. After washing, avidin-peroxidase 
conjugate was added and the amount of bound peroxidase subsequently quan-
titated. 
The method described in this chapter would not have the problems associated 
with coating microtiter plates with glycosphingolipids. Such a coating has to 
be made by evaporating the solvent (i.e. methanol) from a certain critical mixture 
of glycolipid, cholesterol and lecithin. The BSA-glycoconjugates that we used 
show excellent passive adsorption from solution onto the microtiter plates. When 
BSA-lipid conjugates become available they could be used to investigate lectin 
binding to lipids. 
A second difference between the two methods is the addition in our assay 
system of preformed lectin-streptavidin-peroxidase complexes, in contrast to the 
addition of biotinylated free lectin. In view of the possible resolubilisation of 
bound lectin molecules during wash cycles (Cerven et a!., 1981), we preferred 
the complexing oflectin molecules through streptavidin before use. In our method 
no loss during wash cycles was observed. This was not tested in the other method. 
A reversed technique has been developed recently, in which the lectins RCA, 
WGA and Con A are immobilized to· Sepharose and BSA-glycoconjugates are 
passed over the lectin column. Maltose BSA, lactose-BSA and (GicNAc)rBSA 
were bound to immobilized Con A, RCA and WGA-Sepharose, respectively 
(Ito, 1985). In principle, the results obtained with lectin column chromatography 
of BSA-glycoconjugates should be comparable with our lectin-enzyme binding 
assays in BSA-glycoprotein-coated plates. 
At present only a relatively small number ofBSA-glycoconjugates are available 
for testing. This still limits the application of the method to those lectins that 
bind to one or more of the available glycoconjugates. However, in the near 
future much more glycoconjugates will certainly become commercially available. 
A second limitation that exists at present is found in the structures of the 
glycoconjugates. These structures are synthesized in th~ test tube, and not all 
of them occur linked to plasma glycoproteins. Although they are useful as 
indicators of the binding specificity of the lectins, they may or may not give 
information with respect to the binding of lectins to naturally occuring gly-
covariants of N-linked and 0-linked glycans. It is expected that this limitation 
will be overcome in the near future in two ways. Firstly, an abundantly available 
glycoprotein with one or two simple glycans (i.e. transferrin) may be used to 
prepare a set of glycovariants. The neccessary enzymes (i.e. neuraminidase, /3-
galactosidase, {3-N-acetylglucosaminidase, a-fucosidase, etc.) are at present 
available or becoming available. The separation and purification of the gly-
covariants may be accomplished by chromatofocusing or anion-exchange chro-
matography if sialic acids are involved (chapter 3), and by lectin affinity 
chromatography. 
Secondly, the enzymatic removal of complete glycans from glycoproteins by 
enzymes such as N-glycanase, 0-glycanase and Endo F allows the production 
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on a preparative scale of free glycans, which may subsequently be coupled by 
chemical means to inert carriers such as BSA. 
In conclusion, the binding of lectin-enzyme conjugates to microtiter plates 
coated with BSA-glycoconjugates enables the specificity oflectins towards several 
carbohydrate units to be investigated rapidly. 
4.5.1. The investigation of lectin-enzyme binding to purified human plasma 
glycoproteins adsorbed in microtiter plate wells 
In order to achieve a high sensitivity of lectin-enzyme binding assays in a 
clinical setting, the lectin used should not bind to the glycoprotein in plasma 
from healthy subjects. It should bind, however, to the (minor) fractions of the 
glycoprotein that are abnormally glycosylated during disease. Thus, a suitable 
lectin should meet two conditions. Firstly, there should be little binding to the 
normally glycosylated protein. This condition is explored in the experiments 
described here. Secondly, the lectin should bind to the glycoprotein in certain 
disease states. This condition is explored in chapter 5 where a number of lectins 
are tested for their ability to discriminate between a glycoprotein from healthy 
subjects and from a number of patients. 
Various ways exist to investigate the binding of a lectin to glycoproteins present 
in normal plasma. One might think of affinity chromatography of whole plasma 
over immobilised lectin columns (chapter 2), or crossed affino-immunoelectro-
phoresis with a lectin in the first dimension. These techniques are very laborious 
and large amounts of lectin are needed. It was therefore decided to explore 
the lectin-enzyme binding in microtiter plates coated with the major human 
plasma glycoproteins in purified state. This technique needs very small amounts 
of the purifed glycoproteins because complete adsorption is achieved with 
approximately one microgram per well. The technique also uses only extremely 
small amounts of the lectin: nanograms per well. The ease and speed of the 
assay were also considered to be superior over other techniques, allowing the 
screening of a large number of lectins. 
Microtiter plates were coated with eighteen plasma glycoproteins purified from 
normal plasma. The binding of 30 biotinylated lectin-STAP complexes was 
quantitated. 
4.5.2. Materials and Methods 
The lectins used were selected from table 4-1. The human plasma proteins used 
were those from table 4-5. 
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Table 4-5. Purified human plasma proteins used in lectin-enzyme binding studies. 
Protein 
Lactoferrin 
Thyroxin-binding Globulin 
Hemopexin 
Gc-Globulin 
8Sa3-Glycoprotein 
a2- HS- G I ycoprotei n 
Acid-a 1-Glycoprotein 
a 1,6-Glycoprotein 
Haptoglobin 
/32-Glycoprotein 
Transferrin 
a 1-Antitrypsin 
Ceruloplasmin 
Immunoglobulin A 
Immunoglobulin G 
a 2-Macroglobulin 
Immunoglobulin M 
Albumin 
Sources: 
Cat no. 
K.Nr.J90875 
K.Nr.271184 
K.Nr.J70382 
K.Nr.241277 
K.Nr.J50482 
K.Nr.091285 
K.Nr.080378 
K.Nr.280 180 
K.Nr.280379 
K.Nr.261182 
K.Nr.040223 
K.Nr.090379 
K.Nr.291082 
No. I-1010 
No. I-4506 
No. M-4514 
No. 401107 
88377 
a. Gift from Behringwerke (Marburg, West-Germany). 
b. Obtained from Sigma Chemical Company (St. Louis, USA). 
c. Obtained from Calbiochem (Behring Diagnostics, La Jolla, USA) 
d. Obtained from KabiVitrum (Stockholm, Sweden). 
Coating of human plasma (glyco)-proteins to microtiter plates 
Footnote 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(a) 
(b) 
(b) 
(b) 
(c) 
(d) 
All plasma proteins were dissolved in PBS to a final concentration of 5 f.lg I 
mi. 50 f.ll was transferred in duplicate to the microtiter plates obtained from 
Flow Laboratories. 
After one hour the plates were washed four times with PBS containing 0,05% 
Tween-20, tapped empty on paper tissue and allowed to dry. Plates were wrapped 
in aluminium foil and stored in -20°C until use. 
Biotinylation of lectins 
Lectins were biotinylated as described under 4.3.2.4. 
Determination of the optimal concentrations of biotinylated Lectin and Strep-
tavidin-Peroxidase-Complex 
This procedure is described under 4.3.2.5. 
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Lectin enzyme binding assay 
For each lectin, 50 j.d of the lectin-streptavidin-peroxidase (Lectin-STAP) 
complex was prepared as described above, and added in the microtiter plates 
precoated with the eighteen plasma proteins. Besides, one row was left uncoated 
(blank value). One row was coated with biotinylated albumin and one row was 
coated with avidin to check the composition and concentration of the lectin-
STAP complex. 
After 120 minutes incubation at 37°C, the plates were washed four times 
with PBS-Tween, and tapped dry on paper tissue. 160 ,ul of peroxidase reagent 
(0PD-H20 2) was added, and color development was allowed to take place at 
room temperature in the dark for 20 minutes. The reaction was stopped with 
40 ,ul of 2.5 M H2S04, and the absorbance read at 492 nm. 
4.5.3. Results 
The absorbance due to the peroxidase enzyme activity in the avidin coated 
lane is taken as 100%. Readings between 80% and 100% are expressed in table 
4-6 as +++, higher values as ++++. Values between 50% and 80% are 
++,between 80% and 20% are+ and between 20% and 10% are±. 
4.5.4. Discussion and conclusion 
The binding of lectin-STAP complexes to passively adsorbed glycoproteins 
is influenced by a number of variables. First, the density of the various coated 
glycoproteins is probably not the same because some glycoproteins coat "better" 
than others. Second, the glycan density on the molecule may be involved, as 
well as the spatial arrangement of these branches. Third, the presence of structures 
for which the lectin has affinity is a prerequisite for binding. Together, these 
three variables determine the amount of lectin bound to the microtiter plate 
well. 
From the glycoproteins tested, IgM appears to bind to most lectins. This 
is probably due to a number of factors. First, in contrast to all other plasma 
glycoproteins, the immunoglobulins are very heterogenous with respect to their 
aminoacid sequence, and in consequence their glycosylation at the Fab-arms 
is extremely diverse. Many immunoglobulin molecules do not have any Fab-
arm-linked glycans, while others have one or more of these glycans. On the 
average 0.8 glycan is present on the Fab-arm (Rademacher et al., 1984). Fc-
glycosylation is heterogenous with respect to the glycan structures only. The 
number of Fc-linked glycans is fixed per immunoglobulin class. 
Second, due to the pen tam eric structure of IgM, the number of glycans bound 
to one molecule is relatively large. This fact may facilitate the binding of lectins 
which have restricted spatial arrangements by allowing a large number of possible 
interactions. The same is probably true for a 2-macroglobulin, which has an 
Table 4-6. Binding of 30 lectin-STAP complexes to 17 immobilized human plasma glycoproteins and albumin. 
I EGA I EGO I LGA I PNA I IMA I GJA I VVA IUlexliUlex21Jaca-l AGA ILotusl EEA I DSA I BSA I 
l __ l __ l __ l __ l __ l __ l __ l __ l __ llin l __ l __ l __ l __ l __ l 
""'"La-c-to-=f-er_r..,in ___ l - I - I +++ I - I ± I + I - I ++ I + I ± I - I - I - I - I + I 
l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
=Th-y-ro-x-r1n,_b~.G,l-.ob-u'"li,_n--l - I - I - I - I - I - I - I - I - I - I - I - I - I + I - I 
l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
"""He-m-op_e_x1.---.n-----l - I - I - I - I - I - I - I - I - I++++ I++++ I - I - I + I - I 
~........--,---..--.-----l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l Gc-globulin I - I - I - I - I - I - I - I - I - I + I ± I - I - I + I - I 
l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
=as=-a---=G~ly-c-op-r-ot-e.-in-1 - I - I + I - I - I - I - I - I - I ++ I + I - I - I ++ I - I 
3 l_l_l_l __ l_l_l __ l_l_l_l_l_l_l_l __ l 
a -HS-Glycoprotein I - I - I - I - I - I - I - I - I - I++++ I++++ I - I - I - I - I 2 l_l_l __ l_l_l_l_l_l_l_l_l_l_l_l __ l 
Acid-a -Glycoprotein! - I - I - I - I - I - I - I + I - I +++ I ++ I - I - I + I - I 1 l_l_l_l_l_l_l __ l_-_l_l_l_l_l_l_l __ l 
a -~=Glycoprotein I - I - I - I - I - I - I - I + I - I + I - I - I - I - I - I 1 I I l __ l __ l_l I 1_-_l_l_l_. l_l_l_l __ l 
Lptoalo61n 1---~---1 - I - I - 1---~---1 - I - I - I - I - I - I++++ I - I 
----,~-..,---.----l_l_l_l_l_l_l __ l_l_l_l_l_l_l_l __ l 
~ 2 -Glycoprotein I - I - I + I - I - I - I - I ± I - I - I - I - I - I + I - I 
=----.,------;-----l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
Transferrin I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
----:-;-.,-------.---l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
a -antitrypsin I - I - I - I - I - I - I - I - I - I + I + I - I - I + I - I 1 l_l_l_l_l_l_l __ l_l_l_l_l_l_l_-_1 __ 1 
IgA I - I - I ++ I + I - I + I - I - I - I++++ I++++ I ± I + I - I ++ I 
~.,------,---~.----l_l_l_l_l_l_l_l_l_l_l_' l_l_l_l __ l 
a2-Macroglobulin I - I - I + I - I - I - I - I - I - I ++ I + I - I - I - I ± I :--:-:-_____ l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
IgM I ++ I - I ++ I + J + I + I - I - I - I + I + I ++ I - I + I +++ I 
-~.,.---~--l_l_l_l_-_l_-_l_l_l_l_l_l_-_l_l_l_-_1_1 
eeruloplasain I - I - I + I + I + I + I - I - I - I - I - I - I + I + I - I 
..,....-r---.,-____ l_l_l_l_-_l_-_l_-_l_l_l_l_l_l_l_-_l_-_1_1 
A16uain I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
IgG I - I - I ++ I - I + I - I - I - I - I + I + I + I + I - I ++ I 
_______ l_l_l_l __ l_-_l_l_l_l_l_-_1_-_l_-_l_l_l __ l 
00 
0\ 
I LFA I PCA I AAL IPHA.LI RCA I VGA I PSA I STA I LPA I BPA I MPA IPHA-EICon AI APA I AAA I 
.---:----;:---.----'-'-'-'-'-'-'-'-l_l_l_l_f_l_l_l Lactoferrin I - I +++ I +++ I - I +++ I - I ++ I + I + I + I - I + I + I +++ I ++ I 
l_l_l_l_l_l_l_l_-_l_-_1_1_1_1_1_1_1 
=Th_y_r_ox~i~nb~.~G~lo~b~ul~i-n-1 + I + I - I - I +++ I + I - I - I + I + I - I - I + I +++ I - I 
..-----...-----'-'-l_l_l_l_l_l_l_-_l_-_1_1_1_1_1_1 Hemopexin I - I + I - I - I +++ I ++ I - I - I + I - I - I - I + I +++ I - I 
l_l_l_l_l_l_l_l_l_-_l_l_l_l_-_1_1_1 
,....Gc--~gl...-o.-bu-,l-.--in,------1 - I - I - I - I - I - I - I - I - I - I - I - I - I + I - I 
l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
=as~~--~G=l-yc_o_p-ro~t-el~.n---1 ++ I +++ I + I - I +++ I ++ I + I - I + I - I - I - I ++ I +++ I - I 
3 l_l_l_l_l_l_l_l_l_-_1_1_1_1_1_1_1 
~ -HS-Glycoprotein I - I + I - I - I ++ I +++ I - I - I - I - I - I - I + I ++ I - I 2 l_l_l_l_l_l_l_l_l_l_l_l_l_-_1_1_1 
Acid-~ -Glycoprotein! - I + I + I - I + I ++ I - I - I - I - I - I - I - I ++ I - I 1 l_l_-_1_-_l_l_l_l_l_l_l_l_l_l_l_l_l 
~ -e-Glycoprotein I - I + I - I - I +++ I - I - I - I - I - I - I - I ± I +++ I - I 1 l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
laptoglobin I ++ I +++ I - I +++ I +++ I - I + I - I - I - I - I - I ++ I +++ I - I 
----,.........--...,......-r---1 I 1_1_1 1_1_-_l_l_l_l_l_l_l_l_l 
e -Glycoprotein 1-----1~1 + I - I +++ I + I + I - I - I - I - I - I + I +++ I - I 2 1_1_1_-_l_l_l_l_l_l_l_l_l_l_l_l_l 
Transferrin I - I + I - I - I ++ I - I - I - I - I - I - I - I + I ++ I - I 
-~-----,---1_1_-_l_l_l_l_l_l_l_l_l_l_l_-_1_1_1 
~ -antitrypsin I - I + I - I - I ++ I + I - I - I - I - I - I - I + I +++ I - I 1 I I 1_1_1 l_-_l_l_l_l_l_l_l_-_1_1_1 
IgA 1-----1~1 +++ I - I +++ I +++ I ++ I + I + I +++ I +++ I ++ I +++ I +++ I - I 
---...------.,--,...,....----1-l_l_l_l_l_l_l_l_-_l_l_l_l_l_l_l 
~ -Macroglobulin I + I +++ I + I - I +++ I ++ I + I + I + I - I + I + I - I +++ I - I 2 l_l_l_l_l_l_l_l_-_l_-_l_l_-_1_1_1_1_1 
IgM I + I +++ I ++ I + I +++ I ++ I +++ I +++ I ++ I ++ I + I +++ I +++ I +++ I + I 
1_1_1_1_-_l_l_l_l_l_l_l_-_l_l_l_l_l 
""'ce-r-u"lo-p.,la_s_m-.in ___ l + I - I - I - I ++ I + I - I + I - I - I - I - I + I ++ I - I 
~----.-----l_l_l_l_l_l_-_l_l_-_l_l_l_l_l_-_1_1_1 
Albumin I - I - I - I - I - I - I - I - I - I - I - I - I - I - I - I 
~-----l_l_l_l_l_l_l_l_l_l_l_l_l_l_l_l 
IgG I - I ++ I ++ I - I +++ I + I ++ I ++ I + I - I - I + I + I +++ I - I 
______ 1_1_1_1_1_1_-_l_l_l_l_l __ l_l_l_l_l 
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estimated 23 glycans per molecule. If the intermolecular distances are large 
in comparison to the intramolecular distances between glycans, this aspect of 
glycan density is of importance. Third, IgM probably binds well to polystyrene 
surfaces due to its average pi and molecular weight. Some lectins bind even 
better to IgA than to IgM, i.e. PNA and MPA. No doubt this is caused by the 
presence of o::l-3 linked galactose in 0-linked glycans that occur in IgA 1• The 
excellent binding of BPA is also to be noted. The binding characteristics of 
these three lectins are similar, although not the same (Wu, 1984). 
IgG shows slight binding to a large number of lectins. Here the glycan diversity 
mentioned above for IgM has the same effect. 
a 2-macroglobulin also binds slightly to a large number oflectins. The described 
effect of molecular size and glycan density on lectin binding is of importance 
here. Absence of binding of a 2-macroglobulin to PNA and BPA is noteworthy. 
Haptoglobin also shows a peculiar reaction pattern. Of the galactose-specific 
lectins, it shows very strong binding to RCA. This interaction is confirmed by 
the unique affinity of DSA for haptoglobin. DSA binds only to terminal galactose 
groups (Yamashita et al., 1987). On the other hand, ECA did not bind to 
haptoglobin, although it is also galactose-specific. A number of other lectins 
appear to bind to fractions of haptoglobin, or bind with lower affinities. 
Two proteins did not show any binding to the lectins tested. One is albumin 
which is not a glycoprotein, thus no lectin binding is expected. It merely served 
as a control to detect any nonspecific binding of the lectin-streptavidin-peroxidase 
complex to the protein-coated wells. Gc-globulin (vitamin D binding protein 
or group-specific component) is bound weakly by Jacalin, ACA, DSA and APA. 
This protein, however, is a glycoprotein. It probably contains one non-sialylated 
N-linked glycan (Uhlenbruck et al., 1979). Apparently, this is not enough to 
bind most of the lectins. Its coating efficiency to polystyrene microtiterplates 
is unknown. 
The broad specificity of RCA towards plasma glycoproteins, as described earlier 
by Uhlenbruck (1978) for plasma asialoglycoproteins, is confirmed by our results. 
Part of this reactivity may be explained by the low affinity of RCA for innerchain 
Gal,B 1-4-structures as in sialylated N -linked glycans (Baenziger et al., 1979, 
Narasimhan et al., 1986; see also chapter 4.4). In contrast to a2-6-linked, the 
a2-3-linked sialic acids allow some interactions with the penultimate galactoses, 
both with RCA I as with lrPHA and E-PHA lectins (Green et al., 1987a, b). 
WGA also seems to bind (fractions of) most glycoproteins; az-HS glycoprotein 
and IgA binding best. Monoclonal human IgG3 interacts with RCA, in contrast 
to IgG1, IgG2 and IgG4 (Saltvedt et al., 1975). a 2-macroglobulin, haptoglobin, 
IgM and IgA are retarded by immobilized RCA (Harboe et al., 1975). 
The similar binding specificity of LCA and PSA (Kornfeld et al., 1981) is 
confirmed in this study. The binding to lactoferrin suggests the occurrence of 
fucose, probably a general finding in milk glycoproteins. The lectins Jacalin 
and ACA from two Artocarpus species (jackfruit and breadnut) also show a 
strong resemblance in binding. 
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Con A like WGA binds to (fractions of) most plasma glycoproteins, although 
its pattern is clearly different from WGA. Con A did not bind to a 1-acid 
glycoprotein, a finding contrasting with results obtained by crossed affino-
immunoelectrophoresis (Hanson et al., 1984). The reason for this discrepancy 
is unknown. As WGA binds to AGP a low coating efficiency of AGP due to 
its extremely low pi of AGP (2.8) cannot be the reason. Con A is said to bind 
only to biantennary glycans without intersecting GlcNAc. However, if the sialic 
acids are missing, an intersected biantennary glycan is bound (Baenziger, 1985). 
Of the lectins used, PNA was the most selective, binding only to IgA and 
traces of IgM. The limited binding of DSA lectin to all glycoproteins except 
haptoglobin suggests that during the purification of the glycoproteins from human 
plasma few sialic acids are lost. In contrast to RCA, DSA appears to have no 
affinity at all for inner chain galactose (Yamashita et al., 1987), just as the 
Erythrina lectins (Debray et al., 1986). Using lectin column chromatography 
it was shown that most haptoglobin and ceruloplasmin from normal serum bound 
to Con A (Mallet et al., 1987). 69% of a 1-antitrypsin bound, and 2% of AGP. 
However 72% of AGP and 27% of AAT were retarded, indicating a weak 
interaction with Con A. In the lectin-enzyme assay in its present form no distinction 
can be made between firm and weak binding. This problem may be solved 
by adding increasing amounts of the competing sugar to the assay. A loss of 
signal at low inhibitor concentration indicates a weak interaction, and a loss 
of signal at high inhibitor concentration indicates a strong interaction. These 
experiments remain to be done. 
Baumstark (1983) also performed Con A column chromatography. a2-
macroglobulin and ceruloplasmin appeared to bind most strongly, that is, were 
eluted by the highest mannose concentration. In our assay IgA and IgM gave 
the highest binding, followed by a 2-macroglobulin, haptoglobin and 8Sar 
glycoprotein. Ceruloplasmin showed a weak binding in our assay. The reason 
for these discrepancies is at present unknown. The binding of plasma glycoproteins 
to the immobilized lectins PHA-E4 and PHA-L4 from the red kidney bean 
was recently investigated (Glad et al., 1984). Some haptoglobin bound to PHA-
L4, while in our assay some IgM was bound. PHA-E4 bound best to IgM and 
haptoglobin, as well as a 2-macoglobulin, IgA and IgG, while in our assay IgM 
and IgA bound best, followed by a 2-macroglobulin and IgG. 
In earlier studies no separation was made of the two PHA lectins which have 
quite different binding specificities. Using a column of immobilized PHA 
(containing unknown amounts of E4 and L4) the following plasma glycoproteins 
were found to bind (Spengler, 1981): 
- IgM +++ 
- a2-macroglobulin ++ 
- apo-B ++ 
- AGP + 
- IgA + 
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In our assay the order would be: 
- IgM +++ 
- IgA ++ 
- a2-macroglobulin + 
- apo B ? 
- IgG + 
- AGP 
This lectin-enzyme binding system appears to be more sensitive than pre-
cipitation assays. For instance, no precipitation was seen of transferrin with Con 
A (Young et al., 1974), although slight binding of Con A to adsorbed transferrin 
was detected in our assay. This binding is confirmed by lectin-column chro-
matography (Baumstark, 1983). On the other hand, the precipitation of transferrin 
and LCA found by the authors could not be reproduced by us: no binding of 
LCA-enzyme complex was detected in our system. This is to be expected given 
that the presence of core a 1-6-linked fucose is a prerequisite for binding (Kornfeld 
et al., 1981) and the absence of fucose in human serotransferrin. Another source 
of discrepancies is the fact that binding does not necessarily lead to precipitation 
(Felsted et al., 1976; Bhattacharyya et al., 1988a,b), i.e. the absence of a 
precipitation reaction (arc formation in gels or turbidity formation in solutions) 
does not mean the lectin does not bind to the glycoprotein. 
A good correlation is obtained between the results described above and those 
obtained with lectin-column chromatography as described in chapter 3. The 
selective binding of MPA to lgA is confirmed, but the lectin-enzyme binding 
assay also detects weak binding ofMPA to a 1-acid glycoprotein, a 2-macroglobulin 
and IgM. 
In the case of RCA the lectin-enzyme binding studies suggest that the lectin 
has a weak affinity for (fractions of) nearly all plasma glycoproteins, although 
the RCA lectin column retains only the ones with stronger affinities such as 
haptoglobin and IgA. Only Gc-globulin shows no affinity at all for RCA in 
the lectin-enzyme binding assay, apart of course from albumin. The results also 
indicate that a sufficient coating of the glycoproteins has been achieved. Thus, 
the observed low binding of a number of lectins for many glycoproteins is not 
due to a low coating efficiency. The results of WGA binding confirm this. 
GalNAc was found by chemical techniques to occur linked to a2-HS gly-
coprotein, IgA, 8Sarglycprotein, ,82-glycoprotein Ill and IgD (Uhlenbruck et 
al., 1979). IgD was not tested in our system. We found binding of the lectins 
from Artocarpus integrifolia (Jacalin) and Artocarpus communis to a 2-HS-
glycoprotein, lgA, Hemopexin, 8Sarglycoprotein, AGP and a2 macroglobulin. 
,82-glycoprotein III did not bind. As these lectins appear to be GalNAc-specific, 
these correlations provide a validation of the lectin-enzyme binding studies, 
although some discrepancies remain. 
Recently, affinodiffusion experiments in gels were done to investigate the 
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precipitation of plasma glycoproteins with a number of lectins (Domer et al., 
1986). The results are of interest in the light of our binding assays with the 
same lectins and glycoproteins. BPA did not precipitate with IgA and IgM, but 
it does with lactoferrin. The binding ofMPA to IgA and AGP (weak) is confirmed, 
however no precipitation occurs with a2M and IgM. 
ECA precipitates with a 2M and haptoglobin, but our lectin-enzyme binding 
assays show binding to IgM only. 
DSA precipitates only haptoglobin. The lectin-enzyme binding assay shows 
a strong reaction with haptoglobin, and a weak binding to six other plasma 
glycoproteins. 
A number of conclusions may be drawn from our experiments and their 
comparison with other techniques. 
First, except Gc-globulin, which shows very weak binding by a few one lectins, 
all other glycoproteins bind well to at least one lectin, and in some cases to 
many. Large differences in coating efficiency cannot therefore be the reason 
for the absence of binding of certain lectins to certain glycoproteins. Only in 
the case of Gc-globulin one might argue that the possibility of an exceptional 
low coating efficiency of Gc-globulin could be the reason for its lack of binding 
to all lectins. However, a more realistic explanation may be found in the very 
low carbohydrate content of Gc-globulin: it probably contains only one small 
glycan. 
Second, the lack of binding of DSA which has a preference for biantennary 
asialo chains (Crowley et al., 1984) to most plasma glycoproteins indicates that 
few sialic acid groups if any were lost from the glycoprotein during its purification. 
This confirms remarks from Behringwerke who supplied the glycoproteins. 
Third, the immunoglobulins appear to bind to many lectins to some extent. 
Indeed, immobilized IgG has even been advocated as a universally applicable 
column for the isolation of lectins (Franz et al., 1981), most of which will bind 
to the IgG column depending on its size, among other things. One of the reasons 
will be the heterogeneity in Fab and Fe glycosylation. This means that antibodies 
may not be used in lectin-enzyme immunoassays without one or more forms 
of pretreatment. One might consider chemical or enzymatic removal of 
carbohydrates, or adsorption of the binding fraction of the antibodies on columns 
containing immobilized lectins. Our preliminary studies (unpublished) indicate 
that these pretreatment measurements are not without problems. When antibodies 
can be prepared which do not contain carbohydrate or bind lectins, the lectin-
enzyme immunoassays may be applied to many glycoproteins. 
Fourth, the lectin-enzyme binding assay confirms results obtained with most 
other techniques to study lectin-glycoprotein interaction. However, weaker 
binding affinities are found using our assay which remain undetected by some 
other methods. A few reasons might be thought of. 
1. Weak binding glycoproteins are retarded by lectin columns, but are still washed 
away by the buffer flow only. Depending on the volume of the unbound 
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fraction in relation to the column bed volume, they may either be found 
in the "unbound" or in the "bound" fraction, although they belong to neither. 
2. Binding of lectins to glycoproteins does not necessarily lead to precipitation 
(Montreuil et al., 1983). This phenomenon still has to be explored in greater 
detail. 
Fifth, the correlation between the binding patterns of LCA and PSA, and 
also of Jacalin and ACA validate aspects of the lectin-enzyme binding assay. 
These two pairs of lectins are both known to have similar binding specificities. 
The fact that they show comparable reaction patterns towards various glyco-
proteins coated in microtiter plates indicate that their purity, their way of isolation, 
their degree of biotinylation and the exact lectin-STAP complex composition 
are of very little influence on the observed lectin binding. These findings facilitate 
a more widespread use of lectin-enzyme binding assays. 
Discrepancies between lectin-enzyme binding assays and lectin-column chro-
matography or lectin precipitation techniques could be due to the following: 
- Impossibility to compare directly a lectin-column chromatogram pattern with 
absorbance measurements in the LElA technique. 
- Differences in glycoproteins in plasma and those subjected to an isolation 
procedure. 
- Inability of some lectins to precipitate glycoproteins after binding (Glad et 
al., 1984). 
- Uneven coating of glycoprotiens in microtiter plates (Butler et al., 1987). 
- Different susceptibilities of various techniques for the number of glycans per 
molecule. 
- An observed precipitation in gels or in solution is not easily quantified: it 
may be 10% or 100% of the glycoprotein. 
- Differences in binding may exist between immobilized lectins and lectins in 
solution (Montreuil et al., 1983). 
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CHAPTERS 
APPLICATION OF VARIOUS FORMS OF LECTIN-ENZYME 
BINDING ASSAY TO INVESTIGATE THE GLYCOSYLATION 
OF IgG, HAPTOGLOBIN AND HCG 
5.1. Introduction 
To investigate the applicability of lectin-enzyme binding assays three proteins 
are selected of which disease-associated glycan modifications have been described 
recently. IgG from patients with rheumatoid arthritis contains less galactose 
(Parekh et al., 1985; Pekelharing et al., 1988). Haptoglobin from cancer patients 
shows increased fucosylation (Thompson et al., 1987), while HCG produced 
by tumors shows complex changes in glycosylation (Endo et al., 1987). 
The three types of lectin-enzyme binding assays that we explored are different. 
IgG from RA patients was purified and passively coated to microtiter plates, 
after which lectin binding was studied. In the case of haptoglobin, its binding 
to hemoglobin coated in microtiter plates was exploited, followed by lectin binding 
studies. In this case the hemoglobin acts as the scavenger of haptoglobin from 
plasma, comparable with anti-haptoglobin antibodies, but it is not glycosylated. 
Only with HCG the lectin enzyme immunoassay variant was explored. 
This chapter describes the three types of lectin-enzyme binding assays for 
IgG, haptoglobin and HCG, respectively. 
5.2.1. Alterations in carbohydrate composition and lectin binding of serum IgG 
from patients with rheumatoid arthritis and from pregnant women 
Immunoglobulin G is a major plasma glycoprotein containing, on average, 
2.8 N-linked carbohydrate chains per molecule, of which 2 are located on the 
Fe fragment (Rademacher et al., 1984). The carbohydrate chains consist of a 
variety of diantennary complex-type structures, some containing an extra "in-
tersecting" N-acetylglucosamine or a fucose residue. 
The plasma of patients with rheumatoid arthritis (RA) contains aggregated 
immunoglobulins. These so-called "immune-complexes" differ from antigen-
antibody complexes in several ways. Because of the absence of antigen it is 
suggested that the aggregates consist of certain immunoglobulins with affinity 
for other immunoglobulins (autoantibodies). The strength of the interaction 
between the immunoglobulins (Ka = 105 M·1) is less than that observed for 
normal antigen-antibody interactions, indicating that a different type of interaction 
may be involved (Mannik et al., 1985). 
The recent finding of a reduced galactosylation of the diantennary carbohydrate 
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chains of total IgG in patients with RA (Parekh et al., 1985) and a reduced 
B-cell galactosyltransferase (Axford et al., 1987) has led to a new hypothesis 
concerning the aggregation of IgG molecules. Less sugar constituents in the 
N-linked glycans of IgG could make IgG more "sticky" due to a lectin-like 
activity. 
If incomplete glycosylation of IgG causes the formation of harmful IgG 
aggregates, then conditions inducing an increased plasma glycoprotein glyco-
sylation, such as pregnancy (Raynes, 1982), could reverse this aggregation. A 
decrease in C 1q-binding activity has indeed been found in RA patients during 
pregnancy (Pope et al., 1983), while a remission of RA during pregnancy is 
commonly observed (Ostensen et al., 1983; Persellin et al., 1981), indicating 
that the finding of an increased glycosylation of IgG during pregnancy would 
support the suggestion of a key role for the glycosylation oflgG in the pathogenesis 
of immune aggregates in rheumatoid arthritis. 
To compare the carbohydrate composition of IgG samples from serum of 
pregnant women, patients with RA and healthy blood donors, detailed quantitative 
monosaccharide analysis by means of gas-liquid chromatography was performed. 
Lectin binding to the purified IgG preparations passively adsorbed to micro titer 
plates was done as described in chapter 4. 
5.2.2. Materials and Methods 
1. Isolation of IgG 
Blood samples were obtained from pregnant women, healthy blood donors, 
and from patients with active RA visiting the rheumatology clinic. Serum 
was extracted with an equal volume of n-hexane to remove lipids, and dialysed 
for 24 h against 0.0175 M phosphate buffer, pH 6.3 (buffer A). After filtration, 
2 ml serum samples were applied to a column (35 x 2 em) of diethylaminoethyl-
cellulose (DEAE) (Pharmacia, Uppsala, Sweden) equilibrated with buffer A. 
IgG was in the unbound fraction and eluted with buffer A. The bound fraction 
was eluted with 0.4 M phosphate buffer, pH 5.2, containing 2 M NaCl, and 
discarded. The column was regenerated by washing with 0.25 M phosphate 
buffer, pH 6.3 followed by buffer A. 
2. Purity check 
Immunoelectrophoresis of the bound and the unbound fractions was carried 
out using a rabbit antiserum against human plasma proteins as well as specific 
rabbit antisera against IgG, IgA and IgM. 
3. Sample preparation 
The isolated IgG was dialysed against distilled water for 3 days at 4 °C. The 
samples were then freeze-dried and stored over P 20 5 for 24 hours. 
4. Monosaccharide analysis 
Carbohydrate samples were subjected to methanolysis (1.0 M methanolic HCl, 
24 hours, 85°C) followed by gas-liquid chromatography of the trimethyl-
silylated (N-reacetylated) methyl glycosides on a capillary CPsil5 WCOT fused 
95 
silica column (0.34 mm x 25 m, Chrompack, Middelburg, The Netherlands) 
(Kamerling et al., 1982). 
5. Lectin-enzyme binding assay 
50 ~1 of a solution of 5 ~g /ml of the purified IgG in PBS was transferred 
to microtiter plates and allowed to adhere for 4 hours at 37°C. Subsequently, 
plates were washed and the lectin binding studied as described in chapter 
4. 
5.2.3. Results 
Immunoelectrophoresis of the unbound fraction with rabbit antiserum against 
human IgG showed only one large precipitation arc in the IgG region. With 
antiserum against human plasma proteins no other proteins were detected, 
in particular no IgA and IgM were detected. The bound fraction was found 
to contain all other plasma proteins together with a small amount of IgG 
(slides not shown). 
The sugar analysis data of IgG obtained from ten blood donors, nine patients 
with RA and six pregnant women are given in table 5-1. 
In table 5-2 the significance of the differences of the mean monosaccharide 
and sugar contents is given, calculated using the Mann-Whitney test. 
The IgG from RA patients contained 20% less galactose than IgG from 
healthy subjects. The mean N-acetylglucosamine content was increased by 
20%. The mean fucose and sialic acid contents were not different from normal. 
In pregnancy, the mean galactose content was increased by 13% and the 
mean sialic acid content by 44%, whereas N-acetylglucosamine and fucose 
contents were not different from normal. 
The binding of one of the lectins (RCA) shows a relationship with the 
IgG carbohydrate composition (figure 5-1). Rheumatoid arthritis IgG binds 
significantly less of the galactose specific lectin. With the other lectins, galactose 
specific or not, no such relationship was found. 
5.2.4. Discussion and conclusions 
The monosaccharide analysis of IgG from patients with RA shows a 
significantly lower amount of galactose as compared to IgG from healthy 
individuals, whereas the N-acetylglucosamine content is significantly higher 
(Table 5-2). Although the analysis of carbohydrate content does not give 
information with respect to the glycan structure, it is reasonable to assume 
that the major difference between IgG from RA patients and normals is the 
reduced galactosylation of the diantennary glycans, with a concomitant increase 
in N-acetylglucosamine content. In an earlier study, only the under-galac-
tosylation was indicated (Parekh et al., 1985). It was stated that there are 
no apparent changes in the levels of the ,8-N-acetylglucosaminyltransferase 
96 
Table 5-l. Monosaccharide composition per 3 mannoses and percent sugar of IgG from ten blood 
donors (N), nine patients with RA (RA) and six pregnant women (P). 
Man GlcNAc Gal NeuAc Fuc %Sugar 
N 1 3 3.09 0.79 0.20 0.70 2.9 
N2 3 3.08 1.03 0.24 0.73 2.1 
N3 3 2.94 0.74 0.14 0.72 2.1 
N4 3 3.26 0.83 0.21 0.76 2.2 
N5 3 3.29 0.87 0.16 0.71 2.4 
N6 3 3.13 0.75 0.13 0.69 2.2 
N7 3 2.93 0.82 0.22 0.67 2.5 
N8 3 3.30 0.93 0.20 0.77 3.0 
N9 3 2.91 0.71 0.18 0.66 2.3 
N 10 3 3.01 0.88 0.14 0.63 1.9 
Mean N 3 3.09 0.84 0.18 0.70 2.36 
RA 1 3 3.50 0.61 0.14 0.73 2.2 
RA2 3 3.30 0.59 0.20 0.74 2.2 
RA3 3 3.49 0.59 0.14 0.74 2.4 
RA4 3 3.24 0.57 0.12 0.71 2.0 
RA5 3 3.30 0.58 0.14 0.72 2.1 
RA6 3 3.19 0.62 0.11 0.68 1.8 
RA 7 3 3.23 0.92 0.28 0.63 1.9 
RA8 3 3.24 0.69 0.13 0.78 2.0 
RA9 3 3.32 0.88 0.21 0.68 1.9 
Mean RA 3 3.31 0.67 0.16 0.71 2.06 
p 1 3 3.23 0.95 0.26 0.84 2.1 
P2 3 3.18 0.98 0.21 0.64 3.5 
P3 3 3.15 0.77 0.23 0.71 2.1 
P4 3 3.16 0.96 0.22 0.65 2.1 
P5 3 3.14 1.10 0.24 0.70 2.3 
P6 3 3.17 0.94 0.23 0.70 2.3 
MeanP 3 3.17 0.95 0.23 0.71 2.40 
Man : Mannose; GlcNAc: N-acetyl-glucosamine; NeuAc : N-acetyl-neuraminic acid; Fuc : Fucose. 
enzymes GnT I, GnT II, GnT III and a(l-6)-fucosyltransferase. Taking into 
account that only diantennary structures were detected (Parekh et al., 1985), 
the observed increase ofN-acetylglucosamine in this study has to be explained 
as a change in GnT III activity, responsible for the attachment of the intersecting 
N-acetylglucosamine. The presence of this sugar residue reduces the galac-
tosylation of the Man a(l-3)-arm by about 78% (Narasimhan et al., 1985). 
Thus, if the 20% increase ofN-acetylglucosamine residues are of the intersecting 
type, this would result in a decrease of galactose residues of about 16%, 
comparable with the 20% that we found. Taken together, our results suggest 
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Table 5-2. The mean monosaccharide content (per 3 mannoses) and sugar content (%), standard 
deviations and significance of the differences of IgG from healthy blood donors (n = 
1 0), patients with RA (n=9), and pregnant women (n = 6). 
Blood donors RA patients P Value 
GlcNAc 3.09 ± 0.15 3.31±0.11 p < 0.01 
Gal 0.84 ± 0.10 0.67 ± 0.13 p < 0.05 
NeuAc 0.18 ± 0.04 0.16 ± 0.06 NS 
Fuc 0.70 ± 0.04 0.71 ± 0.04 NS 
Sugar(%) 2.36 ± 0.35 2.06 ± 0.19 p < 0.05 
Blood donors Pregnant women 
GlcNAc 3.09 ± 0.15 3.17 ± 0.03 NS 
Gal 0.84 ± 0.10 0.95 ± 0.11 p < 0.05 
NeuAc 0.18 ± 0.04 0.23 ± 0.02 p< o.os 
Fuc 0.70 ± 0.04 0.71 ± 0.07 NS 
Sugar(%) 2.36 ± 0.35 2.40 ± 0.55 NS 
Pregnant women RA patients 
GlcNAc 3.17 ± 0.03 3.31 ± 0.11 p < 0.01 
Gal 0.95 ± ').11 0.67 ± 0.13 p < 0.01 
NeuAc 0.23 ± 0.02 0.16 ± 0.06 p < 0.05 
Fuc 0.71 ± 0.07 0.71 ± 0.04 NS 
Sugar(%) 2.40 ± 0.55 2.06 ± 0.19 NS 
Values are mean ± SD. NS: not significant: p > 0.05; Mann-Whitney test 
a 20% increase in intersecting N-acetylglucosamine residues resulting in under 
galactosylation of IgG in patients with RA. Direct measurement of B-cell 
galactosyltransferase indicates lower enzyme activity in RA patients (Axford 
et al., 1987). Other recent studies also point towards abnormal glycosyltrans-
ferase activities in autoimmunity (Imai et al., 1988). 
Using a solid phase lectin binding assay, others found that IgG from patients 
with RA bound significantly more to the immobilised plant lectins Peanut 
agglutinin (PNA) and Concanavalin A (ConA) than IgG from normals (Malaise 
et al., 1987). 
This indicates either an increased content or an increased availability of 
terminal galactose groups (binding to the PNA lectin) and diantennary sugar 
chains (binding to the ConA lectin). As our results and those obtained by 
others (Parekh et al., 1985) indicate a decreased galactose content and suggest 
a decreased Con A binding owing to the intersecting GlcNAc, a conformational 
change in the structure of IgG in patients with RA leading to increased lectin 
binding could explain these results. Indeed, an altered conformation of IgG 
in RA has recently been suggested (Hanson et al., 1985). 
Our findings could support a viral aetiology of the disease. Viruses may 
alter the glycosylation of cell glycoproteins (Groen, 1984; Due Dodon et al., 
1984; Avango et al., 1988). If the IgG producing B-cells are infected by a 
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virus, for instance the RA associated Epstein-Barr virus (Yao et al., 1986) 
which has a preference for B-lymphocytes (Frade et al., 1985), the result 
could be a modified glycosylation of IgG produced by the infected cells. This 
mechanism has been shown to occur in lymphoblastoid cells infected by 
influenza virus, where decreased glycoprotein sialylation takes place and is 
only partially compensated for by an increased cellular sialyltransferase (Due 
Dodon et al., 1984). Another example is the polyoma virus transformation 
of baby hamster kidney cells, which induces a twofold increase in the activity 
of the enzyme GnT V that adds N-acetylglucosamine {31-6 to the cd-6linked 
mannose (Yamashita et al., 1985). Quite recently the lowered galactosyltrans-
ferase of B-cells has indeed been found in RA patients (Axford et al., 1987). 
An alternative explanation suggests that mycobacterial antigens are involved 
in the development of RA (Shoenfeld et al., 1988; Rook et al., 1988). 
If a reduced galactose content of IgG is a prerequisite for the appearance 
of (some of) the symptoms associated with RA, conditions of increased 
galactosylation could form a compensation and could be the basis of a 
therapeutic approach. Such a condition may exist for IgG during pregnancy 
or estrogen therapy, two processes where an increased glycosylation of other 
plasma glycoproteins has been found (Raynes, 1982). 
Our results show that a significant increase (13%) occurs of the galactose 
content of IgG during pregnancy. The galactose content of IgG in pregnancy 
is 42% higher than in the RA group. Thus, a partial compensation during 
pregnancy of the IgG under galactosylation in female patients with RA can 
be imagined. IgG from one female RA patient during pregnancy was analysed 
(results not shown). It contained high levels of galactose as found in the 
pregnancy group, and also high levels of N-acetylglucosamine as found in 
the RA group. Owing to the slight variation in carbohydrate analysis within 
each group this ·result has to be confirmed by carbohydrate analysis of IgG 
obtained from a larger number of pregnant women with RA. 
Together with an increase of IgG galactose during pregnancy an increase 
of sialic acid is also found. This suggests a more complete glycosylation of 
the diantennary glycans of IgG during pregnancy. The N-acetylglucosamine 
content of IgG during pregnancy is not different from normal. 
Given the fact that the half-life of IgG in the circulation is approximately 
three weeks, the recurrence of symptoms in female patients with RA a few 
weeks after delivery can also be explained, because the more galactosylated 
and sialylated IgG produced during pregnancy will gradually be replaced by 
the RA-associated undergalactosylated IgG with possible aggregating 
properties produced thereafter. Alternatively, the increased N-acetylglucosa-
mine content of RA IgG could also have a role, but no decrease has been 
found to occur during pregnancy. 
The changes in IgG glycosylation in pregnancy may be due to the altered 
hormonal state. Estrogens (Raynes, 1982; Starr et aL, 1985) as well as prolactin 
(Bradshaw et al., 1985) influence glycoprotein glycosylation. The association 
99 
between autoimmune diseases such as RA and steroid hormones has been 
well described (Ahmed et al., 1985; Masi et al., 1984). Oral contraceptives 
(Van den Broucke et al., 1982, 1986) as well as the number of pregnancies 
(Silman, 1986) also have an influence. These results suggest that the gly-
cosylation of IgG may play a role in the occurence of symptoms in RA. The 
differences between infusion therapies with placental IgG and serum derived 
IgG could thus be explained (Sany et al., 1987). 
Studies with asialylated IgG prepared in vitro underline the relation between 
the IgG glycosylation and rheumatoid factors (Due Dodon et al., 1981; 
Galloway et al., 1983). It would be of interest, in view of our results mentioned 
above, to extend these experiments with asialo-agalacto IgG prepared in vitro. 
Other studies have shown that differences in glycosylation of one Fab arm 
exist between precipitating and non-precipitating antibodies (Leoni et al., 1986; 
Labeta et al., 1986). Thus, the characteristics oflgG are delicately dependent 
on the glycosylation of the molecule. 
The fact that remission of the symptoms often occurs in women with RA 
during pregnancy, together with our finding of an increase in IgG galacto-
sylation in healthy pregnant women, support the view (Parekh et al., 1985) 
that IgG glycosylation have play an important role in the disease. The 
carbohydrate analysis of IgG of female patients with RA during pregnancy 
and the investigation of aggregating characteristics of asialo-agalacto IgG 
prepared in vitro could clarify this point. 
A relationship between carbohydrate composition of IgG and lectin binding 
was obtained with only one of the lectins (RCA). As shown in figure 5-1 
the RCA binding gives a good representation of the galactose content of IgG. 
AE 
RCA 
2000 
1500 
1000 0 0. 
.sf 
• PREGNANCY 
• NORMAL 
0 RHEUMATOID ARTHRITIS 
0 
• • 
···lf!!l "L• 
.. 
• 
• 
• 
soo+---..-,---,r---.--,--,--...----..-,---. 
o.s 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 Gai/2Man 
Figure 5-1. Relationship between RCA binding to microtiter plate wells coated with lgG and the 
IgG galactose content. 
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The reason why RCA is the only binding lectin may be found in its broad 
specificity with respect to asialo glycoproteins, as discussed in chapter 1. 
Summarising, our results show that in principle quantification of IgG 
galactose content is possible using the lectin-enzyme binding assay. Our assay 
employed passive adsorption of purified IgG. The further development of the 
assay should focus on the pretreatment of an IgG-catching "first" antibody 
or Protein A coating of the solid phase in such a way that no binding of 
RCA lectin occurs in the absence of sample. One might think of enzymatic 
pretreatment (such as N-glycanase or Endoglycosidase) or chemical pretre-
atment. Our results also indicate that with a glycoprotein purified from various 
patients it is possible to select the lectin which is able to make a distinction 
between healthy persons and patients. 
All lectins tested show binding to the coated IgG to a greater or smaller 
extent. This means that high background binding is to be expected with 
antibodies to the glycoprotein under study, even when they are from quite 
different species such as rabbit, goat or sheep. While this may seem on first 
sight a serious flaw of the concept of lectin-enzyme immunoassays, it appears 
that in some cases the binding of the lectin-STAP conjugate to the coated 
antibodies is inhibited by the presence of the antigen in question. This 
observation would obviate the use of affinity-purified or monoclonal antibodies. 
In the development of the lectin-enzyme immunoassay for HCG glycovariants 
(chapter 5.4) the phenomenon described above was exploited succesfully. 
5.3 .1. Lectin-enzyme binding assays detect disease-associated changes in gly-
cosylation of serum haptoglobin bound to hemoglobin coated microtiter 
plates 
While studying the feasability of lectin-enzyme immunoassays the problem 
of binding of the lectin to the coated antibody, leading to high background 
values, was encountered. A number of steps were taken in an attempt to lower 
the background binding such as N-glycanase treatment of the antibodies, but 
so far they have been without effect. 
A solution may possibly be found in the use of monoclonal antibodies raised 
in vitro in the presence of glycosylation inhibitors. At present, however, the 
binding oflectins to the carbohydrate determinants ofthe coated immunoglobulins 
remains a problem to be solved. 
However, if one wishes to investigate the application of lectin-enzyme binding 
assays with serum samples in the clinical practice without using antibody coating, 
the affinity of haptoglobin for hemoglobin could be exploited. Hemoglobin is 
a non-glycosylated intracellular protein found in erythrocytes, which forms a 
stable complex with extracellular haptoglobin when hemolysis occurs. 
Haptoglobin occurs in three genetic phenotypes: Hp 1-1, Hp 2-1 and Hp 2-
2. The basic structure of haptoglobin is a four-chain molecule with two a- and 
two ,8-chains. Haptoglobin 1-1 contain a 1 chains, while haptoglobin 2-2 contains 
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a 2 chains. Both a 1 and a 2 chains are present in haptoglobin 2-1. The /3-chain 
contains the oligosaccharide units: eight asparagine-linked carbohydrate chains; 
four of them being biantennary and four being triantennary branches. Analysis 
of intact human haptoglobin revealed virtually identical amounts of carbohydrate 
on all three subsets. 
Modifications of haptoglobin glycosylation have been demonstrated recently 
in sera of patients with cancer (Thompson et al., 1987) using lectin-column 
extraction followed by SDS-PAGE and Western blots or silver staining. To 
investigate serum haptoglobin glycosylation with lectin-enzyme binding we 
developed the assay based on hemoglobin-coated microtiter plates. 
5.3.2. Materials and Methods 
Hemoglobin (type IV, Sigma, St. Louis) was dissolved in 0.1 M carbonate 
buffer pH 9.5 containing 0.2 g 11 sodium azide, to a concentration of 50 p,g I 
ml. Coating was accomplished by incubating 100 p,l of the solution in micro titer 
plate wells at room temperature for 24 hours. Five washings with PBS-Tween 
(0.05%) followed. Dried plates were stored in aluminium foil at -20°C. 
Haptoglobin concentrations in serum samples were determined using a Behring 
Nephelometer Analyser (BNA) with Behring antiserum according to the manu-
facturers instructions. Samples were diluted with PBS-Tween to a haptoglobin 
concentration of 50 p,g /ml. 100 p,l diluted serum was allowed to interact with 
the hemoglobin-coated wells for 2 hours at 37°C, followed by five washings 
with PBS-Tween. 
The lectin-enzyme binding assay was done as described in chapter 4. As a 
buffer Tris-buffered saline (TBS) was used with the following composition: Tris 
100 mM, NaCl 100 mM, MgCl2.6H20 0.5 mM, CaC12.2H20 1.0 mM. Set pH 
at 8.0 with 1.0 M HCl, add MnC12.4H20 0.1 mM. Washings were done with 
TBS-tween (0.05%). Incubations of lectin-STAP complex were done at 4°C. 
All assays were done in duplicate. 
Serum samples were used from patients with cancer showing an elevated tumor 
marker, such as CEA (n=8), AFP (n=2), paraprotein (n=7) or prostatic acid 
phosphatase (n=5), and from normal blood donors (n=4). 
In a separate experiment differences of lectin binding to haptoglobin were 
determined for six lectins and ten normal serum samples. 
5.3.3. Results 
The mean extinction in the lectin-enzyme binding assay of the control samples 
(blood donors) is set at 1 for each lectin. For the individual cancer sera, results 
are given in table 5-3 and expressed as the extinction found divided by the 
mean extinction of the control groups. The differences between the lectin binding 
assays of the normal blood samples (n=10) proved to be small. The most extreme 
values are given at the bottom of table 5-3. 
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Table 5-3. Extinctions in haptoglobin lectin-enzyme binding assays, expressed as times the mean 
of normal. 
Patient Elevated LCA WGA BPA AAA Lotus AAL 
tumor 
marker 
CEA 1.0 1.4 0.8 0.9 1.6 1.0 
2 CEA 1.0 1.6 0.6 0.8 1.8 1.0 
3 CEA 1.3 2.2 1.2 1.2 2.3 1.2 
4 CEA 0.8 2.4 0.6 0.9 2.0 1.1 
5 CEA 0.9 0.8 1.0 0.7 l.O 1.3 
6 Au+ 1.2 1.6 1.2 0.9 1.5 1.5 
7 Au+ 1.2 2.0 1.0 1.0 1.6 1.6 
8 lgAk 0.7 2.4 0.8 0.8 1.7 l.l 
9 IgGA. 0.6 1.8 0.8 0.8 l.l 1.0 
10 lgGA. 0.9 1.2 0.7 0.6 0.7 0.9 
11 lgAk 0.7 1.5 0.7 0.7 1.3 1.3 
12 IgGk 1.0 3.7 0.9 1.0 2.7 1.4 
13 IgGA. 0.7 3.0 0.7 0.9 2.1 0.9 
14 IgMk 0.9 3.3 0.8 1.0 1.8 1.5 
15 PZF 0.8 1.6 0.9 0.7 1.7 0.9 
16 PZF 0.7 1.8 0.6 0.6 2.0 0.9 
17 PZF 0.7 1.0 0.5 0.4 1.2 1.0 
18 PZF 0.9 1.4 0.8 0.6 1.2 1.5 
19 PZF 0.6 4.0 0.9 1.0 3.7 0.9 
20 CEA 1.2 1.0 1.0 11.3 1.6 0.5 
21 CEA l.l 2.8 4.6 1.3 1.7 3.9 
22 CEA 1.7 >4.0 1.7 1.8 3.1 1.6 
Normal range (n=10) 0.7-1.3 0.7-1.2 0.7-1.3 
(extremes) 0.9-l.l 0.8-1.2 0.6-1.4 
5.3.4. Discussion and conclusions 
In most cancer patients our lectin-enzyme binding assay detects cancer-
associated changes in serum haptoglobin glycosylation (table 5-3). 
Using six lectins, 4 out of 22 cancer sera showed abnormal binding of one 
lectin, 15 sera showed increased binding of two lectins. One serum sample did 
not show abnormal haptoglobin glycosylation as tested with the lectins used. 
This does not imply, however, that no change in haptoglobin glycosylation occurs 
in these patients, because the glycosylation of haptoglobin also affects the binding 
of haptoglobin to hemoglobin (Katnik, 1984). Thus, if aberrantly glycosylated 
subfractions of haptoglobin that do not bind hemoglobin are present in serum, 
they will also not bind to the hemoglobin-coated wells of the microtiter plate 
and remain undetected in this system. Such fractions can only be quantitated 
using antihaptoglobin coated microtiter plates, assuming that the glycosylation 
does not have an influence on the binding of antibodies. The inability of certain 
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haptoglobin subfractions to bind hemoglobin could explain the persistence of 
haptoglobin in the circulation of some patients with a proven chronic hemolysis. 
The increase in the aberrantly glycosylated haptoglobin subfraction is higher 
than the factor of the ratio described above. In ELISA systems an increase in 
extinction with a factor 4 may correspond to an increase in concentration with 
a factor 100. Thus, the observed changes in haptoglobin are much more 
pronounced than the extinction ratio would suggest. 
The mechanism behind the abnormal plasma haptoglobin glycosylation remains 
unclear. Synthesis and excretion by tumors of aberrantly glycosylated haptoglobin 
has not yet been described (except in case of primary liver cell carcinoma), 
and if it occurs its contribution to the plasma haptoglobin concentration will 
remain extremely small. It is more likely that certain active factors have an 
influence on the liver, just as monokines have on acute phase protein synthesis, 
resulting in the appearance of unusual subfractions of haptoglobin. 
Low-grade hemolysis in the tumor leading to the accumulation of subfractions 
not capable of hemoglobin binding may also occur, but these fractions are probably 
not detected in a hemoglobin-based assay such as the one described above. 
A few patients haptoglobins show extremely elevated binding of one or two 
of the lectins (patient 19 with WGA and Lotus, patient 20 with AAA, patient 
21 with BPA and patient 22 with WGA). The reason and significance of these 
findings remain to be clarified. 
Two lectins out of the six tested show by far the greatest discriminating capacity, 
both highly binding to fifteen out of the twenty-two cancer sera haptoglobin. 
These results confirm those obtained with lectin affinity chromatography with 
one of these two lectins (Lotus), followed by ID or 2D PAGE and silver staining, 
where increased binding of haptoglobin in sera from cancer patients was also 
noted (Thompson et al., 1987). The increase of serum fucose content in cancer 
(Waalkes et al., 1983) could be caused by elevated levels of highly fucosylated 
haptoglobins. 
The column technique also detects increased Lotus binding of haptoglobin 
from rheumatoid arthritis sera, although the apparent molecular weight of these 
haptoglobins in SDS-PAGE is different from cancer sera haptoglobin. Our most 
recent results (not shown) with the lectin-enzyme binding assay confirms increased 
binding of Lotus lectin to RA haptoglobin. However, no increased WGA binding 
was found as with cancer sera haptoglobin, while highly increased MPA binding 
was found which does not occur with the cancer samples. Taken together, using 
a panel of lectins both mutual and different glycosylation modifications in 
haptoglobins from cancer patients and from rheumatoid arthritis patients may 
thus be detected. 
There appears to be a linkage between WGA and Lotus binding. This suggests 
increased sialic acid content (increased branching and terminal glycosylation, 
a common finding in cancer) leading to increased WGA binding, and increased 
fucose incorporation (not uncommon in cancer as well) leading to more Lotus 
binding. The fucose is probably located at the branches of haptoglobins glycans, 
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as LCA (binding to biantennary glycans with a1-6 at the base) does not show 
increased binding. Any relationship with the haptoglobin subtypes, although highly 
unlikely, remains to be investigated. 
In conclusion, the lectin-enzyme binding assay detects certain aberrantly 
glycosylated subfractions of haptoglobin bound to hemoglobin-coated microtiter 
plates in patients with cancer, as well as certain other diseases. Detailed clinical 
studies are necessary to elucidate the significance of these findings. 
5.4.1. Malignancy-associated modifications in serum HCG glycosylation are 
detected by lectin-enzyme immunoassays 
HCG contains two N-linked glycans at aminoacids 52 and 78 in its a-chain 
and two in its hormone-specific /3-chain at positions 13 and 30. Compared with 
LH and FSH, the /3-chain of HCG has an extra peptide which contains four 
0-linked glycans at aminoacids 121, 127, 132 and 138. The a-chain of HCG 
produced by a tumor has an increased content of a 1-6-fucosylated biantennary 
sugar chains, and appears to possess the unusual a1-6-fucosylated tri- and tetra-
antennary chains. Aberrant phosphorylation may also occur (Cox, 1986; Saccuzzo 
et al., 1986; Endo et al., 1987; Kobata, 1988; Iwase, 1988). Attempts have 
been made to quantitate these changes by lectin affinity chromatography (Koyama 
et al., 1986; Cole et al., 1984; Nishimura et al., 1985; Chapman et al., 1984), 
by chemical analysis of the HCG-linked sugar chains (Cole, 1987; Mizuochi 
et al., 1983) or by lectin-immunoradiometric assay (Imamura et al., 1987). 
We investigated the feasability of lectin-enzyme immunoassays with a number 
of lectins to see if the assays are capable of distinguishing HCG produced by 
the placenta and by tumors, as well as HCG produced by hydatidiform mole. 
This latter category is of especial interest as an invasive mole may transform 
into a trophoblastic tumor. 
The results indicate that with certain lectins this distinction can be made using 
lectin-enzyme immunoassays. 
5.4.2. Materials and Methods 
- Samples were obtained from Nijmegen University (Dr. Idema) and from the 
Daniel den Hoed Cancer Clinic Rotterdam (Dr. Haije). 
- Lectins: the lectins used are described in table 4-1. 
- HCG determination. 
HCG was determined with a RIA technique using a kit from Diagnostic Products 
Corporation, Los Angeles, USA. 
- Lectin-enzyme immunoassay 
100 , . .tl monoclonal anti-HCG clone 293A (Sanbio, Uden, Netherlands) diluted 
in carbonate buffer was allowed to coat microtiter plate wells at 37°C for 
4 hours. Plates were then washed 4 times with PBS-tween. Plates were incubated 
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with 50 Ml HCG containing sample, diluted to 200 U /L, at 37°C for 2 hours. 
After washing the plate four times the lectin-enzyme binding was allowed 
to take place as described in chapter 4. 
5.4.3. Results 
Table 5-4 gives the extinctions in anti-HCG coated wells incubated with HCG 
containing serum samples from tumor patients (T), molar pregnancy (M) and 
healthy pregnant women (N). 
5.4.4. Discussion and conclusions 
All lectins bind to some extent to the coated monoclonal anti-HCG in the 
absence of sample ("blank binding" in table 5-4). The presence of 10 U HCG 
in the well decreases the lectin binding in most cases. This is probably an effect 
of steric hindrance: HCG diminishes the accessibility of the lectin for the 
immunoglobin glycans when HCG is captured. If the HCG molecules do not 
possess an equal amount of similar glycans, a decrease in binding may be observed. 
Only in the case of RCA an equal and increased lectin binding is observed 
in the presence of HCG. Any role of the specificity of the anti-HCG antibody 
remains to be established. 
We calculated the mean± two standard deviations ofthe extinction coefficients 
for each lectin in the control group (n= 11 ). Out of these six limits (for six 
lectins) one tumor patient exceeded two, one exceeded three, one exceeded four 
and one exceeded six limits, roughly correlating with the HCG concentrations 
in the original (undiluted) samples. Three out of four tumor patients were outside 
these ranges with respect to binding to the lectins RCA, LCA, Ulex and PNA. 
Two patients showed aberrant AAL binding, and one aberrant AAA binding. 
With respect to the increased fucose lectin-binding these results are consistent 
with the known modifications of HCG glycosylation in patients with HCG 
producing tumors (Mizuochi et al., 1983; Imamura et al., 1987; Endo et al., 
1988; Kobata, 1988). Increased fucosylation may lead to increased binding of 
one or more of the fucose-specific lectins LCA, Ulex 1, AAL, Lotus and AAA, 
depending on the branching pattern and the attachment site and linkage of fucose. 
All of these lectins show increased binding to one to three, out of the four 
HCG's from tumor patients. 
However, while increased RCA and PNA binding was found before by a 
LIRMA technique (lectin immunoradiometric assay), we found decreased RCA 
and PNA binding, indicating a decrease in terminal Galf31-4GlcNAc and Galf31-
3GalNAc structures, respectively. The reason for this discrepancy remains unclear 
at present. Inhibition by other glycoproteins present in the urine may play a 
role, because the LIRMA technique, being comparable to our type I lectin-enzyme 
immunoassay (chapter 2), will show the same drawbacks such as crossreactivity 
by different proteins with comparable glycans. 
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Table 5-4. HCG concentrations and lectin binding in patients with tumor (T), mole (M) compared 
with healthy pregnant subjects (N) with mean, a and limits expressed in milE-extinction units. 
LECTINS 
Blank HCG RCA LCA Ulex I AAL PNA AAA Score 
Binding u /l 245 270 610 1010 215 475 
Tl 1.417 291 94 312 485 55 193 4 
T3 442 316 180 230 679 162 185 3 
T4 89.000 252 144 400 774 98 264 6 
T5 434 298 60 133 343 91 128 2 
Ml 19.280 294 100 !50 471 67 170 3 
M2 19.640 318 97 283 534 92 210 4 
M3 32.780 293 50 134 382 76 264 3 
M4 136.820 262 76 114 431 100 !57 I 
M5 109.330 275 75 232 510 88 200 4 
M7 245.000 271 54 117 460 112 266 2 
M8 10.200 348 58 72 329 88 134 
Nl 15.900 394 98 216 515 116 195 2 
N2 28.000 356 69 110 376 129 170 0 
N3 95.000 314 55 82 444 114 142 0 
N4 11.000 397 70 165 395 130 143 0 
N5 30.000 340 50 128 378 !55 258 1 
N6 35.000 342 51 82 396 Ill 163 0 
N7 13.140 406 64 184 450 !53 166 0 
N8 32.400 352 46 146 377 !59 190 0 
N9 56.830 342 56 94 372 129 124 0 
NIO 21.410 402 56 114 467 162 138 0 
Nil 8.320 401 68 188 406 l§Q 206 1 
T 290 120 268 570 100 190 
a 25 46 100 170 40 47 
M 294 70 !57 445 89 200 
a 25 20 68 66 14 47 
N 370 62 137 416 140 170 
a 31 13 44 44 20 36 
Limits 308- 36- 49- 328- 100- 98-
X±a 432 88 225 504 180 242 
Underlined: values outside limits. 
Score: Number of lectins (out of six) with abnormal binding. 
Of the six patients with molar pregnancy two showed binding outside four 
limits, two outside three limits, one outside two limits and two outside one limit. 
Here, both RCA and PNA detected five out of seven patients, while Ulex, AAL 
and AAA detected two. 
Of the normal samples one had two values (out of six) out of the mean ± 
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2 SD range. These lectins were LCA and AAL both with affinity for biantennary 
glycans with a a 1-6 linked fucose in the core. The significance of this finding 
is unknown at present. A theoretical explanation could be found in the gestation 
time dependent glycosylation (as is the case with AFP glycosylation). HCG early 
in pregnancy could very well be glycosylated differently from HCG produced 
in later trimesters. It is unknown whether the first normal sample was taken 
at a different moment in pregnancy as the others (all were blood group Rhesus 
control samples). Two other normal samples out of the remaining ten showed 
binding of one lectin outside the limits. 
There appears to exist no relationship between the HCG concentration and 
the extent of aberrant glycosylation, that is, the number of lectins highly bound, 
or the extinction measured per lectin, in the molar and normal pregnancy groups. 
The HCG samples were diluted to an equal concentration of 200 U /1. This 
concentration was considered to be sufficient to saturate the antibody coating 
with HCG. This is supported by the fact that in the patient categories both 
lower and higher lectin binding were observed. 
Interference of rheumatoid factors is also excluded by the large dilution factors 
used. Besides, rheumatoid factors are rare in the subject categories studied. 
In conclusion, the lectin-enzyme immunoassays of HCG appear to be able 
to characterise the modifications of HCG glycosylation in patients with hyda-
tidiform mole or persistent trophoblastic disease, who may ultimately develop 
HCG producing choriocarcinoma. The assay will be of value in the understanding 
of the mechanisms of changes in protein glycosylation and the relationship with 
malignancy. The assay will also be of value in the diagnosis and treatment 
of patients in the above categories. However, differences between patients may 
occur as well as in one patient during the disease (Endo et al., 1988). 
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CHAPTER6 
GENERAL DISCUSSION 
Glycoproteins in human plasma show disease-associated modifications of their 
carbohydrate chains. No systematic change has been found: hypo- or hyper-
sialylation, increased branching or fucosylation have been described. Until now, 
fast, sensitive and specific methods to characterise glycan structures were lacking. 
The present work describes the development and application of solid phase 
enzyme binding assays employing lectins to study protein glycosylation. The 
sensitivity, specificity and speed of such assays was considered a major advantage 
over classical carbohydrate analysis and other techniques. 
From the experiments described in chapter 2 it is concluded that the type 
I assay using an immobilized lectin and enzyme-linked antibodies will have 
few applications. The selectivity of the lectins tested is considered insufficient 
due to the possible binding of other glycoproteins to the coated lectin. Still, 
this technique may be applied to purified glycoproteins where the problem of 
cross-reactivity does not exist. One might even think of heterologeous lectin-
enzyme assays which quantitate the binding of two lectins to the glycoprotein 
(Kohn, 1983). This type of assay was not further developed by us. 
Another drawback of the type I assay could be the low affinity of the 
immobilized lectins to the soluble glycoprotein, depending on the average 
intramolecular distance between lectin molecules relative to the size of the 
glycoprotein in question. When the affinity is low due to the rigidity of the 
lectin surface the glycoprotein will be washed away during wash cycles. 
In the type II assay immobilized antibodies are used which do not let their 
antigen go during washing cycles, and a lectin-STAP complex is used which 
probably has a far greater flexibility to overcome spatial restrictions in the 
interaction between (biotinylated) lectin molecules in the lectin-STAP complex 
and antibody-captured glycoprotein glycans. In any case the binding of lectin-
STAP complexes to solid phase bound glycoproteins or glycoconjugates is firm 
enough not to be disrupted during wash steps. 
To study the binding of lectins to immobilized glycoproteins and to investigate 
the dependence of the interaction on the number of interacting carbohydrate 
groups it was necessary to prepare well-defined glycoprotein subfractions. The 
experiments in chapter 3 indicate that the preparation and separation of the 
five transferrin sialovariants could be achieved. This is probably one of the very 
few glycoproteins allowing easy separation on the basis of charge as the result 
of differences of one sialic acid residue. Thus, for other glycoproteins it may 
be more complicated to prepare well-defined subsets. However, high-resolution 
ion-exchange chromatography or high-pressure lectin-column chromatography 
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may provide a solution. In any case, the human transferrin sialovariants are 
easily and completely separated from each other by high-resolution FPLC 
techniques. 
With these five available fractions, aspects of the type II lectin-enzyme 
immunoassay using immobilized antibodies and an enzyme-bound lectin were 
investigated in detail (chapter 3). A standard curve was obtained with these 
well-defined sialovariants bearing whole integers of terminal galactose residues. 
Thus, while the response in the sandwich ELISA is a function of the amount 
of glycoprotein recognized by the enzyme-linked antibody, the response in the 
lectin-enzyme immunoassay is a function of the amount of glycan structure 
recognized by the enzyme-linked lectin. In the case of transferrin and RCA 
lectin results may be expressed as the amount of galactose residues per transferrin 
molecule. 
Standardization is less simple when a glycoprotein has more carbohydrate 
chains. In a number of instances it will prove to be impossible to isolate or 
prepare subfractions or glycovariants of the glycoprotein in question. This 
approach would have the drawback that the standard material is different for 
each lectin, which does not favor the simultaneous binding studies of a large 
number of lectins. In such cases it may be possible to assign an arbitrary value 
to a large pool of standard material of undetermined composition from which 
individual laboratories may obtain small amounts. This is not unlike the WHO 
serum samples, for instance for immunoglobulins. Results are expressed in 
International Units per liter. Another approach would be to determine the reference 
range each time the assay is performed, by inclusion of a number of normal 
samples in the analysis. This approach has been followed in our HCG and 
haptoglobin studies. Results are then expressed in terms of the reference range. 
It should be noted here that the method described may not be directly compared 
with other techniques such as lectin affinity chromatography or crossed affino-
immunoelectrophoresis. Our method gives an overall impression of binding of 
the lectin used to the total amount of the glycoprotein present in the sample. 
The other methods allow the investigation of non-binding, weakly binding and 
strong binding fractions all at the same time. This could be achieved in the 
lectin-enzyme binding assay by adding serial dilutions of a competing sugar 
as described in chapter 4. This area was not further investigated. 
In most cases lectins do recognize an "epitope" of more than a terminal or 
internal sugar group alone. Other groups present in the carbohydrate chain, 
sometimes located at a relatively large distance, may have an influence, sometimes 
decisive, on the strength of the binding interaction. Thus, while the method 
described may be very suitable to detect differences in binding, it is at present 
not interpretable in such a way that conclusions with respect to the exact 
carbohydrate structures can be drawn. When the molecular aspects of glycan 
modifications are known, this drawback will lose importance. On the other hand, 
the lectin-enzyme binding assays proved to be capable of detecting glycan 
modifications in disease (chapter 5), irrespective of the exact molecular basis 
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of the altered lectin binding. In the near future fundamental structural work 
will no doubt uncover the changes in the responsible glycosidases and glyco-
syltransferases (as is the case in rheumatoid arthritis), which lead to the occurrence 
of aberrantly glycosylated glycoproteins in the circulation during disease. 
Classically, the specificity of lectins has been determined by inhibiting the 
lectin-induced hemagglutination with well-defined sugars. Our lectin-enzyme 
binding assay could be a new alternative, provided that the binding of the lectin-
enzyme complex can also be inhibited by simple sugars in a concentration 
dependent manner. The experiments described in chapter 4 show that this is 
indeed the case. The method opens the way to characterize lectin specificities 
in more detail. Macromolecules such as glycoproteins, neoglycoconjugates and 
polysaccharides may also be used. A major advantage is the consumption of 
only extremely small amounts of lectin (typically 0.1 J.Lg per assay). Another 
advantage is the unequivocal representation of the results in terms of 50% 
inhibition concentration. 
In order to compose a lectin-STAP complex consisting of equivalent amounts 
of biotinylated lectin and streptavidin-peroxidase, a new method was developed 
as mentioned in chapter 4.3. The use of avidin coated plates as well as albumin-
biotin coated plates allows the determination of the required lectin-biotin dilution 
and the required streptavidin-peroxidase solution. If during binding experiments 
in microtiter plates, wells coated with avidin and albumin-biotin are introduced 
next to the classical non-coated blank wells, one always has a check if the 
lectin-STAP complex was of the right composition. In all our subsequent 
experiments with plates coated with BSA-glycoconjugates and plasma proteins 
as well as the studies with patient samples we reserved three wells for avidin 
coating and three wells for albumin-biotin coating. We observed no change in 
optimal dilutions during that period with any of the lectins used. 
After having determined the desired composition of a number of lectin-STAP 
complexes, the binding to well-defined neoglycoproteins adsorbed in microtiter 
plates was investigated. This is a new approach employing glycans of extended 
size. The lectin-enzyme binding assay detected large differences in binding of 
the lectins to the various structures. These were generally in accordance with 
results obtained with hemagglutination or lectin column techniques. Our method 
will gain importance when more BSA-glycoconjugates become available, allowing 
the simultaneous investigation of the binding of a large number of lectins to 
a large number of BSA-glycoconjugates. In a later stage the method might be 
used to select lectins for binding to well known structures, as well as to investigate 
unknown structures with a panel of lectins. 
In the same way as described above, the binding of lectin-STAP complexes 
was determined in microtiter plates coated with purified plasma glycoproteins. 
From these studies the background binding in lectin-enzyme binding assays may 
be deduced, which may be of value when selecting the lectin to be used. Also, 
the binding of a large panel of lectins will ultimately lead to more insight into 
the glycan structures of glycoproteins when the specificities of the lectins are 
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known in detail. It is speculated that computerized processing of the results 
will be a necessity. 
Clinical applications of the developed assay were investigated with respect 
to three plasma glycoproteins: IgG, haptoglobin and HCG. 
In the case of IgG, passive coating of the purified protein from rheumatoid 
arthritis patients, pregnant women and blood donors was used, followed by lectin 
binding studies. In general, this method is applicable for each plasma protein. 
However, the purification procedures are time consuming and cumbersome. 
Besides, it has not yet been established that during purification of a glycoprotein 
all its subfractions are obtained with the same yield. When using ion-exchange 
chromatography, for instance, and applying narrow cut-off values to increase 
the purification factor, one selectively dismisses the extremely charged subfrac-
tions of the glycoprotein, i.e. the higher and lower sialylated ones are not present 
in the final product. 
Another drawback may be found in the fact that when columns with immobilised 
antibodies are used to purify proteins by means of affinity adsorption, the acid 
eluting buffer induces sialic acid loss from the purified glycoprotein. 
Although correlations between IgG glycosylation and lectin binding have been 
found, techniques using purification of the glycoprotein are considered unsuitable 
for application in the clinical practice. 
Thus, the second glycoprotein i.e. haptoglobin was analysed in a system making 
use of the unique affinity of haptoglobin for hemoglobin. This approach, although 
successful for haptoglobin, will have very few equals as most plasma glycoproteins 
do not bind to another non-glycosylated protein which is readily available. 
Still, the results obtained with haptoglobin merit further clinical trials. For 
instance, it would be of interest to follow cancer patients during periods of 
remission and relapse of their disease. A fundamental question to be answered 
concerns the mechanism behind changes in glycosylation of proteins produced 
by the liver, due to the presence of a tumor elsewhere in the body. Next, the 
study of haptoglobin glycosylation in other diseases such as RA (where the lectin 
MPA strongly binds haptoglobin) is a necessity, as well as in other autoimmune 
diseases such as SLE. Even within the RA class, subgroups such as RF 
seronegatives and vasculitis patients are of interest. These and other clinical 
studies remain to be initiated. 
As the third application of the technique a lectin-enzyme immunoassay for 
HCG was developed. In comparison with IgG and haptoglobin, more is known 
about its carbohydrate chains and their modifications in relation to hydatidiform 
mole and choriocarcinoma. Unexpectedly, the lectin-enzyme immunoassay was 
able to detect important differences between the HCG samples used. Unex-
pectedly, because most lectins showed a high affinity for the monoclonal anti-
HCG used. However, thanks to a phenomenon yet to be explained, the HCG 
binding to the antibody decreased the unwanted direct binding of the lectin 
to the antibody. Otherwise the discriminating power of the assay would have 
been decreased by the high blank binding. A second phenomenon which remains 
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unexplained is the lower RCA and PNA binding to HCG from hydatidiform 
mole or choriocarcinoma patients. Others have claimed that in these patients 
RCA and PNA reactive HCG is increased. In any case, the application of lectin-
enzyme immunoassays is feasable even without deglycosylation of the antibodies, 
as the results with HCG show. 
For a number of applications a set of lectin-enzyme binding assays should 
be used with a certain panel of lectins. For instance, a glycoprotein having an 
increased fucose content and produced by one tumor could be different from 
the same glycoprotein having an increased terminal galactose content and 
produced by a different tumor. Our results obtained with haptoglobin and with 
HCG suggest that with a certain set of lectins one may be able to detect several 
different changes in glycosylation. 
The comparison between the results obtained with the lectin-enzyme binding 
assays and other lectin techniques should be made with caution, as differences 
in the binding properties may exist between immobilized lectins and lectins in 
solution (Montreuil et al., 1983). The same holds true for comparisons with 
crossed affino-immunoelectrophoresis (Salier et al., 1980). Not always will 
changes in the glycosylation lead to changes in lectin binding, even when the 
affinity of the lectins for the glycans have changed. It could be imagined, for 
instance, that a: 1-6 fucosylation of a biantennary glycan will lead to an increase 
of LCA binding. However, if, at the same time, the branching pattern of the 
glycan changes from biantennary to triantennary or tetraantennary, this will lead 
to a decrease in LCA binding. Thus, the simultaneous change of a glycan's 
structure towards increased affinity as well as towards decreased affinity will 
lead to an unchanged binding of the lectin used, although the glycan in question 
is different from its original structure in two respects. Besides lectin-enzyme 
immunoassays, other lectin based (or monoclonal anti-carbohydrate antibody 
based) techniques suffer from this same phenomenon. 
Changes in the glycan structure may occur without a change in affinity of 
a certain lectin for the glycan. In such a case the lectin in question is unsuitable 
to detect this modification. At present, the selection of lectins on a tria1 and 
error basis is probably the fastest way to find meaningful combinations of the 
triad glycoprotein, disease and lectin. 
Applications of lectin-enzyme binding assays outside the field of medicine 
may also be thought of. For instance, the study of the specificity of glycosyl-
transferases and glycosidases towards neoglycoconjugates or other glycoproteins 
immobilized in microtiter plate wells is possible after incubation of the enzyme, 
followed by determination of changes in lectin-binding. 
The study of the glycosylation of glycoproteins produced by recombinant 
techniques for therapeutic use, such as clotting factors, will be easy using lectin-
enzyme immunoassays. In such proteins the right glycosylation is of paramount 
importance to ensure maximum stability and to avoid uptake by membrane 
lectins due to incomplete glycosylation. One could imagine the selection of the 
right clones on the basis of the glycoprotein reactivity in lectin-enzyme im-
munoassays. 
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The techniques described in chapter 4 allow a detailed description of the 
lectin binding specificity. These techniques will gain importance as more BSA-
glycoconjugates, more purified plasma glycoproteins and more lectins become 
availab1e. 
In short, the work described here has lead to the development of the concept 
of lectin-enzyme binding assays, in particular the lectin-enzyme immunoassays; 
new tools for the analysis of protein glycosylation. 
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SUMMARY 
This work describes the development and application of lectin-enzyme binding 
assays, new analytical techniques, to investigate the glycosylation of glycoproteins. 
Glycoproteins are characterized by the presence of one or more covalently bound 
carbohydrate chains linked to a protein backbone. In human plasma the 
glycosylation of glycoproteins is subject to dynamic modifications, as is described 
in chapter 1, independent of the concentration of the glycoprotein. We studied 
the feasability of the use of lectins, specific carbohydrate binding proteins, in 
solid-phase enzyme-assays employing the lectins as immobilized binder (type 
I assay) or as soluble enzyme-bound binder (type II assay). A theoretical discussion 
of the use of lectins in ELISA techniques is given in chapter 1. 
The potentials of the type I assay with an immobilised lectin are investigated 
indirectly. Chapter 2 describes experiments in which normal human serum with 
or without neuraminidase treatment was fractionated on a number of galactose-
specific lectins bound to Sepharose. The bound and the unbound fractions were 
subsequently analysed by immunoelectrophoresis and by laser nephelometry. It 
is concluded that immobilized lectins will have very few applications in solid-
phase enzyme-immunoassays using an antibody-enzyme conjugate to quantitate 
glycoproteins with terminal galactose groups, as a consequence of the pheno-
menon of cross-reactivity of many glycoproteins for the lectins used. 
To develop the type II assay with immobilized antibodies and using a lectin-
enzyme conjugate well-defined transferrin sialovariants were used, whose pre-
paration and separation are described in chapter 3. 
With these five transferrin sialovariants a lectin-enzyme immunoassay was 
developed with the lectin from Ricinus communis (RCA) as the galactose-specific 
lectin and peroxidase as the marker enzyme. In the final protocol both lectin 
and peroxidase are biotinylated and linked together by virtue of the biotin-binding 
protein Streptavidin. A number of variables have been investigated, resulting 
in an assay which shows a linear response with the number of terminal galactose 
groups on transferrin. 
The lectin-enzyme binding assay may also be used to determine the lectin 
specificity by inhibition of the binding by simple saccharides. The principles 
of this lectin-enzyme binding inhibition assay, investigated with RCA as the 
lectin, are described in chapter 4.2. 
With the lectin-enzyme binding assay the best results are obtained using 
biotinylated lectin and streptavidin-enzyme complexes or conjugates. However, 
the optimal ratio of the two compounds, leaving neither one in excess, and the 
most suitable dilution of the complex thus formed are not easily found, as may 
be concluded from the experiments described in chapter 3. In chapter 4.3 a 
new method is described which allows a fast and easy determination of the 
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point of equivalence of lectin-biotin and streptavidin-enzyme, employing avidin 
and biotinylated albumin coated microtiter plates. Another advantage of this 
method is that the lectin binding function is not used, making the method 
independent of lectin specificity and applicable for other binding proteins as 
well, such as antibodies, Protein A and others. 
After establishment of the optimal composition and dilution of a large number 
of lectin-streptavidin-peroxidase complexes, the binding of each complex to a 
number of neoglycoproteins adsorbed in microtiter plates was studied (chapter 
4.4). These BSA-glycoconjugates produced in vitro have extended glycan 
structures. Their lectin-enzyme binding gives more detailed information with 
respect to the lectin specificity as compared to the inhibition results described 
in chapter 4.2. In fact, both methods can be considered to be complementary 
to each other. New insights may be obtained in terms of the fine specificity 
of the lectin when studying the lectin-enzyme binding to neoglycoproteins, as 
examplified for the RCA lectin. 
The concept of lectin-enzyme binding assay has also been used to determine 
the lectin binding to normal human plasma glycoproteins coated to microtiter 
plates. These experiments are described in chapter 4.5. It may be concluded 
that this technique compares favourably with affinodiffusion in gels or with lectin-
column chromatography. 
Three aplications of the developed assay were investigated with patient samples. 
First, IgG was purified from serum from blood donors, pregnant females and 
patients with rheumatoid arthritis. The IgG preparations were analysed with 
respect to their carbohydrate composition, and they were coated to microtiter 
plates. A correlation was found between the diminished galactose content of 
IgG from RA patients and the binding of a galactose-specific lectin (chapter 
5.2). A possible explanation is put forward for the temporary remission of RA 
during pregnancy owing to the increase in IgG galactose content during pregnancy. 
Second, the glycosylation of haptoglobin was investigated by lectin-enzyme 
binding after incubation of serum in hemoglobin-coated microtiter plate wells. 
Associations with certain diseases were noted. Haptoglobin in serum of a number 
of cancer patients showed elevated binding of some of the lectins used. The 
experiments are described and discussed in chapter 5.3. 
Third, the HCG glycosylation was studied in serum from patients with HCG 
producing tumors and molar pregnancies, as well as from normal pregnant women. 
Malignancy-associated differences in HCG glycosylation were detected by the 
lectin-enzyme immunoassay in microtiter plate wells coated with monoclonal 
anti-HCG (chapter 5.4). 
A general discussion on the results obtained and on the prospective areas 
of application of lectin-enzyme binding assays is given in chapter 6. 
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SAMENVATTING 
Dit proefschrift beschrijft de ontwikkeling van lectine-enzym bindingsanalyses, 
een nieuwe techniek om de glycosylering van glycoproteinen te onderzoeken. 
Glycoproteinen onderscheiden zich door de aanwezigheid van een of meer 
covalent gebonden koolhydraatketens. In het plasma van de mens is de gly-
cosylering van de glycoproteinen dynamisch van aard, zoals in hoofdstuk 1 wordt 
beschreven, en onafhankelijk van de concentratie van het glycoproteine. 
De toepasbaarheid van lectines, specifieke koolhydraat-bindende eiwitten, als 
geimmobiliseerde binders of als enzym-gebonden binders in ELISA technieken 
werd bestudeerd. Een theoretische discussie van het gebruik van lectines in ELISA 
technieken wordt gegeven in hoofdstuk 1.4. De mogelijkheden van type I 
bepalingen, waarbij het lectine geimmobiliseerd is, werden indirect onderzocht. 
Hoofdstuk 2 beschrijft experimenten waarin humaan serum, al dan niet behandeld 
met neuraminidase, gescheiden werd op een aantal Sepharose kolommen waaraan 
galactose specifieke lectines zijn geimmobiliseerd. De gebonden en de onge-
bonden fracties werden vervolgens geanalyseerd door middel van immunoelec-
troforese en laser nefelometrie. De conclusie wordt getrokken dat voor de 
combinaties van geimmobiliseerde galactose-specifieke lectines en antilichaam-
enzym conjugaten weinig toepassingen zullen zijn om de eindstandige galactose 
groepen van glycoproteinen te kwantificeren, door het optreden van kruisreakties 
van vele glycoproteinen met de gebruikte lectines. 
Voor het ontwikkelen van de type II bepaling met geimmobiliseerde anti-
lichamen en lectine-enzym conjugaten maakten we gebruik van gedefinieerde 
transferrine sialovarianten, waarvan de bereiding en scheiding beschreven is in 
hoofdstuk 3. 
Met deze vijf transferrine sialovarianten werd een lectine-enzym immunoassay 
ontwikkeld met RCA als de galactose-specifieke lectine en peroxidase als het 
indicator enzym. In het uiteindelijke protocol werd een complex gebruikt van 
gebiotinyleerde lectine gekoppeld aan gebiotinyleerd peroxidase via streptavidine. 
Een aantal variabelen werd onderzocht. Het resultaat is een bepaling waarbij 
een lineair verb and wordt gevonden met het aantal eindstandige galactose groepen 
van transferrine. 
De lectine-enzym bindingsanalyse kan ook worden gebruikt om de specificiteit 
van lectines te bepalen in inhibitie experimenten met simpele suikers. Deze 
techniek wordt beschreven in hoofdstuk 4.2 voor het lectine RCA. 
De beste resultaten van lectine-enzym bindingsanalyses worden verkregen 
door gebruik te maken van gebiotinyleerde lectines en streptavidine-enzym 
complexen of conjugaten. Echter, de optimale verhouding van deze constituenten, 
waarbij geen van beide in overmaat aanwezig is, was niet eenvoudig te bepalen, 
zoals de experimenten beschreven in hoofdstuk 3 aangeven. In hoofdstuk 4.3 
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wordt een nieuwe techniek geintroduceerd waarmee snel en eenvoudig het 
equivalentiepunt van gebiotinyleerde lectine en streptavidine-peroxidase wordt 
bepaald in microtiter platen gecoat met gebiotinyleerd albumine en met avidine. 
Een bijkomend voordeel van de ontwikkelde methode is dat geen gebruik gemaakt 
wordt van de lectine bindingsfunctie, waardoor zij onafhankelijk is van de 
specificiteit van het lectine en algemeen toepasbaar voor andere bin den de eiwitten 
zoals antilichamen, Protein A, etc. 
Na het vaststellen van de optimale verhouding en verdunning van een aantal 
lectine-streptavidine-peroxidase complexen werd vervolgens de binding bestu-
deerd aan een aantal neoglycoproteinen geadsorbeerd in microtiter platen. Deze 
in-vitro geproduceerde BSA-glycoconjugaten kunnen langere suikerstructuren 
bezitten. De binding van lectine-enzym complexen, zoals beschreven in hoofdstuk 
4.4, geeft meer gedetailleerde informatie over de lectine specificiteit als de inhibitie 
techniek, hoewel beide technieken als complementair kunnen worden gezien. 
De binding van het door ons gebruikte voorbeeld van het RCA lectine leverde 
nieuwe gegevens op over details van de specificiteit van het lectine. 
Het idee van de lectine-enzym bindingsanalyse kan ook worden gebruikt om 
de binding van lectines aan normale plasma-eiwitten te bepalen. Deze 
experimenten met aan microtiter platen gecoate plasma-eiwitten staan beschreven 
in hoofdstuk 4.5. De techniek biedt een aantal voordelen vergeleken met 
affinodiffusie of lectine-kolom chromatografische technieken. 
Drie toepassingen van de ontwikkelde bepalingstechniek werden onderzocht 
met patientenmateriaal. Allereerst werd IgG gezuiverd uit bloed van RA patienten, 
zwangere vrouwen en bloeddonoren, en de IgG koolhydraatsamenstelling ge-
analyseerd. Ook werden de IgG preparaten gecoat aan microtiter platen en werd 
vervolgens de binding van lectines bestudeerd. Er werd een correlatie gevonden 
tussen het verminderde galactose gehalte van IgG van RA-patienten en de binding 
van een galactose-specifieke lectine (hoofdstuk 5.2). Een mogelijke verklaring 
wordt geopperd voor de tijdelijk remissie van RA tijdens de zwangerschap, gezien 
de stijging van galactose in IgG tijdens deze periode. 
Als tweede werd de glycosylering van haptoglobine onderzocht met de lectine-
enzym bindingsanalyse, na incubatie van serum in hemoglobine-gecoate mi-
crotiter plaatjes. Associaties met zekere ziekten werden gevonden. Haptoglobine 
van een aantal kanker-patienten vertoonde verhoogde lectine-binding met enkele 
van de gebruikte lectines. Deze experimenten staan beschreven in hoofdstuk 
5.3. 
Als derde werd de HCG glycosylering bestudeerd in serum van patienten 
met HCG producerende tumoren, mola zwangerschappen en gezonde zwangere 
vrouwen. De lectine-enzym immunoassay, gebruikmakend van microtiter platen 
gecoat met monoclonaal anti-HCG, toonde verschillen aan in HCG glycosylering 
gerelateerd aan de maligniteit (hoofdstuk 5.4 ). 
Een algemene discussie van de verkregen resultaten en van de mogelijke 
toepassingsbieden van lectine-enzym bindingsanalyses wordt gegeven in hoofd-
stuk 6. 
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